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ABSTRACT
Sustainable Production of Novel Biomaterials in Escherichia coli

by

Asif Rahman, Doctor of Philosophy
Utah State University, 2014

Major Professors: Dr. Charles Miller and Dr. Ronald Sims
Department: Biological Engineering

Synthetic biological engineering can be used to program microorganisms to
perform a variety of functions such as producing new chemicals, aiding in healthcare, and
environmental cleanup. In this study, two biomaterials were produced in Escherichia
coli: polyhydroxybutyrates (PHBs) and spider silk. While production of biomaterials can
be optimized using synthetic biological engineering, one of the bottlenecks to mass
production of bioproducts is the cost of the carbon substrate. This study coupled synthetic
biological engineering with inexpensive carbon substrates for production of biomaterials.
Currently, there is a need to reduce the dependence on petroleum-derived
commodities and a move towards renewable products. PHBs are a group of
biodegradable plastics that are produced by a wide variety of microorganisms, mainly as
a storage intermediate for energy and carbon. Synthetic biological engineering techniques
were used to create export systems for secretion of bioproducts from the cell. PHAs form
granules inside bacteria and have associated proteins bound to the granule surface.
Phasin, a granule bound protein, was targeted for type I secretion by fusion with a HlyA
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signal peptide and thereby facilitating indirect secretion of PHAs. To help understand
secretion of PHAs, a green fluorescent protein (GFP) was tagged to the PHA polymerase
enzyme encoded by phaC. phaC is part of a three-gene cassette that includes phaA and
phaB, which are required for PHA production.
Spider silk is a highly versatile biomaterial with a range of potential applications.
In this study, spider silk DNA sequences were optimized for production in E. coli and
assembly of DNA constructs was carried out with the use of synthetic biological
engineering. Specific tRNAs were engineered to be compatible with these spider silk
sequences for optimized production.
To address the issue of expensive carbon substrate, a wastewater microalgae
extract was used. One of the side streams of microalgae biodiesel production is an
aqueous phase that contains simple sugars, ideal for recombinant bacteria growth and
bioproduct generation. As a demonstration, PHB production was shown from E. coli
grown on an algae-based medium. Coupling synthetic biological engineering with
inexpensive substrates could potentially make bioproduct production economically
feasible in the future.

(230 pages)
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PUBLIC ABSTRACT
Sustainable Production of Novel Biomaterials in Escherichia coli

The biotechnology revenues in the United States exceeded $100 billion in 2010
and the potential impact of synthetic biological engineering has been identified nationally
as an emerging technology to further expand the national bioeconomy. Synthetic
biological engineering approaches biology from an engineering perspective to make
biology easier to engineer.

The potential to engineer microorganisms for novel

applications can have far-reaching implications and benefits for society. Some of the
potential applications range from biosensors, biofuels, therapeutics, and biomaterials.
In this study two biomaterials were produced in genetically engineered
Escherichia coli: polyhydroxybutyrates (PHBs) and spider silk. PHBs are bioplastics that
have similar properties to petrochemical-derived plastics. Synthetic biological
engineering can be used to optimize PHB extraction from E. coli by secretion of the PHB
polymer outside of the cell.
Another biomaterial, spider silk, was also produced in E. coli. Spider silk is a
unique material with high tensile strength and elasticity and thus could have a wide range
of potential applications. Since spider silk is not naturally produced in microorganisms,
the DNA sequences were optimized for increased production in E. coli.
In addition to optimization of bioproduct production in microorganisms using
synthetic biology, another major cost is the carbon substrate. In this study wastewater
microalgae were used as an alternative carbon substrate. Coupling synthetic biological
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engineering and sustainable engineering could potentially make production of
bioproducts economically viable in the future.
Asif Rahman

vii

VISUAL ABSTRACT
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CHAPTER 1
INTRODUCTION

1.

Overview
Synthetic Biological Engineering holds the promise of benefiting society with the

advancement of recombinant technologies in the medical, agricultural, food,
environmental, and energy sectors. The production of biomaterials using genetically
engineered organisms as a platform is another aspect of synthetic biological engineering
that has gained interest recently. With any new technology, there are many challenges
that need to be overcome in order for it to be economical and self-sustaining. The purpose
of this dissertation is to couple synthetic biological engineering and sustainable
engineering to create platforms for production of useful biomaterials such as bioplastics
and synthetic spider silk using Escherichia coli as a microbial cell factory.
Traditional plastics are derived from petroleum and are non-biodegradable.
Currently, there is a need to reduce our dependence on petroleum derived products and
move towards ‘greener’ biodegradable materials. Polyhydroxyalkanoates (PHAs) are a
group of biodegradable plastics that are produced by a wide variety of microorganisms,
mainly as a storage intermediate for energy and carbon. Recombinant E. coli have been
used to increase PHA yields in bioreactors, however this process is currently not
economically viable. There are two main laboratory-to-market bottlenecks in producing
PHAs in microorganisms: 1) downstream processing of bacterial cultures to extract the
valuable PHA and 2) cost of carbon substrate.
Studies have shown that, in nature, bacteria can accumulate up to 90 % of the dry
cell weight; unfortunately due to the PHA remaining inside the cell the cost of PHA
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isolation can be extremely high. Secreting PHA from E. coli could potentially reduce
downstream processing costs as it can be easier to separate secreted PHA from the
biomass. Since PHAs are polymers they cannot be directly targeted for secretion from
E. coli, instead an intermediate must be used. PHA granules have a variety of associated
proteins. One such protein, Phasin, binds to the PHA granule and can be targeted for type
I secretion. Synthetic biological engineering principles can be used to secrete a PHAbound-Phasin complex outside of the cell and could make PHA production a sustainable
process. In conjunction with secretion, visualizing the secretion process with SEM and
fluorescence microscopy would further enhance the understanding of the PHA secretion
phenomena.
In addition to using synthetic biological engineering for secretion of PHAs from
E. coli, molecular biology techniques can be used to optimize the production of another
biomaterial, synthetic spider silk. Spiders can naturally produce a variety of different
silks and one such silk, dragline silk, has mechanical properties similar to that of Kevlar
and rubber. Spiders are territorial and cannibalistic which makes farming spiders not
possible. E. coli can be used as a microbial factory for producing spider silk proteins and
production can be optimized using synthetic biological engineering tools to optimize
protein expression levels.
To address the issue of expensive carbon substrate, inexpensive alternatives can
be used. A cheap carbon substrate is ideally free and requires little or no modification.
One such alternative is the use of a wastewater algae-based media for bacterial growth
and subsequent production of recombinant products. Algae have been well studied as a
production platform for the manufacturing of various bioproducts. From algal-based
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biofuel production processes, “waste” streams can be generated and utilized for the
production of other value added products, thus reducing the overall production cost of the
biofuel. The method of creating a sustainable biorefinery can draw parallels to a
traditional chemical refinery system, where production of specialty chemicals is market
driven.
In the United States over 7,000 lagoon systems are used to treat domestic
wastewater. The city of Logan, Utah processes approximately 15 million gallons per day
of its wastewater in a 460 acre open pond facultative lagoon system. Microalgae grown in
these ponds can be harvested and processed with a wet lipid extraction procedure
(WLEP). The WLEP produces 4 streams, and one stream (aqueous phase) can be used to
culture recombinant E. coli. As an example, growing PHA producing bacteria in an
aqueous phase algal medium can potentially make PHA production sustainable. The
approach of utilizing “algae-waste” as a substrate for biomaterial production could
potentially make the process of PHA and other recombinant product manufacturing
sustainable.

2.

Significance
The impact of the studies presented in this dissertation could have far reaching

implications. Synthetic biological engineering holds the promise for production of
bioproducts but the “bench-to-market-barrier” needs to be overcome. If PHAs are able to
be successfully secreted with synthetic biological engineering techniques, the process can
be further engineered to a larger scale using bioreactors. Preliminary studies have already
been completed with scale-up of the process and results thus far are encouraging.
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Using synthetic biological engineering to produce other biomaterials such as
synthetic spider silk can also create many new applications. Spider silk has highly
desirable properties, which from a materials engineering standpoint could replace
traditional manmade materials. The goal to engineer bacteria to express a range of sizes
of spider silk protein at a higher level can lead to a variety of potential applications.
The production of algae-based bioproducts sustainably has great implications to
society as a whole. Remediation of wastewater systems with algae to remove nitrogen
and phosphorus, along with the subsequent harvesting and bioproduct generation has the
potential to impact everyday lives. The addition of PHA production to an algal
biorefinery model could potentially help make algae bioproducts economical and
sustainable in the future.

3.

Format of Dissertation
This dissertation is structured in a multiple paper format and with the exception of

Chapter 2, all subsequent chapters have been formatted as publications. Chapters 4, 7,
and 8 were published prior to the completion of this dissertation.
The initial chapters are a review of the literature: Chapter 2- “Literature Review”
and an explanation of synthetic biological engineering: Chapter 3- “BioBricks to
Bioproducts: The case for Synthetic Biological Engineering.” Chapter 4- “Secretion of
Polyhydroxybutyrate in Escherichia coli using a Synthetic Biological Engineering
approach” studies the process of type I secretion of polyhydroxybutyrates (PHB) from E.
coli (published). Chapter 5- “A Synthetic Biological Engineering approach to
understanding type I secretion of polyhydroxybutyrates from Escherichia coli” explores
secretion of GFP-tagged PHB granules from E. coli. The focus of Chapter 6-“A Synthetic
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Biological Engineering approach to produce Argiope aurantia spider silk in Escherichia
coli” is to biomanufacture spider silk in E. coli using synthetic biological engineering
techniques.
The next part of the dissertation focuses on production of bioproducts from
wastewater microalgae. Chapter 7- “Bioremediation of domestic wastewater and
production of bioproducts from microalgae using waste stabilization ponds” is an
editorial (published) on the potential of wastewater microalgae to make bioproducts.
Chapter

8-

“Effects

of

wastewater

microalgae

harvesting

methods

on

polyhydroxybutyrate production” is a research article (published) on the conversion of
wastewater microalgae to polyhydroxybutyrates (PHB). Finally, Chapter 9- “Summary”
reviews the work presented in the dissertation and provides details on potential future
work.
The appendix contains an additional manuscript on bioproduct production from
algae. Additionally, the appendix also includes front covers of three patent applications
related to the work carried out in this dissertation. All strains, constructs, and
oligonucleotides used in this study are also provided.
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CHAPTER 2
LITERATURE REVIEW

1.

Motivation for study
Plastics are a large part of everyday life. Over the last 70 years synthetically made

plastics derived from petroleum have been produced in significantly large quantities. It
has been well documented that fossil reserves are a finite resource and our dependence on
plastics has added to the pressure on petrochemically derived products. In 2010
approximately 190 million barrels of liquid petroleum were used in the United States to
produce plastics. Additionally, approximately 400 billion cubic feet of natural gas was
used to produce other plastic products [1]. Petroleum and natural gas derived plastics are
generally non-biodegradable and can be toxic to the environment.
One of the major concerns with petroleum derived plastics is that they accumulate
in landfills. A study by the United States Environmental Protection Agency (EPA) found
that plastics account for approximately 13% (or 32 million tons) of all municipal solid
waste (MSW) before recycling in 2011, Figure 2.1 [2]. After recycling, the proportion of
plastics in the MSW system goes up to approximately 19% as most petroleum derived
plastics cannot be recycled. Petroleum derived plastic production has steadily increased
since 1960 (Figure 2.2) but as a percentage of MSW has increased from 1% (in 1960) to
13% (2010) which poses problems for both the petrochemical industry and local
municipal councils [2].
As worldwide demand for plastic based products continues to grow, production
will likely continue to increase, adding stress on our infrastructure. At this current rate,
the continued use of petroleum based plastics is not sustainable. While plastic recovery
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through recycling (Figure 2.2) has increased since 1990 it is not able to keep up with
plastic production levels. Alternative means of producing plastics in large quantities
which are both economically and environmentally friendly have gained considerable
attention recently [3]. Part of the challenge of alternative plastic production is that the
raw plastic product needs to have comparable properties to petroleum derived plastics. If
the properties of this new plastic are similar, then the final plastic products could be the
same as petroleum derived plastics. This “drop in” technology is currently desired in the
alternative energy sector where energy generation needs to fit current systems to avoid
additional cost of changing infrastructure [4].

Figure 2.1. Total United States Municipal Solid Waste Generation in 2011 (Before
Recycling, modified from: EPA report 2013 [2]).

million tons

8

year

Figure 2.2. Plastic generation and recovery in the United States from 1960 to 2011
(modified from EPA report 2011 [2]).

2.

Bioplastic companies
Economic and sustainable production of bioplastic is a global problem. Different

companies around the world are pursuing the possibilities of a bioplastic economy. In
conducting a thorough literature search only one recent study compared the production of
ten different commercial polyhydroxyalkanoates [5]. To understand the impact that
bioplastic has in the global market, an internet based survey was conducted to evaluate
the different bioplastic commercial ventures around the world. The survey explored the
geographic location of companies, types of bioplastics produced by the companies,
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applications of bioplastics, and primary carbon substrate of the plastic produced.
Additionally, intellectual property was also briefly surveyed.
It was found that the word “bioplastic” is a term loosely used by many companies
that produce plastics that are either: 1) completely biological in origin, 2) biodegradable,
or 3) in part biologically derived. In addition, only information obtained from the
company website was used to create the figures and charts seen in this section of the
dissertation. Active bioplastic companies were surveyed exclusively and non-active
companies were disregarded from the survey.

2.1

Global distribution of companies
A total of 97 companies were surveyed from across the world and it was found

that bioplastics companies were active in Europe, Asia, Oceania, North America, and
South America. There were no active bioplastic companies found in the African continent
when this survey was conducted. Figure 2.3 shows the global distribution of bioplastic
companies marked in red. Figure 2.4 shows the share of each continent’s bioplastic
companies. North America and Europe have the majority of the bioplastic companies
with over 74 companies out of the 97 located in these two regions (76% of total). Not all
the companies surveyed were exclusively producing bioplastics, for many of the
companies bioplastic were a secondary product that was being manufactured. This is an
interesting observation, as it suggests that for a bioplastic company to thrive it needs to
take a combined approach (in producing more than one product) in order to be profitable.
The value of a combined approach to producing multiple bioproducts on a single
manufacturing platform will be discussed in a later section of the dissertation.
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Figure 2.3. Worldwide distribution of bioplastic producing companies. Red dots are
individual companies with their approximately location in each respective country. 97
bioplastic producing companies are represented on the map.

4%
North America

20%
41%

Europe
Asia
Oceania

35%

Figure 2.4. Location of bioplastic producing companies around the world.
2.2

Type of bioplastic manufactured
From the different companies surveyed there was a wide range of biopolymers

that each produced. Figure 2.5 shows the variety of bioplastics that the different
companies manufactured. This survey found that not all companies reported on their
website what type of bioplastic was produced either for proprietary reasons or lack of
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large scale manufacturing. Polylactic acids (PLAs) had around 25% share of the
bioplastics produced. This is not surprising as many products made from PLAs have been
approved by the United States Food and Drug Administration (FDA) for human use [6].
PLAs while biological in origin, (e.g. derived from corn starch) are typically
manufactured with an inorganic catalyst. Polyhydroxyalkanoates (PHAs) and
polyhydroxybutyrates (PHBs) make up approximately 12% of all bioplastic production
and are produced exclusively in bacteria. PHA polymers hold many advantages such as
having high diversity of branched side groups and being biodegradable. Having a variety
of branched groups gives PHAs a wide range of possible applications as these side groups
affect the chemical and physical properties of the biopolymer.

PLA

10
18

PHA

3

PHB
TPU/TPS

5

Unclassified or No Data
Blends

27

4
3

Other

Figure 2.5. Types of bioplastic polymers produced commercially.
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Miscellaneous
Transportation
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Figure 2.6. Commercial applications of bioplastics.
2.3

Commercial bioplastic applications
There are many applications observed for currently available bioplastics (Figure

2.6). Of the companies surveyed, the majority had applications in agriculture and
packaging. Most packaging plastics have a lifetime of 1 year or less from the time of
production to disposal and continue to accumulate in landfills, thus having an alternative
biological plastic would seem like an ideal solution. Food related plastics such as cups,
dishes, cutlery, and bottles are also plastic products that have a short lifetime therefore
landfills would also benefit from a plastic that is biodegradable.

In addition, the

motivation for the company to produce a particular plastic is two-fold. Either the
application of the plastic is the driving force, or the primary carbon substrate locally
found is the motivating factor for production. The primary carbon substrate will
determine the type of plastic produced and hence the application.

2.4

Carbon substrate
Geographically, bioplastic companies are located close to the primary carbon

substrate source used produce the respective bioplastic. For instance, in North America
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companies located in the Midwest typically use corn or other starchy crop based carbon
substrates for production of bioplastic. In the Pacific Northwest, tree based carbon
substrate are used for bioplastic production. Figure 2.7 shows the type of carbon based
compounds that are used for bioplastic production purposes. The most common source
for bioplastic production is a plant based carbon substrate.
In order for the bioplastic industry to be sustainable, a consistent carbon substrate
source is paramount to its success. A carbon substrate that is a finite resource such as
crude oil for petroleum products is not sustainable. Additionally, crop based carbon
substrates such as corn, potatoes, and sugar beet are not feasible as long term sustainable
carbon substrates, as many of these crops are grown on fertile land that would be more
suited for food production that plastic production. Furthermore, the cost associated with
production of such crop-based plastics will not make the resulting bioplastic costcompetitive with petroleum based plastics. An ideal carbon substrate would be renewable
wastes or a waste product of another process, thus effectively making the carbon source
free. Some potentially sustainable carbon substrates could be algal based carbon
substrates from algae cultivation on wastewater or waste products from cheese
manufacturing that could be used to produce bacterial based bioplastics such as PHAs.
Starch
12%

18%

Unknown Feed Stock
12%

Simple Sugars
Oils and fats

39%
15%

Products that form naturally in plants
and other complex organisms
Other Organic

4%

Figure 2.7. Carbon substrates for industrial bioplastic production.
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2.5

Intellectual property
Another discussion point is the number of bioplastic patents issued in each of the

respective parts of the world. From the internet based search approximately 2,000 such
patents exist. Of these patents, over 50% were issued in Asia, 20% in Europe, and 25% in
North America. The remaining percentages of patents were issued in South America,
African, and Oceania. While Asia having 50% of the bioplastic patents may come as a
surprise seeing that North America and Europe have the majority of the bioplastic
companies, it should be noted that patent filing in each respective country is different.
Another explanation for the disparity between Asia and the rest of the world is that Asia
has a larger population and hence a greater need for alternative sources of plastic
material, thus more intellectual property. With the population in Asia and Africa set to
expand in the foreseeable future it is expected that the number of patents issued in these
regions will also continue to grow.

2.6

Conclusions and future work
The survey shown in this section shows the many potential possibilities with

regards to bioplastic production. There are different ventures across the world that are
pursuing the possibilities of large scale production of bioplastics.
Although the survey carried out was extensive, it was not comprehensive. This
survey was insightful and provided motivation for some of the studies conducted in this
dissertation, to get a complete understanding of commercial bioplastic ventures, a
comprehensive survey will need to be conducted. This was not carried out here as it was
beyond the scope of the dissertation and due to significant time constraints in conducting
a full survey. A comprehensive study would involve sending a detailed survey to each
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company and compiling the results into similar figures seen above. The detailed survey
would also ask questions such as: cost of manufacturing, specific type of polymer
produced, and quantity of polymer produced per day. Additionally, a statistical analysis
could also be performed on the data.

3.

The case for polyhydroxyalkanoates
Replacing

traditional

plastic

with

biodegradable

plastic

such

as

polyhydroxyalkanoates (PHA) could potentially reduce total MSW waste by up to 20%
[7]. Polyhydroxyalkanoates (PHA) are produced by a variety of microorganisms (e.g.
Ralstonia eutropha, and Cyanobacteria) as an intercellular storage medium for energy
and carbon and can accumulate up to 90% of the cell dry weight [8].
PHAs are biodegradable polymers. The biodegradability can range from
approximately several months to several years [8]. There are 155 different confirmed
types of PHA monomer subunits, each with varying monomer repeat number and side
groups [9]. This means that PHAs have a variety of possible applications, thus if scaled
up could replace traditional plastics derived from petroleum [5]. Some of the possible
applications of PHAs include: packaging, medical, agricultural uses [10], and more
recently in carbon nanotubes [11]. PHAs was first identified by Lemoigne in 1926 [12]
and Henry Ford made a vehicle out of plastic derived from soy fibers in 1941, thus
demonstrating that applications for biologically derived plastic have been ongoing since
before World War II [13].
The general polymer structure of PHA is shown in Figure 2.8. The PHA molecule
contains an ester group hence makes this type of polymer biodegradable via hydrolysis.
The most studied PHA is polyhydroxybutyrate (PHB), where R is a methyl (CH 3). PHB
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has a melting temperature of approximately 179oC [14] and crystallinity between 3070% [15]. The molecular weight of PHAs can range from 2x105-3x106 Da, and this
weight range is dependent on the microorganism or carbon substrate used [10].

Figure 2.8. General structure of PHA where the R side chain variation gives the PHA
different chemical properties. If R is methyl (-CH3) this polymer is known as
polyhydroxybutyrate or PHB.

If R is an ethyl (-C2H6) this is known as

polyhydroxyvalerate (modified from:[14]).

To demonstrate that PHB can be used to replace petroleum based plastics Table
2.1 compares some of the physical properties. The mechanical properties of PHB are
comparable to polypropylene and polystyrene in terms of melting temperature, Young’s
modulus and tensile strength. This is advantageous in two ways: Firstly, replacing
petroleum based plastics or creating hybrid polymers with PHB is possible and secondly,
downstream processing equipment such as extruders, molders, and reactors can be used
to process the PHB polymer.

Table 2.1. Properties of some common petrochemically derived plastics compared with
polyhydroxybutyrate (Adapted from: [14]).
Polymer

Melting Point (oC)

PHB
Polypropylene
Polystyrene

179
170
110

Young’s Modulus
(GPa)
3.5
1.7
3.1

Tensile strength
(MPa)
40
34.5
50
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3.1

Polyhydroxybutyrate genetic system and pathway
The production of PHB can be carried out in either wild type bacteria or

recombinant bacterial systems. Wild type bacterial PHB production is seen in (not limited
to)

Cupriavidus

necator,

Rhodopseudomonas

palustris,

and

Methylobacterium

organophilum [10]. Recombinant systems could include E. coli and Cyanobacteria [16,
17].
For scale up and large scale production of PHB E. coli is generally seen as an
ideal candidate due to relatively simple cultivation and ease of downstream processing of
bioproducts that are produced. The PHB producing genes from R. eutrophus (previously
known as Alcaligenes eutrophus) were successfully cloned, identified, and subsequently
expressed in E. coli by Schubert et al. [12]. The study by Schubert et al. was able to
demonstrate up to 30% of cellular dry mass as PHB [12]. Spiekermann et al. cloned in the
three gene PHB cassette from R. eutrophus into the plasmid pBHR68 [16]. The pBHR68
plasmid is widely used in recombinant E. coli systems for the production of PHB.
The pathway to produce PHB from acetyl-CoA is depicted in Figure 2.9. Three
genes encoding for beta-ketothiolase (phbA), acetoacetyl-CoA Reductase (phbB), and
PHB polymerase (phbC) (or PHB synthase) are required for production of PHB [9].
Figure 2.9 shows two acetyl-CoAs are condensed to acetoacetyl-CoA with βketothiolase, the acetoacetyl-CoA is reduced to 3-hydoxybutyryl-CoA with acetoacetylCoA reductase. Polymerization with PHB polymerase occurs as a step-wise process as
shown in detail in Figure 2.10. Figure 2.10A shows the PHB polymerase and three
conserved amino acids: histidine, aspartic acid, and cysteine. A proposed theory suggests
that a catalytic triad is formed when two PHB polymerase come together. The histidine
activates the thiol group of the cysteine, which in turn carries out a nucleophilic attack on
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the thioester bond of the 3-hydoxybutyryl-CoA, this is now a 3-hydroxy-fatty acid
attached to the cysteine as shown in Figure 2.10B. Since there are two PHB polymerase
together in a catalytic triad a second 3-hydroxy-fatty acid attached to the cysteine would
be present as shown in Figure 2.10C. The aspartic acid of the first PHB polymerase
activates the hydroxyl group of the first 3-hydroxy-fatty acid. The first 3-hydroxy-fatty
acid then attacks the thioester bond on the second 3-hydroxy-fatty acid attached to the
second PHB polymerase (Figure 2.10C). This is the beginning of the first monomer units
coming together to start a polymerization process (Figure 2.10D). This process is
repeated with new 3-hydroxy-fatty acid molecules adding to the growing polymer chain,
while the PHB molecule remains covalently attached to the PHB polymerase (Figure 2.10
D and E) [18].
In addition to understanding the genetic mechanism for PHA production, the
formation of PHA granules has gained interest recently. As the PHA polymer is being
created, the PHA synthase remains covalently attached and forms an amphipathic
molecule with hydrophilic (polar) and hydrophobic (non-polar) ends, this aids in the
formation of a PHA granule [19]. A typical PHA granule is shown in Figure 2.11, with
associated proteins attached [15]. A study by Peters and Rehm 2005 demonstrated that
the PHA granule localization begins at the polar regions of the cell [20]. A study by
Tomizawa et al. demonstrated that the PhaC synthase can adversely affect the molecular
weight of the PHA generated; this is of interest as the molecular weight range can
significantly affect the downstream processing of PHA [21]. In addition, the phasin
protein is another protein which is bound to the PHA granule. Studies have shown that
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phasin proteins play an important role in PHA granule formation as they are tightly
bound to the PHA core as shown in Figure 2.11 [22].

Figure 2.9. General pathway used to produce PHB from Acetyl CoA using a three protein
system. Proteins (blue) β-ketothiolase (phbA), acetoacetyl-coA reductase (phbB), and
PHB polymerase (phbC). Species and compounds (green). Note: CH3 group can change
depending on substrate.
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Figure 2.10. A, B, and C. Catalytic mechanism of PHA synthase part I. (adapted from:
[18]).
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Figure 2.10. D, E, and F. Catalytic mechanism of PHA synthase part II. (adapted from:
[18]).
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Figure 2.11. Characteristic of a PHA granule showing the PHA core and proteins
adhering to the granule. PhaC and Phasin are commonly found on the surface of a PHA
granule (adapted from: [15]).
4.

Isolation and recovery of non-secreted PHAs
A bottleneck in scaling up PHA production is the isolation of the PHAs. Currently

techniques that are used to isolate PHA from E. coli are invasive and generally use toxic
chemicals. These techniques involve lysing open the cellular membrane prior to isolation
of the PHAs. There are a variety of methods that have been suggested in recovery of
PHAs from microorganisms such as: organic solvent extraction, enzymatic digestion, and
extraction using supercritical CO2. These methods present the problems of cost,
scalability, and viability of the biomass after such harsh treatment procedures [3]. A
detailed review of the different PHA isolation methods is outlined in Jacquel et al. [23].
There are a number of different methods that have been used to purify and isolate
PHAs from microbes. The problem with the use of current methods is that the biomass
cannot be reused for PHA production. A review by Jacquel et al. highlighted the
techniques that are currently being employed to extract PHAs from microorganisms. The
main isolation methods can be placed into four major categories: Solvent extraction,
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digestion, mechanical disruption, and others [23]. Table 2.2 provides the major extraction
methods.
All the aforementioned PHA isolation methods mentioned in Table 2.2 are
invasive methods of PHA isolation. As discussed earlier, it is desired to develop a
technique that will not harm the cell culture, rather, allow for it to be recycled. In
addition, these methods present further complications such as: the solvent extraction can
be highly toxic (due to the use of halogens), digestion methods can degrade the polymer,
and enzymatic digestion is expensive. Most of these approaches present major hurdles
with regard to scale up of the downstream processes involved in extraction and
purification of PHA.

Table 2.2. Summary of the different techniques used to extract PHAs from various
microorganisms (adapted from: [23]).
Extraction Method
Solvent Extraction
Digestion
Chemical Digestion - surfactants
Digestion by sodium hypochlorite
Digestion by sodium hypochlorite
and chloroform
Surfactant- hypochlorite digestion
Surfactant- chelate digestion
Enzymatic digestion
Mechanical disruption
Breadmill disruption
High pressure homogenization
Centrifugation and chemical
treatment
Others
Supercritical fluid
Using cell frugality
Dissolved air flotation

Reference
[24], [25], [26]
[27], [28]
[29]
[30], [31], [32]
[33]
[27]
[34], [35], [36]
[37]
[38], [37]
[39]

[40], [41]
[42], [43], [44]
[45]
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5.

Development of a PHA secretion system
The development of a secretion mechanism eliminates the need for cell

disruption by mechanical or chemical means, and may lead to continuous (or semicontinuous) PHB production systems. In gram-negative bacteria like E. coli, compounds
are exported via six major secretory pathways [46-49]. Recombinant proteins can be
targeted to type I and II secretory pathways through genetic fusion with signal peptide
targeting sequences.
PHAs are non-proteinaceous polyesters and therefore cannot be directly targeted
for translocation by signal peptide fusion. Phasins are low-molecular weight proteins that
play a role in PHA granule formation by binding to the PHA granule surface [22, 50].
Phasins are structural proteins found in organisms that naturally produce PHAs and are
similar in function to oleosins which are found in plants [50, 51]. Currently, oleosins are
used to purify various compounds such as pharmaceuticals from plants [52].
Translocation of PHAs is possible through optimization of granule size, which
reportedly varies from 50 to 1,000 kDa based on growth parameters and host strain [8].
One of the functions of phasin is to increase the surface-to-volume ratio of granules so
that higher accumulation levels can be achieved [22, 53, 54]. Therefore, the size of the
PHA granule can be decreased significantly through phasin overexpression. In one such
study, overexpression of phasin resulted in a decrease of PHA granules from 70-310 nm
diameter to 20-60 nm [53].
Type I secretion is a simple one step secretion system that can translocate proteins
from the cytoplasm to the extracellular medium without protein interaction with the
periplasm [55].

Proteins of nearly 900 kDa (large adhesion protein, LapA) have
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reportedly been secreted to the extracellular milieu by the type I secretory mechanism of
gram-negative bacteria [56, 57]. Specifically using the Hemolysin (HlyA) secretion
mechanism proteins such as β-galactosidase (117 kDa) [58], β-gal-OmpF (56 kDa) [59],
and green fluorescent protein (GFP) (27 kDa) [60] have been secreted by E. coli. The
physical characteristics of the secretion channel are approximately 3.5 nm in diameter
with a length of 14 nm as reported by Fernández et al., which makes the secretion
phenomena of large proteins very interesting [61].
A synthetic biological engineering approach has been previously used to
demonstrate the feasibility of HlyA, GeneIII, PelB, and TorA secretion systems in E. coli
with the use of GFP [60]. From the aforementioned study, the type I secretion system
using the HlyA signal peptide yielded the best results for secretion of GFP outside of the
cell and into the medium [60].
Secretion of PHA from E. coli can reduce downstream processing costs by using
less invasive recovery methods, and elimination of the use of toxic chemicals, in addition
the biomass can be recycled. Therefore, scale up and downstream processing of
bioplastics can potentially be economically viable.
The positive impacts of this new technique of PHA isolation can be summarized
as follows:
·

Allows the recycling of microbial biomass as it will not be damaged/lysed

·

Non-invasive technique used, thus also reducing the damage to the
product

·

Can potentially be a continuous/semi continuous process

·

Minimize use of toxic solvents for extraction
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6.

Analytical methods to analyze polyhydroxyalkanoates
There are a variety of different methods to detect, analyze, and quantify PHB

produced from microorganisms. These methods include: Gas Chromatography (GC),
Nuclear

Magnetic

resonance

(NMR),

Gel-permeation

chromatography

(GPC),

Differential Scanning Calorimetry (DSC), and Thermogravimetric analysis (TGA).

6.1

Gas chromatography (GC)
Purpose: Detection, purity, and recovery
Gas chromatography is a process used in PHA detection and concentration

determination. PHA polymers are hydrolyzed and methylated to produce volatile
monomers [62], these volatile monomers are processed through GC and compared with
standards. In the case of PHB, it is converted to 3-hydroxybutyrate (bpt 144 oC) and
analyzed with GC.

Jian et al. used a GC method to determine PHA content and

composition. The parameters used were oven temperature of 80oC for 1.5 min, which was
changed to 140oC at a heating rate of 30oC/min and then heated to 220oC at a rate of
40oC/min. Temperature of the injection and detector were 200oC and 220oC [63]. Another
study by Hahn et al. used GC as a method of determining purity and recovery of PHB. In
this study GC was used following the methods outlined in Linton et al. [64]. This GC
method was a modification of the Branunegg et al. method using acidified methanol to
convert PHB to 3-hydroxybutyrate [65].

6.2

Nuclear Magnetic Resonance (NMR)
Purpose: Detection and structure
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NMR was used by Hahn et al. as a method of detection and structure
determination of PHB [66]. In this study quantitative NMR was used following the
methods outlined in Linton et al. [64], where standard curves were created linking NMR
spectra integration with GC results.

6.3

Gel-permeation chromatography (GPC)
Purpose: Molecular weight
Gel-permeation chromatography (GPC) is a standard method used to determine

the molecular weight of polymers. C.W. Lo et al. used GPC as a method to determine
molecular weight of polymers, especially PHB polymers. C.W. Lo et al. mentions that a
polymer/chloroform solution (0.01g/2ml) was used as the loading solvent on two styragel
columns. The flow rate used was 1.0 ml/min at 40oC, and the system was calibrated with
a narrow range polystyrene standards. The narrow range polymer standards were used
since it would then be easier to determine the molecular mass of the PHB [67]. Hahn et
al. 1995 also used GPC as a method determining molecular weight of the samples.
Polystyrene was used as the molecular weight standards with 100 µl of PHB sample
(0.1% wt/vol) was used [66].

6.4

Differential Scanning Calorimetry (DSC)
Purpose: Melting point and crystallinity
DSC is used to measure the melting temperature of PHB. C.W. Lo et al. used a

DSC with a temperature range of -40 oC to 200 oC and a heating rate of 10 oC/min [67].
Hahn et al. used the DSC as a method for melting point determination, and in addition
also uses DSC to determine the crystallinity of the resulting PHB [66].
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In this study a TA instruments DSC 2910 Modulated DSC machine was used to
determine the melting temperature of the PHA. Nitrogen was used as the coolant and air
was used to purge the system. Five milligrams of PHA sample was loaded in a DSC pan
with a lid. The initial temperature was set to 25 oC and held for 1 min. The pan was
heated at a rate of 5 oC/min and heated to 220 oC where the temperature was held for 1
min. Integration of the peak melting temperature was carried out with the computer
software.

6.5

Thermogravimetric analysis (TGA)
Purpose: Decomposition temperature
Hahn et al. used TGA as a means of determining the thermal stability of PHB.

The TGA in this study was operated with a nitrogen flow rate of 20 ml/min and a
scanning rate of 10 oC/min [66].

7.

Polyhydroxyalkanoate imaging techniques
In order to fully understand PHA localization and secretion, different imaging

methods can be employed.

7.1

Fluorescence microscopy
As mentioned previously, the PHA synthase remains covalently attached to the

PHB granule and phasin is targeted for secretion. A study by Peters et al. demonstrated
the fusion of green fluorescent protein to phaC to visualize PHA location in E. coli [20,
68]. If this system can be included in the PHA secreting system it could help understand:
1) from where PHA secretion is occurring and 2) when secretion takes place. E. coli
could be visualized using a fluorescent microscope.
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7.2

Scanning electron microscope (SEM)
SEM is widely used in material science to visualize surfaces of metals and

plastics. Table 2.3 shows SEM’s use with PHA visualization. Clearly SEM is not widely
used for PHA analysis as a surface topographical analysis is of little use. In the case of
secretion however, SEM can provide an image of what is occurring at the surface of the
bacteria when secretion is occurring.

7.3

Transmitting Electron Microscope (TEM)
TEM allows visualization of internal granules of PHB as cross sections of bacteria

can be visualized. Table 2.4 demonstrates that TEM is widely used as an imaging method
to visualize PHB granule formation in a variety of microorganisms. TEM could also be a
useful tool to help understand secretion of PHAs from E. coli.

Table 2.3. Studies using scanning electron microscope (SEM) to visualize
polyhydroxyalkanoates.

Organism

Type of Polyhydroxyalkanoate

Reference

E. coli

PHB

[86]

Comamonas sp.,

PHA

[92]

Pseudomonas
Lemoignei

PHA

[92]

Pseudomonas
Fluorescens GK13

PHA

[92]
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Table 2.4. Different studies that utilize Transmitting Electron Microscope (TEM) for
polyhydroxyalkanoate granule visualization.
Organism

Type of Polyhydroxyalkanoate

Reference

Cupriavidus necator, Pseudomonas
mendocian, and Rhodococcus opascus
Pseudomonas putida KT2442mmi_7450
402..418

PHA

[69]

PHA

[70]

Comamonas sp. EB172

PHBV

[71]

Pseudoaltermonas sp. SM9913

PHA

[72]

Rhodobacter capsulatus

PHB

[73]

Ralstonia eutropha strain A-04

P(3HB-co-4HB)

[74]

E. coli

Unknown biopolymer

[75]

Pseudomonas aeruginosa 42A2

PHA

[76]

Rhodobacter
sphaeroides

PHB

[77]

Caryophanon latum

PHB

[78]

E. coli MG1655

PHB

[79]

W. eutropha H16

PHB

[80]

W. eutropha

PHB

[81]

Wautersia eutropha H16
R. eutropha

PHB
PHB

[82]
[83]

P.putida

[84]

E. coli JM109 pBPP1

PMV

[85]

E. coli

PHB

[86]

E. coli JM109 pBPP1

P(3HB-co-5 mol% 3HHx)

[87]

Pseudomonas putida

[88]

E. coli (pTZ18U-PHB, pSH2)

[89]

Pseudomonas lemoignei

PHB

[90]

Bacteria (unknown)

PHB

[91]
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8.

Using synthetic biology to optimize spider silk production in E. coli
Synthetic biological engineering could be used to secrete PHAs outside of an E.

coli cell. Similarly, optimization of spider silk DNA sequences for the purposes of
increased production using synthetic biological engineering could also be carried out.
Spider silk is an ancient biomaterial with remarkable properties. Orb-web
weaving spiders have seven different types of silk glands, with each gland producing
different spider silk protein each with unique characteristics [93]. Interestingly, dragline
spider silk has a strength of approximately 4x109 N/m2 and energy to break of 4x105 J/kg
[94]. These mechanical properties similar or more superior to other more commonly used
materials such as Kevlar and rubber [94]. In the future there could be a possibility for
these spider silk proteins to replace currently available materials if the spider silk protein
can be produced in large qualities and specific application-based downstream processing
conducted.
One of the six different fibers that orb weavers can produce is the major ampullate
dragline silk. Dragline silk consists of two proteins: the major ampullate spidroin 1 and 2
(MaSp1 & MaSp2) [95] and can be produced in different species of spiders such as
Nepila clavipes and Argiope aurantia [96].
Due to the fact that spiders are territorial, cannibalistic, and that the actual spider
web silk which is spun by a spider is an average of at least four different silks, it is not
desirable to manufacture spider silk on a large scale using spider farms. These
confounding factors mean that an alternative spider silk production mechanism (such as a
synthetic biological engineering approach) is necessary.
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Dragline spider silk has been expressed in a few different organisms: yeast [97],
plants [98], silkworms [99], mammalian cells [100], and Escherichia coli [101]. Each
host production system has its advantages and disadvantages ranging from yield of
protein generated, cost of production, and production time [102].
From the different aforementioned host organisms, Escherichia coli is
advantageous as it offers a quick and efficient system for DNA propagation and doubling
time of approximately 20 min. Additionally, purification of protein from E. coli is well
established and can be cost effective. Several studies have expressed different dragline
spider silk proteins in E. coli: Xia and colleagues produced 55-285 kDa MaSp 1 Nephila
clavipes spider silk protein [103], a study by Lewis et. al demonstrated production of 31112 kDa MaSp 2 spider silk protein of N. clavipes [104], and Brooks et al. produced
MaSp 2 protein from A. aurantia [101].
E. coli was chosen as the organism to express genes from the spider Argiope
aurantia in this study. Spider silk genes are generally simple, yet highly repetitive in
nature so choosing a suitable cloning technique to assembly genes together is an
important factor to consider which designing an expression system. An article by
Tokareva and colleagues highlight some of the different cloning approaches for
recombinant spider silk production systems [102]. A novel cloning method is to use
synthetic biological engineering and BioBrick™ standard assembly [105], multiple
repeats of the spider silk subunit can be assembled together quickly and easily. Another
advantage of using BioBrick™ standard assembly is that different sizes of spider silk
repeat units can be assembled together to produce a variety of different synthetic spider
silk sizes. Different sized spider silk protein could lead to many potential applications. A
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typical MaSp 2 protein from A. aurantia only has six amino acids of which, 44% are
glycine. With the highly repetitive nature of spider silk sequences, the available tRNA
pool in E. coli could be diminished, thus engineering the DNA sequences of MaSp 2 with
specific tRNAs, could substantially increase the yields of spider silk produced in E. coli.
In addition to designing a suitable cloning and expression system for spider silk
expression system in E. coli, an efficient purification system is required. In previous
spider silk expression systems in E. coli, cells were lysed and protein purified from a cell
lysate. One study used a chemical based method where cell lysate was acid precipitated
and spider silk protein was soluble under acidic conditions. An additional step of
ammonium sulfate precipitation further enhanced recover with a purity of close to 90%
[103]. Another chemical treatment method utilized propionic acid and bacterial proteins
were clarified via centrifugation [106]. One of the most commonly used methods for
protein purification is immobilized metal ion affinity chromatography (IMAC). Bacterial
cells are lysed and the mixed protein solution is passed over a metal immobilized column,
typically for spider silk protein purification, nickel is used as the immobilized metal and
the protein is tagged with a histidine residue [101, 104, 107]. Histidine affinity tags for
protein purification can yield in 90% of protein recovery and can be easily scaled up, thus
giving it many advantages over other methods [108, 109].

9.

Production of biomaterials from unrelated carbon sources
As mentioned previously, the economic production and scale-up of biomaterials is

dependent on a cheap carbon substrate. The cheapest carbon substrate is one that is
completely free and is a waste product of another process. Previous studies have
demonstrated production of PHB from: anaerobic digesters [64], food wastes [110], and
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waste glycerol from biodiesel production using a variety of microorganisms [111].
Interestingly, the use of different carbon sources can create PHA polymers with different
properties. For example propionate addition can be used to produce co-polymers of PHB
and polyhydroxyvalerate (PHV) [112]. To our knowledge, the production of synthetic
spider silk from E. coli grown in waste carbon substrates has not been previously
demonstrated.
Microalgae have been extensively studied as a feedstock for biodiesel production
[113]. High growth rates, low fresh water requirement, and high photosynthetic
efficiency are few of the important characteristics that have made microalgae the obvious
choice as a biodiesel production platform [114]. Microalgae can remediate wastewater by
assimilating phosphorus and nitrogen as growth nutrients, thereby achieving tertiary
treatment [115]. In the United States over 7,000 lagoon systems are used to treat domestic
wastewater (U.S EPA, 2002, Report No. EPA 832-F02-014) [116]. Lagoon systems
represent one solution to wastewater treatment and are suitable for developing countries
and rural areas. The city of Logan, Utah processes approximately 15 million gallons per
day of its wastewater in a 460 acre (~1.9 km2) open pond facultative lagoon system
shown in Figure 2.12. This system consists of seven ponds with an average depth of five
feet (~1.5 m). Microalgae grown in these ponds can be harvested to provide a sustainable
supply of biomass for bioproduct generation [116].
Algae harvested (chemically or mechanically) from the lagoons can be processed
through the wet lipid extraction procedure (WLEP) creating four streams (as illustrated in
Figure 2.13), three of which have been previously utilized [117, 118]. The first stream
(hydrolyzed algal biomass) was used to generate acetone, butanol, and ethanol (ABE) by
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Clostridium saccharoperbutylacetonicum N1-4 fermentation [119]. The remaining two
side streams, the lipid extract and resultant aqueous phase can be used to produce
biodiesel and to grow genetically engineered E. coli respectively.

Figure 2.12. 460 acre facultative lagoon system in Logan, UT treating 15 MGD domestic
wastewater.

This aqueous phase from this process is the most useful for culturing E. coli and
was demonstrated to give growth up to 1012 CFU/mL that is comparable to standard E.
coli growth media [118]. Evaluating the effects of various wastewater microalgae
harvesting techniques on the resulting algae-based media (from WLEP) to support E .coli
growth and production of bioproducts will be important moving forward.

10.

Summary
To summarize, large scale production of recombinant biomaterials (PHA and

spider silk) is currently hindered by two main factors: 1) downstream processing to
separate the bioproduct from the biomass, and 2) the cost of the carbon source. These two
issues can be address by: 1) using synthetic biology to optimize production and 2) using a
wastewater based algae carbon substrate.
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Figure 2.13. Wet lipid extraction procedure to produce various bioproducts from a wet
algal feedstock (adapted from: [118]).

11.
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CHAPTER 3
BIOBRICKS™ TO BIOPRODUCTS: THE CASE FOR SYNTHETIC
BIOLOGICAL ENGINEERING

1.

Abstract
The foundations of synthetic biological engineering are built on molecular

biology and genetic engineering. One of the purposes of synthetic biological engineering
is to make biology easier to engineer by the creation of standardized biological parts and
devices. There are a wide range of potential applications for synthetic biological
engineering and a variety of approaches to constructing parts and systems. The focus of
this commentary is two-fold: 1) to explain abstraction and standardization of biological
systems, and 2) briefly review the production of bioproducts created from standardized
biological parts (BioBricks™) at the annual International Genetically Engineered
Machine (iGEM) competition.

2.

What is synthetic biological engineering?
Synthetic biological engineering approaches biology from an engineering

perspective to benefit society by: making new chemicals, aiding in healthcare, and
alleviating environmental concerns [1]. Three major categories involve: 1) DNA-based
device construction, 2) Genome-driven cellular engineering, and 3) Protocell creation [2].
The first classification’s major objective is to make biology easier to engineer by
designing, building, and testing biological parts and devices. The potential to engineer or
program microorganisms for novel applications can have far reaching implications and
benefits to society. The problems with existing biological systems are the complexities
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with design and assembly. Synthetic biological engineering aims to reduce these issues
by making it easier to engineer biological systems [3]. The second category, Genomedriven engineering, aims to synthesize complete genomes and transfect them into cells.
By showing just how reprogrammable cells are, novel synthetic organisms with
specialized industrial or environmental functions can be created. The third category’s
approach is to construct minimal cellular systems and to understand non-synthetic
biological engineering. Finding a minimal genome can help to elucidate the origins of
microorganisms and provide an insight into the complex interactions that occur within
cells. However, the third classification of synthetic biology is not widely used and the
first two categories are increasing in popularity due to their immediate impact on societal
needs. DNA-based device construction is by far the simplest form of synthetic biological
engineering. The relatively simple concepts and decreasing economic barrier to entry
allows those not trained in the traditional fields of molecular biology and genetics to
create new, functional genetic devices. In fact, do-it-yourself (DIY) synthetic biological
engineering laboratories have begun to appear worldwide, where the main focuses of
DIY groups are: 1) remain non-profit, 2) use cost effective tools and equipment, 3)
demonstrate open source innovation, and 4) be self-empowered [4]. The focus of this
manuscript is on this first category of synthetic biological engineering because of its
popularity, simplicity, and impact.
There are many practical applications of synthetic biological engineering, ranging
from biosensors, biofuels, biomaterials, and biologically-derived therapeutics [5].
Applications of synthetic biological engineering to produce useful bioproducts have
already been demonstrated, including microbial production of artemisinic acid [6, 7],
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biliverdin [8], biofuels [9-11], bioplastics [12-14], and spider silk [15, 16]. Recently, the
first fully synthetic microorganism was created by the J. Craig Venter Institute starting
from a digital copy of the (1.08 Mbp) Mycoplasma mycoides genome [17]. The
possibility to create new life from a simple DNA sequence and ‘booting up’ an organism
opens many new possibilities for synthetic biological engineering and the creation of
useful bioproducts [18].
The impact of synthetic biological engineering is making waves in the public and
private sectors. A non-exhaustive study by Oldham and colleagues in 2012 found that
there were close to 3,000 researchers in over 40 countries engaged in research related to
synthetic biological engineering [19]. In that same year, the White House released the
National Bioeconomy Blueprint stating that in 2010 the revenues from industrial
biotechnology were in excess of $100 billion in the United States. On page one of this
document, the White House identifies that synthetic biological engineering will play a
role as an emerging technology to expand the United States bioeconomy in the future
[20].
The International Genetically Engineered Machines (iGEM) competition
(http://igem.org) is a worldwide undergraduate synthetic biological engineering
competition. iGEM started out as a one month class in 2003 with 16 students at the
Massachusetts Institute of Technology, and has since become the showcase event for
synthetic biological engineering [21]. In 2004, five university teams participated [22, 23],
2007 saw 60 teams join [24], and with 245 teams registered to compete in 2014, this
year’s competition will include thousands of student participants from across the globe
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[25]. According to the iGEM website, approximately 15,000 students have participated in
the first decade of competitions from 2004-2013 [26].
The basis of the iGEM competition is that during the summer months student-led
groups design, build, and test biological circuits and devices, then compete head-to-head
in a World Jamboree at the Massachusetts Institute of Technology. Groups submit their
standardized

biological

parts

to

the

Registry of

Standard

Biological

Parts

(http://parts.igem.org/), an open source biological parts repository that was started in
2004 [23]. Teams also present their work in formal conference style settings with podium
presentations, poster presentations, and the creation of a team website.
The cost of participating in the iGEM competition can be in the tens of thousands
of dollars per team due to team and individual registration fees, laboratory materials cost,
and traveling expenses [25]. Money spent is not always proportional to success in the
competition as there are many factors that are considered when projects are judged and
prizes are handed out at the end of the Jamboree. An article by Materi in 2012 suggested
that there are various ways in which to maximize resources for a successful iGEM project
and that each team is run differently depending on available funding and team objectives
[27]. The iGEM competition awards various prizes ranging from Best Poster to Best
Human Practices Advance. In many cases teams choose to place emphasis on only a few
categories in which they feel present the greatest chance for team success.
Since iGEM is an open source biological engineering competition, safety
considerations are important. The iGEM competition promotes safe environments with
strict requirements on teams having faculty mentors, institutional support, additional
safety checks, and approval of a team’s project by a safety committee. iGEM teams also
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develop safety mechanisms themselves such as “kill switches” for destroying bacteria if
in the unlikely case the modified organism manages to escape the laboratory. A study by
Guan and colleagues in 2013 suggested that while safety and the creation of new
biological parts to aid in a safer working environments has improved since the start of
iGEM, there are still issues that need to be addressed [28]. It has also been recommended
that new biological parts submitted to the aforementioned registry of standard biological
parts be put into separate safety categories depending on the part’s properties [29].
Additionally, the intellectual property discussion surrounding this open source field will
continue to be discussed in academic and industrial circles [30].

3.

Abstraction
Synthetic biological engineering is a fusion science combining concepts from

different disciplines [31]. Tom Knight (widely regarded as the Father of standardized
assembly and iGEM) published the first document on standardized BioBrick™ assembly
in 2003 [32]. The first tangible idea of abstraction was brought to light by
Andrianantoandro et al., with the concept that the goals and methods of synthetic
biological engineering were similar to those of computer engineering [33]. All
engineering disciplines use standards and guidelines. In electrical engineering, for
example, there are set parameters for how electronic circuits are built. Resistors,
transistors, LEDs, etc. are arranged in a systematic fashion to create circuits. In computer
programming, sequential coding of a program is written in order for a program to
function. In chemical engineering, unit operations (mass and heat transfer operations) of
a refinery are arranged in such a way as to give the best recovery and separation of
products. Endy compared synthetic biological engineering to the railway industry where
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railroads have standards associated with railway construction and measurements [3]. In
every engineering discipline there is a trend to build more complex systems from initially
simple devices and parts to complex operations as depicted in Figure 3.1. To further draw
parallels to electrical engineering, if the first transistor was developed in 1947, it been
suggested that we are currently in the 1960s with synthetic biological engineering [1].
The analogy of synthetic biological engineering compared to chemical
engineering is also an interesting concept (Figure 3.1). A biological system is constructed
using biological parts similar to how a chemical plant is assembled. Once all the parts are
assembled, a microbial cell factory is constructed, which is analogous to a chemical plant,
both producing valuable commodities. Additionally, optimization of biological systems
occurs in a similar manner to chemical engineering systems. For example, heat transfer
operations in chemical engineering systems are optimized to have the greatest energy
efficiency and thus greatest economic output. Biological systems can also be optimized to
control flux balances by gene additions, knockouts, or via optimization of key metabolic
pathways. Feedback loop systems exist both in a chemical engineering context and a
synthetic biological engineering one. As an example, buildup of a toxin in a microbial
system could trigger a system to start exporting it outside of the cell. This is analogous to
a chemical plant where buildup of a toxin in a plant starts a chain reaction to remove it
from the factory.

While the scale of biological systems and chemical systems are

different, there are many intersecting features and thus many overlapping industries and
research activities.
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Figure 3.1. Abstraction–comparing synthetic biological engineering to more established
fields such as electrical and chemical engineering.

4.

Assembly Standards
Standardization in synthetic biological engineering is also a key step in

maintaining functionality in a genetic circuit. The biological engineer cannot simply
assemble a DNA circuit randomly, rather a systematic and standardized approach must be
taken. A basic biological circuit consists of a promoter, ribosome binding site (RBS),
gene, and transcriptional terminator (Figure 3.1). Just like in an electrical circuit, the
order of these components is important for a circuit to function (promoter – rbs–gene of
interest– transcriptional terminator). Additionally, the biological circuit is typically
placed in a closed loop extrachromosomal circular DNA (plasmid DNA), much like an
electrical circuit is arranged in a closed loop system. Plasmid DNA has well-defined
cloning regions (where the standard biological circuit is inserted), antibiotic resistance
marker (for selection), and origin of replication. The fundamental characteristics of a
DNA plasmid can also be modified as reported by Shetty and colleagues, where specific
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engineered BioBrick™ vectors are constructed for the sole purpose of BioBrick™
propagation [34]. The completed plasmid system is transformed into a microorganism, or
“chassis,” as the plasmid system is now used to program the cell for a specific function.
Synthetic biological engineering is not limited to cellular production systems as recently
there has been interest in cell-free, in vitro systems where competing biochemical
reactions and the inherent variability that a living organism displays can be minimized
[35].
The complexity of a system is not limited to that seen in Figure 3.1, which is a
promoter system driving single gene expression. A complex biological system contains
many different parts and devices that could depend on each other and have feedback
loops typically seen in engineering systems. Voigt in 2006 highlighted the three major
categories for making complex biological systems comprised of many parts: sensors,
genetic circuits, and actuators [36]. Keasling summarizes the major synthetic biological
engineering tools needed for increased production of bioproducts through metabolic
pathways: chassis, vectors, promoters, coordinated expression of genes, CAD tools, and
debugging systems [37, 38].
Standardization exists in all engineering disciplines, yet recombinant biological
systems did not have any major standards in place until the onset of synthetic biological
engineering. In addition to creating a functional biological circuit, the ability to create
circuits quickly means that microorganisms can be programmed to carry out a specific
task rapidly. Utilizing standard, interchangeable biological parts is akin to the
interchangeable electric components in computer engineering. Furthermore, just like any
system, the use of standards allows other synthetic biological engineers to follow and
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understand the assembly process that was employed. If errors are found they can be
identified and remediated quickly. Müller and Arndt suggested that in addition to having
standardized assembly of DNA parts, there should also be standardized methods of part
characterization. Some of these guidelines include: physical composition of the part,
experimental

environment

(host

cell/chassis),

experimental

results,

potential

implementation, security/safety, and intellectual property claims by authors [39].
Currently there are many different standards for the assembly of synthetic
biological systems and devices [40]. One of the most common assembly methods used is
the BioBrick™ standard assembly. A BioBrick™ is a standard, interchangeable
biological part that performs a specific function and that has been engineered to meet
specific design requirements [41]. Tom Knight suggested the first standard biological
assembly strategy in 2003 [32], termed the “BioBrick™ standard assembly.” The
BioBrick™ standard assembly procedure uses a defined set of rules to first create simple
BioBrick™ parts and then, using a systematic approach, assemble these parts together to
make more complex devices.
The major guidelines for making these standardized biological parts are as
follows: 1) before the BioBrick™ part should be the restriction enzyme sites EcoRI and
XbaI (also known as the prefix), 2) after the BioBrick™ should be the restriction sites
SpeI and PstI (also known as the suffix), 3) the BioBrick™ coding region cannot have
any of these restriction sites, if so, they must be removed, and 4) the plasmid DNA
hosting the BioBrick™ part cannot have any of the above mentioned restriction sites
[32]. Figure 3.2 outlines the basic characteristics of a standard BioBrick™ part.
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One of the fundamental features of the BioBrick™ design is the compatibility of
the XbaI (TCTAGA) and the SpeI (ACTAGT) sites in the prefix and suffix. When the
XbaI site is cut the overhanging DNA sequence is CTAG, this is compatible with the
overhanging sequence of a cut SpeI site with a DNA sequence of GATC. This design
feature allows for systematic assembly of BioBricks™ together in series and regeneration
of the BioBrick™ cloning sites. Figure 3.3 demonstrates an example of standard
BioBrick™ assembly. BioBrick™ A could be cut with SpeI and PstI and BioBrick™ B
could be cut with XbaI and PstI. BioBrick™ B is now just a fragment and it can be
cloned behind BioBrick™ A as the restriction enzyme cut sites are compatible. The same
orientation would result if BioBrick™ A was cut with EcoRI and SpeI and BioBrick™ B
was cut with EcoRI and XbaI. If instead it was desired to have BioBrick™ B assembled
ahead of BioBrick™ A the steps needed for this would be similarly straightforward.
Every time two BioBricks™ are assembled together there is a creation of a BioBrick™
“scar” between each BioBrick™ that is an artifact of cloning using this method. Knight
formulated this concept of BioBrick™ assembly in 2003 and it is one of the most robust
DNA assembly systems currently used, and is commonly known as assembly standard 10
(BBF RFC 10).

Figure 3.2. Standard Biological Part in a plasmid

63

Figure 3.3. Standard BioBrick™ assembly RFC 10 and RFC 23

The aforementioned BioBrick™ scar from Knight’s original construction (BBF
RFC 10) in 2003 was found to cause a frame shift when linking two coding regions
together. The RFC 10 scar also creates a premature stop codon (TACTAGAG). In 2006
Phillips and Silver modified the BBF RFC 10 assembly standard to allow for in-frame
protein fusions. This new assembly standard (called Silver BBF RFC 23) follows the
same rules and requirements as Knight’s BBF RFC 10 and includes the same restriction
sites. However, the BioBrick™ prefix and suffix have shortened sequences (one base pair
deletions, G proceeding the XbaI site and T before the SpeI site) to allow for an in-frame
scar site. This new, RFC 23 6 bp scar site (ACTAGA) codes for the amino acids
threonine and arginine [42].
Another widely used standard is the Berkeley RFC 21, or BglBrick standard,
developed in 2009. This standard assembly method uses the restriction enzymes EcoRI
and BglII in the prefix and BamHI and XhoI in the suffix. The advantage of this system is
that in-frame protein expression is possible and the resulting scar site is a glycine-serine
(GGATCT) compared to the threonine-arginine (ACTAGA) in BBF RFC 23 assembly
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standard. Glycine-serine fusion is harmless in a protein fusion context in E. coli [43, 44].
The major drawbacks of RFC 21 is that the BioBricks™ and vectors used in this system
are not compatible with RFC 10 or RFC 23 due to different restriction enzyme sets being
used, which makes converting existing parts already produced using RFC 10 or RFC 23
to RFC 21 problematic.
Two other standards currently supported by the Registry of Standard Biological
parts are the BioBrick™ BB-2 Standard (RFC 12) [45] and Freiburg Standard (RFC 25)
[46]. Since these are not widely used by the synthetic biological engineering community
they will not be here. Additional synthetic biological engineering assembly methods can
be found in a review by Ellis [40].
An assembly standard that has gained attention recently is the Gibson Assembly
method. The Gibson Assembly method is a one tube reaction that combines multiple
fragments together at once. The idea is that two pieces of DNA could be assembled
together as they share the same end DNA sequence overlap. A T5 exonuclease removes
nucleotides from the 5’ end of each of the DNA strands and the complementary strands
from each of the pieces of DNA are assembled together with a polymerase to fill in
missing gaps in DNA sequence and ligase to assemble the pieces together. The whole
procedure takes place in a thermocycler. The advantages of this process are that large
DNA fragments can be sequential assembled together in one reaction tube potentially
saving time and money for the synthetic biological engineer. It was reported that products
as large as 900 kb could be assembled from DNA fragments [47]. iGEM teams have
started adopting this assembly system in recent years to assemble more complex
biological systems and pathways.
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A survey by Kahl and Endy in 2013 found that Gibson Assembly, de novo
synthesis, and BioBrick™ standards were the three most used assembly standards in
synthetic biological engineering. Additionally, in this study it was reported that the iGEM
registry (http://parts.igem.org/) was the most widely used public registry for synthetic
biological engineers, where researchers both submitted and utilized parts from the
registry [48].

5.

BioBricks™ to Bioproducts
Many of the aforementioned assembly strategies have been used by different

iGEM groups to produce a wide range of BioBrick™-based bioproducts. Different
microorganisms (chassis) have been used to host these biological circuits including:
Escherichia coli, Yeast, Cyanobacteria, and Bacillus subtilis. Each organism is chosen on
the basis of optimization or novelty of the bioproduct production system.
The iGEM competition first began presenting an award for the Best
Manufacturing Project in 2008 (Table 3.1). The concept was to reward the team that
demonstrated production systems in an organism by either programming the organism to
produce a novel bioproduct or, optimization of production systems. The number of teams
selecting manufacturing as their track ranged from 11-17 each year from 2008-2013. The
2008 Imperial College project, “Biofabricator Subtilis,” used B. subtilis for their chassis
to produce self-assembling biomaterials. Cornell University’s “BioFactory” project in
2011 used a cell-free method to produce complex biomaterials from E. coli. More
recently, Utah State University’s team “Arachnicoli” in 2012 used BioBricks™ to
produce synthetic spider silk in E. coli. In 2013, the Imperial College team “Plasticity”
produced the bioplastic polyhydroxybutyrate (PHB) in E. coli. While this award is
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presented in a manufacturing context, this is not the only track in the iGEM competition
that bioproduct production from BioBricks™ takes place. For example, teams may select
the “Food and Energy” or “Health and Medicine” tracks if their bioproduct has
implications in any of a number of different research areas.
Many teams build upon previous team’s work, and in doing so advance the field
of

synthetic

biological

engineering.

As

an

example,

the

production

of

polyhydroxybutyrates (PHBs) in an iGEM context was first suggested by the 2008 Utah
State team. However, the team was not able to demonstrate successful production using
BioBricks™ at the time. The 2012 Tokyo Tech team demonstrated a functioning PHB
production system from BioBrick™ parts. The following year, the 2013 Imperial College
team demonstrated an 11x increase in production of PHB compared to the Tokyo Tech
team in 2012 with the use of a hybrid promoter system and a BioBrick™ based operon.
Interestingly, the Imperial College team also collaborated with the Yale 2013 team as
Yale was trying to produce polylactic acid (another plastic) in E. coli. Imperial College’s
ability to build and improve upon previous team’s work, demonstrate a functional
production system, and collaborate followed the iGEM spirit set out almost 10 years
prior.

Table 3.1. Best Manufacturing prize for iGEM projects 2008-2013 (igem.org)
Year
2013
2012
2011
2010
2009

Team Name
Imperial College
Utah State
Cornell
MIT
Imperial College

2008

Imperial College

Project name
Plasticity
Arachnicoli
BioFactory
Living Materials
The
E.ncapsulator
Biofabricator
Subtilis

Bioproduct/process
Bioplastic
Spider silk
Cell-free bioproduct synthesis
Self-assembly of biomaterials
Encapsulation of proteins for
therapeutic purposes
Self-assembling biomaterials
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Another category that includes groups using BioBricks™ to generate bioproducts
is the “Food and Energy” division. This section started receiving a specialized award in
2007 and out of the 8 awarded teams, 5 teams worked towards energy production from
BioBricks™. In 2008 a team from Harvard University used Shewanella oneidensis as a
microbial fuel cell and in 2013, the Bielefeld-Germany team used E. coli in a similar
endeavor. Successful drop-in fuel BioBrick™ production systems were constructed by
teams from: Alberta in 2007 (Butanol), UNIPV-Pavia in 2009 (Ethanol), and Washington
in 2011 (Biodiesel).

Table 3.2. Best Food and Energy Project prize for iGEM projects 2007-2013 (igem.org)
Year
2013
2012
2011

Team Name
BielefeldGermany
Groningen
Washington (tie)

Project name
Ecolectricity

Bioproduct/process
E. coli as a microbial fuel cell

2011

Yale (tie)

2010
2009

BCCS-Bristol
UNIPV-Pavia

2008

Harvard

Food Warden
Make It or
Break It
Nature’s
Antifreeze
agrEcoi
Ethanol? Whey
not!
bactricity

Spoiled meat detector
Diesel Production

2007

Alberta

Butanerds

Antifreeze protein production
Soil fertility sensor
Whey to ethanol
Electricity production in
Shewanella oneidensis
Butanol production

In 2013 over 10% of teams focused on production of bioproducts from
BioBricks™ (Table 3.3). The bioproducts that each group aimed to produce ranged from
biomaterials to additives for food. Also, many groups used different chassis organisms
such as E. coli, Bacillus, and Clostridia for their BioBrick™ systems, which opens up
many doors for future teams.
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Table 3.3. iGEM 2013, teams that focused on production of bioproducts from
BioBricks™ (igem.org)
Team Name
Berkeley
BielefeldGermany
Biwako
Nagahama
Bordeaux
British
Columbia

Project name
Genes to Jeans: a green solution
to blue denim
Ecolectricity

Bioproduct
Indigo

Track
Manufacturing

Microbial fuel cell

Food & Energy

AgRePaper&E.coli-ink

Cellulose

Environment

Flavored yogurts
Vanillin, caffeine, and
cinnamaldehyde

Food & Energy
Food & Energy

Biodegradable
Styrofoam substitute

Manufacturing

Biodiesel

Environment

Bioethanol
Stevia
Mambalgin-1 peptide

Environment
Food & Energy
Health &
Medicine

Mussel adhesive
proteins
Spider silk

Manufacturing

Bioplastic
Pearl powder (nacre)
Palm oil

Manufacturing
Environment
Food & Energy

Human insulin

Manufacturing

Eucalyptol

Food & Energy

Isopropanol, butanol,
and ethanol

Food & Energy

The Dairy Planet
CRISPR Mediated Automated
Design Employed to Bring You
Ultrabiotics
Cornell
Organofoam: Genetically
Engineering Fungal Mycelium
for Biomaterials Development
Costa Rica
Genetic transformation of
Cibus
Bacillus subtilis for lactose
consumption
Edinburgh
WastED
Frankfurt
Steviomyces-sweeter than sugar
Georgia State
Mamba Juice: Expression of
Exogenous Mambalgin Peptide
Using the pGAPzα Vector
System
GreensboroBioadhesive Production Using
Austin
an Expanded Genetic Code
Groningen
Engineering Bacillus subtilis to
self-assemble into a biofilm that
coats medical implants with
spider silk
Imperial College Plasticity
Korea U Seoul
Pearl-coli
Manchester
E. c(oil)i; The Lean, Green,
Fat-Producing SynBio Machine
Minnesota
The pMNBB vector system: A
toolkit approach for engineering
Pichia pastoris
MSOE
Synthesizing Eucalyptol from
Milwaukee
Spend Grain Waste
OU-Norman OK A shuttle vector for Clostridial
Chassis Organisms

Health &
Medicine
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Penn State
SDU-Denmark

Plants as Plants
Bacteriorganic Rubber

Vanillin and butanol
Rubber

Manufacturing
Manufacturing

Tsinghua-E

Darwinian evolution for
microbial cell factory: in vivo
evolution engineering towards
tryptophan-overproduction
superbug

Tryptophan

Manufacturing

TU-Delft

Antimicrobial peptides

Health &
Medicine

Keratinase

Environment

Geraniol

Food & Energy

Uppsala
Utah State
Valencia-CIPF

Peptidor: Detection and killing
of S. aureus using antimicrobial
peptides
Keratinase Expression System
in E. coli and B. subtilis
Geraniol production via novel
protein expression tools
LactoNutritious
AMPed up E. coli
Project - Freshellent Yeast

Food additives
Antimicrobial peptides
Aromas and repellents

Food & Energy
Manufacturing
Environment

Wageningen UR

Aspergillus niGEM: A lov story

Lovastatin

Manufacturing

Yale

Converting E. coli into a
foundry for bioplastics

Poly(lactic acid)

Manufacturing

UChicago
UGA-Georgia

While many teams have illustrious aims when first setting out on a team project,
many teams are not able to accomplish their goals due to a variety of reasons such as:
complexity of the project, lack of experience, short time frame, or insufficient funding.
From the bioplastic example mentioned previously, the first team that came up with the
idea did not necessarily achieve all their project objectives, but rather provided a
foundation for other groups to build upon. The purpose of iGEM is not solely to make a
profitable bioproduct from BioBricks™, because regardless of the final product that was
created, the students will have gained valuable teamwork and laboratory experience along
the way.
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6.

Conclusions
One the purposes of synthetic biological engineering is to make biology easier to

engineer and this idea is seen most prominently in the iGEM competition. Synthetic
biological engineering will have a greater role in the global bioeconomy and iGEM will
continue to add to this growing field through innovations in projects and training of
students. In an iGEM context, there are various assembly standards currently being
utilized and there will inevitably be further advancement and new assembly standards
seen in the future. With the sustained expansion of the BioBrick™ registry and the iGEM
competition, there will be a continued development of BioBrick™-based bioproducts.
The field will also see many new applications for BioBrick™-based synthetic biological
engineering as we progress towards increasingly complex systems.

7.
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CHAPTER 4
SECRETION OF POLYHYDROXYBUTYRATE IN ESCHERICHIA COLI USING
A SYNTHETIC BIOLOGICAL ENGINEERING APPROACH1

1.

Abstract

1.1

Background
Polyhydroxyalkanoates (PHAs) are a group of biodegradable plastics that are

produced by a wide variety of microorganisms, mainly as a storage intermediate for
energy and carbon. Polyhydroxybutyrate (PHB) is a short-chain-length PHA with
interesting chemical and physical properties. Large scale production of PHB is not widespread mainly due to the downstream processing of bacterial cultures to extract the PHB.
Secretion of PHB from Escherichia coli could reduce downstream processing costs. PHB
are non-proteinaceous polymers, hence cannot be directly targeted for secretion. Phasin,
PhaP1, is a low molecular weight protein that binds to PHB, reducing PHB granule size.
In this study PHB is indirectly secreted with PhaP1 from E. coli via type I secretion using
HlyA signal peptides.

1.2

Results
This study demonstrated the successful secretion of phasin and phasin bound PHB

outside of the cell and into the culture medium. The secretion of PHB was initiated
between 24 and 48 h after induction. After 48 h of culturing, of the total PHB produced in
the secreting strain, 36 % was collected in the secreted fraction and 64 % remained in the

1

Coauthors: Elisabeth Linton, Alex Hatch, Ronald C. Sims, and Charles D. Miller

77

internal fraction. To further support the findings of this study, the PHB secretion
phenomenon was observed using SEM.

1.3

Conclusions
From this study, the ability to use type I secretion to: 1) secrete phasin and 2)

successfully secrete PHB has been shown.

2.

Background
Fossil derived plastics are non-biodegradable and toxic to the environment.

Based on an United States Environmental Protection Agency study in 2011, there was an
increase in non-biodegradable plastic accumulation in municipal solid waste systems
from 0.5 % to 12.4 % during 1960 to 2010 [1]. Alternative means of producing plastics in
large quantities that are both economically and environmentally friendly have recently
gained considerable attention [2].
Replacing

traditional

plastic

with

biodegradable

plastic

such

as

polyhydroxyalkanoates (PHAs) can potentially reduce total waste by up to 20 % [3].
PHAs are produced by a variety of microorganisms as an intercellular storage medium
for energy and carbon and can accumulate up to 90 % of the cell dry weight [4]. PHAs
are biodegradable polymers. The biodegradability can range from days [5] to months [6]
with degradation either taking place extracellularly or intracellularly. Extensive review
on degradation of PHAs can be found in Jendrossek et al. 2002 and Jendroseek et al. [7,
8]. There are 155 different confirmed types of PHA monomer subunits, each with varying
monomer repeat number and side groups [9]. Additionally, PHAs have melting
temperatures between 50-180oC and crystallinity of 30-70 % [10]. Thus, PHAs have a
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variety of possible applications, that could replace traditional plastics derived from
petroleum [11]. Some of the possible applications are highlighted in previous studies [12,
13] and include: packaging, medical uses [14], agricultural uses, and in carbon nanotubes
[15].
Polyhydroxybutyrates (PHB) are a short-chain-length (scl) PHA polyester with
between 3-5 carbon monomers [9]. The production of PHB in recombinant systems such
as Escherichia coli has been made possible by the isolation of the phaCAB operon from
Ralstonia eutropha (Cupriavidus necator) and cloning into pBluescript SK- to generate
plasmid pBHR68. pBHR68 has been widely used for recombinant production of PHB in
E. coli. The phaCAB operon is a three-step enzymatic process by which acetyl-CoA is
converted to PHB: phaC (PHA synthase), phaA (β-ketothiolase), and phaB (acetoacetylCoA reductase) [4, 16]. After production of PHB, the polymer forms spherical granules
with a hydrophobic core and attached proteins at the surface, including PHA synthase and
phasin, PhaP1 [17-19].
The cost of producing PHAs is approximately US$ 4-6/ kg and one of the major
bottlenecks in scaling up recombinant PHA production systems is the isolation of the
PHAs [12, 20]. Current techniques that are used to isolate PHB from E. coli are invasive,
including mechanical, chemical, and biological treatments. These techniques involve
lysing the cellular membrane prior to isolation of the PHBs. There are a variety of
methods that have been suggested for recovery of PHBs from microorganisms and a
detailed review of the different PHB isolation methods is outlined in Jacquel et al. [20].
The development of a secretion mechanism eliminates the need for cell disruption
by mechanical or chemical means, and may lead to continuous (or semi-continuous) PHB
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production systems. In gram-negative bacteria like E. coli, compounds are exported via
six major secretory pathways [21-24]. Recombinant proteins can be targeted to type I and
II secretory pathways through genetic fusion with signal peptide targeting sequences.
PHBs are non-proteinaceous polyesters and therefore cannot be directly targeted
for translocation by signal peptide fusion. Phasins are low-molecular weight proteins that
play a role in PHB granule formation by binding to the PHB granule surface [19, 25].
Phasins are structural proteins found in organisms that naturally produce PHAs and are
similar in function to oleosins which are found in plants [19, 26]. Currently, oleosins are
used to purify various compounds such as pharmaceuticals from plants [27].
Translocation of PHBs is possible through optimization of granule size, which
reportedly varies from 50 to 1,000 kDa based on growth parameters and host strain [4].
One of the functions of phasin is to increase the surface-to-volume ratio of granules so
that higher accumulation levels can be achieved [25, 28, 29]. Therefore, the size of the
PHB granule can be decreased significantly through phasin overexpression. In one such
study, overexpression of phasin resulted in a decrease of PHB granules from 70-310 nm
diameter to 20-60 nm [28].
Type I secretion is a simple one step secretion system that can translocate proteins
from the cytoplasm to the extracellular medium without protein interaction with the
periplasm [30].

Proteins of nearly 900 kDa (large adhesion protein, LapA) have

reportedly been secreted to the extracellular milieu by the type I secretory mechanism of
gram-negative bacteria [31, 32]. Specifically using the Hemolysin (HlyA) secretion
mechanism proteins such as β-galactosidase (117 kDa) [33], β-gal-OmpF (56 kDa) [34],
and green fluorescent protein (GFP) (27 kDa) [35] have been secreted by E. coli. The
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physical characteristics of the secretion channel are approximately 3.5 nm in diameter
with a length of 14 nm as reported by Fernández et al., which makes the secretion
phenomena of large proteins very interesting [36].
Our group has previously used a synthetic biological engineering approach to
demonstrate the feasibility of HlyA, GeneIII, PelB, and TorA secretion systems in E. coli
with the use of GFP [35]. From the aforementioned study, the type I secretion system
using the HlyA signal peptide yielded the best results for secretion of GFP outside of the
cell and into the medium [35]. The objective of this study was to demonstrate that phasin
can be used to secrete PHB from E. coli using type I secretion machinery.

3.

Results and Discussion
Initial studies were carried out to demonstrate expression and then successful

translocation of phasin, PhaP1, into the extracellular medium.

Once this was

demonstrated, PHB secretion experiments were conducted that included: growth studies,
PHB production in secreted and non-secreted fractions, and visualization with scanning
electron microscopy (SEM).

3.1

Analysis of Phasin Translocation
For E. coli cells expressing pCMEL1 and pLG575, a phasin band is observed at

22-26 kDa in the cytoplasmic fraction, the periplasmic fraction, the membrane fraction,
and the concentrated extracellular media (Figure 4.1). This polyacrylamide gel and
corresponding immunoblot demonstrated: 1) the ability for E. coli to produce non-codon
optimized Phasin (from R. eutropha), a protein not naturally expressed in E. coli and 2)
translocation of phasin into different fractions of the cell. Compared to other studies that
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focused non-translocated phasin, the phasin band sizes in all of the different fractions are
similar [19, 29]. Since the translocation of phasin was successful, secretion of PHB using
phasin was then attempted.

Figure 4.1. SDS polyacrylamide gel and corresponding immunoblot of subcellular
fractions for PhaP1:HlyA. C – cytoplasmic fraction, P – periplasmic fraction, M –
membrane fraction, S – concentrated supernatant (media) fraction. The position of phasin
bands varies from roughly 22-26 kDa.

3.2

Growth studies
The PHB secreting strain consisted of pCMEL3 + pLG575, whereas the non-

secreting strain consisted of pBHR68+pLG575. From the CFU/mL vs. time graph (Figure
4.2) stationary phase was reached at approximately 8-12 h for both non-secreting and
secreting strains. The non-secreting and secreting strains had the highest overall CFU/mL
at approximately 9x1012 and 5x1012 CFU/mL, respectively, after 12 h. There was no
significant difference between CFU/mL for the non-secreting and secreting strains after
24 and 48 h (p>0.05). This statistical analysis on the CFU/mL demonstrated that there
were no significant differences in E. coli growth between the two samples at times when
PHB analysis was conducted (24 and 48 h). Furthermore, this suggests that the secretion
of PHB does not affect cell viability.
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Figure 4.2. CFU/mL vs. Time (h) for secreting and non-secreting strains of PHB
producing E. coli, averaged from triplicate experiments (one standard deviation shown).

Table 4.1. Production of PHB in secreting (pCMEL3+pLG575) and non-secreting
(pBHR68+pLG575) strains of E. coli at 24 and 48 hours.

Strain
NonSecreting
Secreting

%mass of PHB in Dry mass

Production g/L PHB

Time
(hr)

Secreted
fraction

Secreted
fraction

24

0.31±0.35

Nonsecreted
fraction
41.93±13.5

48
24

0.72±0.89
0.69±0.18

47.24±6.0
28.85± 0.41

Total
productio
n
6.05±1.1

g PHB/
g Glucose

0.40±0.27

Nonsecreted
fraction
5.65±1.1

0.50±0.41
0.40±0.06

5.43±1.7
3.42±0.33

5.93±1.8
3.82±0.3

0.40±0.12
0.25±0.02

4.58±2.47

7.15±2.6

0.48±0.17

48
28.29±7.2*
38.80± 15.5
2.57±0.75*
*Indicates statistical significance within column (p<0.05)

0.40±0.07
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3.3

PHB production analysis
PHB production analysis was carried out 24 and 48 h after induction because after

24 h E. coli harboring the plasmid systems were in stationary phase. Previous studies
demonstrated that PHB did not accumulate to significant levels during the exponential
growth phase. Acetyl-CoA is required for cell synthesis during the exponential phase but
is diverted to produce PHB in the stationary phase, thus, there is a delay between carbon
source utilization and PHB production [37].
PHB measured inside the cell is defined as the internal fraction and PHB collected
by the CaCl2 precipitation method is the secreted fraction. Twenty-four hours after
induction, the internal fraction of the cells demonstrated PHB production for both the
secreting and non-secreting strains. While the non-secreting strain accumulated
approximately 41.93±13.5 % of PHB in the dry cell weight at 24 h, the secreting strain
accumulated approximately 28.85±0.41 % (Table 4.1). Forty-eight hours after induction
the non-secreting and secreting strains had accumulated 47.24±6.0 % and 38.80±15.5 %
PHB, respectively. There was no significant statistical difference seen in internally
accumulated PHB in either the non-secreting or secreting strains at 24 and 48 h (p>0.05)
after induction. The internal levels of PHB accumulation in the non-secreting and
secreting strains are comparable to those seen in other studies such as Kang et al. 2008,
where the authors showed accumulation of 42 % PHB in E. coli DH5α harboring
pBHR68 after 24-48 h [38].
PHB secreted fractions were analyzed at 24 and 48 h after induction for the
secreting and non-secreting strains. PHB harvested in the secreted fraction of the nonsecreting strains was 0.31±0.35 % and 0.72±0.89 %, respectively. The PHB present in the
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secreted phase demonstrated that some lysed cells containing PHB were found in this
fraction after CaCl2 precipitation. This is to be expected from a differential centrifugation
technique, such as that used in this study. 24 and 48 h after induction the secreting strain
produced 0.69±0.18 % and 28.29±7.2 % respectively in the secreted fraction. The level of
PHB seen in the secreted fraction of the secreting strain was statistically significant after
48 h post induction, compared to the non-secreting strain (p<0.05). This increase in PHB
present in the secreted phase after 48 h indicates that the secretion system is functioning
and producing higher amounts of PHB, with a small amount of non-secreted PHB ending
up in the secreted fraction. These results demonstrate that PHB secretion is initiated 24 h
after induction.
Secretion of PHB can help in downstream processes by aiding in PHB separation
from biomass. Of the total PHB produced by the secreting strain after 48 h, 36 % was
collected in the secreted fraction and the remaining 64 % was in the internal fraction. The
secreting strain had a total PHB production of 7.15 g/L compared to 5.93 g/L for the nonsecreting strain 48 h after induction.
It has been demonstrated from previous studies that PHB can accumulate in larger
quantities in E. coli when using a bioreactor compared to a shaker flask. A fed-batch
bioreactor study by Choi et al. 1999, reported accumulation of up to 77 % PHB of dry
cell weight [39] and another study reported accumulation of up to 80 % [37]. Future
studies will be performed to determine how well the secreting strain performs under
similar bioreactor growth conditions.
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3.4

SEM analysis
SEM is not widely used for PHB analysis since a surface topographical analysis is

typically of little use. SEM has however been used to visualize PHA granules produced
from recombinant E. coli [40] and PHA degradation from a variety of organisms [41]. In
the case of secretion, SEM can provide images of what is occurring at the surface of E.
coli during the secretion process. Figure 4.3 A shows a PHB non-secreting E. coli strain
harboring the pBHR68 plasmid. Figure 4.3 B shows E. coli that is accumulating PHB
and overexpressing phasin. Figure 4.3 C shows the full secretion system in E. coli
(pCMEL3+pLG757). Figure 4.3 C suggests that PHB is being secreted outside of the
bacteria and into the medium. These observations further demonstrate the functioning of
the PHB secretion system.
The SEM photo in Figure 4.3 C suggests that secretion of PHB occurs at the polar
regions of the cell. Interestingly it has been found in previous studies [42, 43] that PHB
granule formation occurs at the cell poles in E. coli when both phasin and PHB are being
produced. When PHB is being produced the interpretation is that PHA synthase is active,
and it has previously been suggested that PHA synthase has polar targeting information
[43].
It is interesting that E. coli is able to secrete PHB through pore sizes of 3.5 nm
[36] in diameter. From the results of this this study not all the PHB produced is being
secreted, with a large fraction remaining internally, suggesting that there could be
differences between the secreted and non-secreted PHB.
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Figure 4.3. SEM images taken from overnight cultures of E. coli XL1Blue harboring
different plasmid systems: A) pBHR68 (non-secreting), B) pCMEL3 (non-secreting with
phasin overexpression), and C) pCMEL3+pLG575 (complete PHB production and
secretion system).
4.

Conclusions
This study demonstrated the successful expression of phasin, PhaP1, and its

translocation using type I secretion in E. coli. Once translocation of PhaP1 was
successful, a recombinant synthetic biological system to secrete PHBs was designed and
tested. Initiation of PHB secretion occurs between 24 and 48 h after induction. From the
total PHB produced by the secreting strain, 36 % was collected in the secreted fraction
and 64 % remained in the internal fraction after 48 h.
Secretion of PHB should help in downstream processing whereby the PHB is
separated from the cell mass which can aid in PHB recovery and purification. Future
studies will include a detailed comparison of secreted versus non-secreted PHB
characteristics.
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5.

Methods

5.1

Strains and Plasmids
Genetic parts were constructed in accordance with the BioBrick and BioFusion

technical standards [44, 45]. The BioFusion standard was specifically used to create
phasin and signal peptide parts because this genetic fusion system is compatible with the
original BioBrick standard [45, 46].
Descriptions of strains and plasmids used to study PHB and phasin production
and translocation are provided as Table 4.2. Completed BioBrick parts were transformed
in BL21-Gold (DE3) competent E. coli (Agilent Technologies, Santa Clara, CA) for
protein expression studies. PHB production and secretion studies were carried out in E.
coli XL1 Blue (Agilent Technologies, Santa Clara, CA). Plasmid pLG575 includes the
coding regions for proteins HlyB and HlyD [47, 48]. Plasmids pSB1AK3, pSB1A3, and
pSB3K3 are BioBrick standard vectors for assembly and expression of BioBrick genetic
devices [49].

5.2

BioBrick and plasmid construction
All restriction enzymes and related reagents were purchased from Thermo Fisher

Scientific Inc. (Glen Burnie, MD). The signal peptide HlyA was made through synthetic
design and construction as mention in Linton et al. 2012 (DNA 2.0, Menlo Park, CA)
[35]. A BioFusion-compatible phasin BioBrick was constructed by isolating phaP1 from
the genomic DNA of R. eutropha using PCR with primers PhaP1FOR and PhaP1REV
that included the BioFusion prefix and suffix as overhanging ends (Table 4.2).
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Table 4.2. Strains, plasmids, and oligonucleotides used in this study
Strains

Relevant Characteristics

Reference

Strains
BL21-Gold (DE3)

E. coli B F– ompT hsdS(rB– mB–) dcm+ TetR gal λ (DE3)
endA Hte

Agilent
Technologies

XL1 Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´
proAB lacIqZΔM15 Tn10 (Tetr)]

Agilent
Technologies

Cupriavidus necator
H16

Wild type, PHA producing strain

ATCC
17699

Plasmids
pLG575

pACYC184 derivative, HlyBD, p15A origin, CmR

[47]

pBHR68

pBluescript SK−, phbCAB genes from R. eutropha

[16]

pSB1AK3

High copy BioBrick vector, pMB1 origin, AmpR and KanR

[49]

pSB1A3

High copy BioBrick vector, pMB1 origin, AmpR

[49]

pSB3K3

Medium copy BioBrick standard vector, p15A origin, KanR

[49]

pCMEL1

phaP1, C-terminal BioFusion with HlyA signal peptide,
Lac promoter (BBa_R0010), RBS(BBa_B0034), in
pSB1A3

This study

pCMEL2

phaP1, C-terminal BioFusion with HlyA signal peptide,
Lac promoter (BBa_R0010), RBS(BBa_B0034), in
pSB3K3

This study

pCMEL3

phaP1, C-terminal BioFusion with HlyA signal peptide,
Lac promoter (BBa_R0010), RBS(BBa_B0034), in
pBHR68

This study

PhaP1FOR

5’-gaattcgcggccgcttctagaatgatcctcaccccggaaca-3’

This study

PhaP1REV

5’- ctgcagcggccgctactagttcaggcagccgtcgtcttct-3’

This study

g114t

5’-cgtcgagctgaaccttcaggtcgtcaagact-3’

This study

g114t_antisense

5’-agtcttgacgacctgaaggttcagctcgacg-3’

This study

Oligonucleotides
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The 620 bp PCR product was isolated by gel electrophoresis, digested with EcoRI and
SpeI, and ligated into pSB3K3. A PstI site was removed from phaP1 (while conserving
amino acid sequence) using a QuikChange II Site-Directed Mutagenesis Kit and the
QuikChange® Primer Design Program (Agilent Technologies, Santa Clara, CA). The
designed primers (g114t and g114t_antisense) for site-directed mutagenesis are shown in
Table 4.2. The PstI mutation in phaP1 was successfully carried out and confirmed by
sequence analysis.
Step-wise assembly of composite BioBrick devices was primarily carried out in
pSB1AK3. Completed devices were subsequently ligated into pSB1A3 and pSB3K3. The
lac promoter (BBa_R0010) and ribosome binding site (BBa_B0034) were used as
described in Linton et al. [35]. The pCMEL1 plasmid was used for studies on phasin
translocation because its origin of replication (pMB1) was compatible with the origin of
replication of pLG575 (p15A). BL21-Gold (DE3) was co-transformed with pCMEL1 and
pLG575. The pCMEL3 plasmid was used for studies on type I secretion of PHA. The
composite part containing the promoter, RBS, coding region, and terminator were cloned
into pBHR68 from pCMEL2 by digestion with EcoRI and XhoI. XL1-Blue was cotransformed with pCMEL3 and pLG575 for PHA secretion studies. A schematic of the
secretion system is presented in Figure 4.4.
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Figure 4.4. A. Schematic for PHB secretion containing dual plasmid system pCMEL3
and pLG575. Phasin with attached signal peptide binds to PHB granule surface and the
PHB-phasin-signal peptide complex is targeted for type I secretion. B. pCMEL3 plasmid
consisting of phaC, phaC, and phaB genes from pBHR68. pCMEL3 also contains the
genes needed for phasin-HylA production.
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5.3

Cellular Fractionation and Western Blotting
Overnight cultures of E. coli BL21-Gold (DE3) harboring pCMEL1 and pLG575

were used to inoculate (1:100 v/v dilution) 100 ml of LB media containing 25 μg/ml
chloramphenicol (Acros Organics, Fair Lawn, NJ) and 50 μg/ml ampicillin (IBI
Scientific, Peosta, IA) [50]. The lysozyme/EDTA/osmotic shock and chloroform-based
cellular fractionation procedures and methods for analyzing supernatant fractions are
previously discussed in Linton et al. [35]. Briefly, 50 mL of cell culture were centrifuged
and the pellet was resuspended in a buffer and subjected to osmotic shock. Centrifugation
was used to separate the periplasm from spheroplast. Cytoplasm and membranes were
fractionated via ultracentrifugation.
Approximately 40 μg of protein from each of the respective fractioned samples
were separated using precast 12 % SDS-polyacrylamide tris-glycine gels (Jule Inc.,
Milford, CT). Electrophoresis operating conditions were used as specified by the
manufacturer. Phasin immunoblotting was carried out using a PhaP1 specific antibody
[51, 52]. An Anti-Rabbit IgG HRP conjugated secondary antibody was purchased from
Promega (Madison, WI). Respective primary and secondary antibody concentrations of
1:50,000 v/v and 1:2,500 v/v were used.

5.4

PHB Secretion studies
All secretion studies were carried out in triplicate. Secretion studies were

conducted with the secreting system (pCMEL3 + pLG575 in XL1Blue) and non-secreting
system (pBHR68 + pLG575 in XL1 Blue). The non-secreting system does not contain
phasin-HlyA.
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5.5

Media formulation and growth conditions
R. eutropha was cultured following the methods outlined in Linton et al. [53]. M9

salts (Becton, Dickinson and Co, Sparks, MD) supplemented with 1.5 % (w/v) glucose
(ACS grade, Acros Organics, Fair Lawn, NJ) and 0.2 % (w/v) yeast extract (Becton,
Dickinson and Co, Sparks, MD) was used for PHB secretion studies in E. coli [38].
Overnight E. coli cultures harboring specific plasmids were inoculated from freezer
stocks into 5 ml of M9 media with chloramphenicol (34 μg/ml), ampicillin (50 μg/ml),
and grown in an orbital shaker table at 220 rpm at 37 oC. Overnight cultures were then
used to seed larger 250 ml flasks (50 ml media volume) at an initial optical density
(OD600) of 0.05 at time 0 h. 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Gold
Biotechnology, Inc. St. Louis, MO) was added to each flask at time 0 h. Flasks were
removed at 24, and 48 h and analyzed for PHB. CFU/mL was measured at time points 0,
4, 6, 8, 12, and 24 h.

5.6

Recovery of secreted PHB
PHB granules can agglomerate together naturally and previous studies have

demonstrated the use of Calcium chloride (CaCl2) to enhance this process. A study by
Fidler et al. used CaCl2 to purify PHB from lysed cells by selectively aggregating PHB
granules, it was observed that PHB granules fell to the bottom of the test tube after
addition of CaCl2 [54]. Another CaCl2 method for PHB recovery by Resch et al. used a
low speed centrifugation step to further enhance PHB recovery from cell debris [55].
In this study, techniques for secreted PHB recovery were adapted from the
methods outlined in Resch et al.. At 24, and 48 h 0.01 M CaCl2 (final concentration,
Avantor Performance Materials, Inc. Center Valley, PA) was added to the bacterial
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culture and mixed by inverting the tube several times. The tubes were then allowed to sit
for 10 min at room temperature and then centrifuged at 54 x g for 5 min. The supernatant
was removed and transferred to a fresh tube and the pellet was freeze dried. The
supernatant was centrifuged at 3452 x g for 10 min and the pellet was freeze dried. The
pellet from the first centrifugation contained secreted PHB with CaCl2 and the pellet from
the second centrifugation contained bacterial mass and non-secreted PHB. Secretion
studies and PHB analysis were conducted in triplicate.

5.7

PHB concentration determination
PHB concentrations were determined based on a NMR-GC method described in

Linton et al. [53]. Briefly, samples were lyophilized after which approximately 15 mg of
sample was mixed with equal volumes of sodium hypochlorite and deuterated
chloroform. Samples were centrifuged and 1H NMR was carried out on the PHB fraction.
PHB concentration was determined from a NMR-GC standard.

5.8

Scanning electron microscopy (SEM)
To visually show PHB secretion from E. coli, SEM was performed. SEM

protocols were used as mentioned in Mortensen et al. [56]. Briefly, secreting and nonsecreting strains were grown up overnight and fixed onto glass cover slips. Samples were
mounted on aluminum stubs and sputter coated with 10 nm gold. SEM was carried out
using a Hitachi S4000 SEM.
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5.9

Statistical analysis
All growth (CFU/mL) and PHB yield studies were carried out in triplicate to

show consistency of data. Statistical analysis was conducted with Statistical Analysis
Software (SAS 9.3, SAS Institute Inc., Cary, NC). A two-way analysis of variance
(ANOVA) with tukey post hoc comparison performed on significant results (confidence
level 95 %).

6.
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CHAPTER 5
A SYNTHETIC BIOLOGICAL ENGINEERING APPROACH TO
UNDERSTANDING TYPE I SECRETION OF POLYHYDROXYBUTYRATES
FROM ESCHERICHIA COLI

1.

Abstract
Using synthetic biological engineering to secrete bioproducts such as

polyhydroxybutyrate (PHB) from Escherichia coli could potentially lead to many cost
saving measures upon scale-up. In a previous study it was demonstrated that PHB could
be successfully secreted from E. coli using a type I secretion system. In this present
study, secretion of PHB is monitored with green fluorescent protein (GFP) fusion to
PhaC synthase that is covalently bound to the PHB granule. From this study it was
confirmed that PHB accumulation in E. coli occurred at the polar regions of the cell and
secretion of PHB via type I secretion machinery also occurs at the cell poles. This study
gives a qualitative understanding of type I secretion of PHB from E. coli and the results
of this study can be used to understand type I secretion of other synthetic biologically
engineered products.

2.

Introduction
Polyhydroxybutyrates (PHBs) are biodegradable polyesters that can be

recombinantly produced in Escherichia coli. PHBs are one of 155 different polyesters
belonging to the group of polyhydroxyalkanoates (PHAs) [1]. Due to their desirable
properties and fast bacterial cultivation, PHBs are one of the most studied biopolymers.
Widespread production of this polymer in recombinant systems is limited due to high
costs of: carbon substrate [2] and purification to separate PHB from cell mass [3].
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In recombinant systems such as E. coli, PHB can be produced via a three
enzymatic pathway converting acetyl-CoA to PHB. Three genes from Ralstonia
Eutropha encode for beta-ketothiolase (phaA), acetoacetyl-CoA Reductase (phaB), and
PHA polymerase (phaC, or PHA synthase) are required for production of PHB [1]. As the
PHB polymer is being synthesized the PHA synthase (PhaC) remains covalently attached
and forms an amphipathic molecule with hydrophilic (polar) and hydrophobic (nonpolar) ends, this aids in the formation of a PHB granule [4]. There are four classes of
PHA synthases, where class I synthases are responsible for short chain length (scl) PHA
polymerization and class II synthases are used for medium chain length (mcl) PHA
polymerization [4, 5]. Additional proteins such as Phasin also attach to the PHB granules
and play a role in granule formation [6].
There are a variety of techniques that can be used to separate PHBs from cell
mass, such as chemical, mechanical, and biological treatments [3]. However, almost all
these methods are invasive and required some form of cell lysis. Secretion of a
bioproduct from its host is advantageous as it potentially allows for biomass recycling
and also exporting the bioproduct extracellularly helps shift the equilibrium towards
bioproduct generation [7].
Previously, a green fluorescent protein (GFP) was used to understand synthetic
biological engineering secretion systems in E. coli. From this study, type I secretion of
GFP fused to HlyA was determined to be the most successful [8]. Type I secretion is
advantageous as it offers direct secretion of a protein once the HlyA tag has been
expressed at the C-terminal of a protein [9].
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Building upon type I GFP secretion, an approach to secretion of PHB from E. coli
and into the culture medium was developed. Secretion of the PHB outside of the cell
could potentially eliminate the need for a solvent or energy intensive means of PHB
purification. Phasin, a structural protein, aids in PHB granule formation and was used in a
PHB secretion system with Phasin-HlyA protein-signal intermediate to bind to PHB
granules. HlyA, a signal peptide, was targeted for secretion using the aforementioned
type I secretion system. The results from this study demonstrated that 36% of the total
produced PHB was secreted and 64% remained inside the cell [10].
The ability of PHA synthase and proteins such as Phasin to bind to PHA granules
allows the polyester granule to be functionalized. Functionalized PHA granules are being
recognized for their potential utility in a wide range of biotechnological applications [11,
12]. These applications include: protein purification [13-15], enzyme immobilization [16,
17], vaccines [18], and imaging [19, 20].
Previous studies have used a GFP-PhaC binding partner to demonstrate
localization of PHB granules in E. coli. These studies demonstrated that PHA begins to
localize at the polar regions of the cell [19, 20]. A study by Peters and Rehm used the
class I PHA synthase from R. eutropha with GFP bound at the N-terminal of the synthase
[19]. Previous studies have demonstrated that the N-terminal of the PHA synthase (PhaC)
is not crucial for PHA synthase activity and thus a protein fusion at the N terminus of
PhaC will not impede PHA production or covalent binding of the PhaC to the PHA
granule [4, 21]. Interestingly, an additional study has suggested that PhaC-GFP fusions
are also possible due to the fact that the N-terminal of GFP is hydrophobic thus the Cterminal of PhaC can retain its activity [22].
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It has previously been demonstrated that secretion of PHB occurs at the polar
regions of the cell using a Phasin-HlyA type I secretion system with scanning electron
microscopy [10]. Since a synthetic biological engineering approach was demonstrated to
be successful in PHB secretion it was also used to create a GFP-PhaC fusion in this
present study. The objective of this study was to couple the PHB secretion system used in
Rahman et al. with a GFP-PhaC monitoring system similar to that used in Peters et al. to
understand real time type I secretion of PHB from E. coli.

3.

Materials and Methods
All reagents and enzymes were purchased from Thermo Fisher Scientific

(Pittsburgh, PA) unless stated otherwise. All cloning, BioBrick™ assembly, and
expression studies were carried out in E. coli XL1 Blue (Agilent Technologies, Santa
Clara, CA).

3.1

Bacterial strains and growth conditions
Minimal M9 media was used for experiments, containing M9 salts (Becton,

Dickinson and Co, Sparks, MD) supplemented with 1.5% (w/v) glucose (ACS grade,
Acros Organics, Fair Lawn NJ), 0.2% (w/v) yeast extract (Becton, Dickinson and Co,
Sparks MD), and 0.002 M MgSO4 [10, 23]. E. coli strains containing specific plasmids
were cultured overnight from single colonies in 5 ml LB media [24]. Overnight cultures
were then used to seed M9 cultures at an initial optical density (OD600) of 0.05. 0.1 mM
Isopropyl β-D-1thiogalactopyranoside (IPTG) (Gold Biotechnology, Inc. St. Louis, MO)
was added at 0 h. Where necessary, antibiotics were used in the following amounts: 50
µg/mL ampicillin (IBI Scientific, Peosta, IA) and 34 µg/mL chloramphenicol (Acros
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Organics, Fair Lawn, NJ). Cultures were grown in an orbital shaker operating at 225 rpm
and 37oC.

3.2

Construct assembly
Genetic parts were designed and assembled with BioBrick™ and BioFusion

standards [25, 26]. BioFusion standard RFC 23 allows for in frame protein fusions with a
threonine and arginine amino acid sequence between the fused proteins. All strains,
plasmids, and oligonucleotides used in this study are listed in Table 5.1.
BioBrick™ compatible phaC1 was amplified from the plasmid containing the
phaCAB operon (BBa_K934001, partsregistry.org) using the primers KFphaC1F and
KFphaC1RStp. PhaC1 was then cloned into pSB1C3 by digesting the PCR fragment with
EcoRI and PstI.
A cycle 3 green fluorescent protein (GFP) was amplified from the plasmid GFPuv
with the primers AR5 and AR6 and cloned into pSB1C3, primer design accounted for
removing of a stop codon and in frame protein fusion design [8, 27]. GFP had an XhoI
site removed via mutagenesis (while conserving amino acid sequence) using a
QuikChangeII Site-Directed Mutagenesis Kit and the QuikChange® Primer Design
Program (Agilent Technologies, Santa Clara, CA), this mutated GFPuv was now called
GFPmut. Sequencing of GFPmut was carried out with VF2 (BBa_G00100,
partsregistry.org)

and

VR

(BBa_G00101,

partsregistry.org)

primers

to

verify

mutagenesis. Subsequent cloning of GFPmut to the N-terminal of phaC1 was carried out,
Lac promoter (BBa_ R0010, partsregistry.org), ribosome binding site (BBa_B0034,
partsregistry.org), and double terminator (BBa_B0015, partsregistry.org) were cloned
sequentially to give pKF26.
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The complete GFPmut-phaC1 system was cloned with the phaP1-hlyA
(pCMEL2; [10]) into pSB3K3 (pKF29). The plasmid pKF29 was digested with EcoRI
and XhoI, the fragment cloned into pBHR68 giving the plasmid pAKF01. pAKF01 was
co-transformed with pLG575 into XL1 Blue thereby generating the secreting strain
(+hlyA/+hlyBD). Figure 5.1 A shows the genes in the pAKF01 plasmid with associated
proteins on the PHB granule surface and Figure 5.1 B illustrates the complete secretion
system.
A non-secreting system lacking hlyA expression was also constructed. pKF26
was transferred to the p4MT that contains a lac driven phasin expression system to give
pKF30. pKF31 was then made by ligating the insert of pKF30 in pSB3K3. pKF31 insert
was then cloned into the pBHR68 plasmid giving pAKF02. pAKF02 was co-transformed
with pLG575 into XL1 Blue thereby giving the non-secreting strain (-hlyA/+hlyBD).

Table 5.1. Strains, plasmids, and oligonucleotides used in this study
Relevant characteristics
Strains
XL1 Blue

Plasmids
pBHR68
pLG575
pSB1AK3
pSB1C3
pSB3K3
pCMEL2

pCMEL3

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F’proAB lacIqZΔM15 Tn10 (Tetr)]

pBluescript SK−, phbCAB genes from R. eutropha
pACYC184 derivative, HlyBD, p15A origin, CmR
High copy BioBrick™ vector, pMB1 origin, AmpR and
KanR
High copy BioBrick™ vector, pMB1 origin, CmR
Medium copy BioBrick™ standard vector, p15A origin,
KanR
phaP1, C-terminal BioFusion with HlyA signal peptide,
Lac promoter (BBa_R0010), RBS (BBa_B0034), in
pSB3K3
phaP1, C-terminal BioFusion with HlyA signal peptide,
Lac promoter (BBa_R0010), RBS(BBa_B0034), in
pBHR68

Reference
Agilent
Technologies

[28]
[29]
[30]
[30]
[30]
[10]

[10]
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pKF22

phaC1 in pSB1C3, amplified from BBa_K934001 in
pSB1C3
Green fluorescent protein (GFP), BBa_K208000 in
pSB1AK3
Green fluorescent protein (GFP) amplified from pGFPuv.
Stop codon removed and XhoI site mutated, in pSB1C3
In frame fusion [RFC 23] of GFPmut (pKF23) with phaC1
(pKF22). Lac promoter (BBa_R0010),
RBS(BBa_B0034), and double terminator (BBa_B0015),
in pSB1C3

This study

This study
This study
This study
[31]

pKF30
pKF31
pAKF01
pAKF02

EcoRI/SpeI fragment pKF26 and pCMEL2 in pSB1C3
EcoRI/PstI fragment of pKF27 in pSB1AK3
EcoRI/PstI fragment of pKF28 in pSB3K3
promoter (BBa_R0010), RBS(BBa_B0034), phaP1, and
double terminator (BBa_B0015) in pSB1AK3
EcoRI/SpeI fragment of pKF26 in p4MT
EcoRI/PstI fragment of pKF30 in pSB3K3
EcoRI/XhoI fragment of pKF29 (+HlyA) in pBHR68.
EcoRI/XhoI fragment of pKF31(-HlyA) in pBHR68.

Oligonucleotides
KFc426g_antisense

5'-gtgagttatagttgtactccagtttgtgtccgagaatgt-3'

This study

KFc426g

Primer for mutation of XhoI site from GFP
5'-acattctcggacacaaactggagtacaactataactcac-3'

This study

KFphaC1F

Primer for mutation of XhoI site from GFP
5’-tctggaattcgcggccgcttctagaatggctactgggaaaggagc- 3’

This study

KFphaC1RStp

Forward primer to amplify phaC1 from BBa_K934001
5’- tctgctgcagcggccgctactagttcacgcttttgcttttacat- 3’

This study

pGFPuv
pKF23
pKF26

pKF27
pKF28
pKF29
p4MT

[8]
This study
This study

This study
This study
This study
This study

Reverse primer to amplify phaC1 from BBa_K934001
conserving stop codon
AR5

5’-tctggaattcgcggccgcttctagaatggctagcaaagga-3’

This study

AR6

Forward primer to amplify GFP (BBa_K208000)
5’- tctgctgcagcggccgctactagttttgtagagctcatc-3’

This study

Reverse primer to amplify GFP (BBa_K208000) with no
stop codon (taa removed)
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Figure 5.1. Schematic for real time secretion of PHB granules with associated proteins
from Escherichia coli harboring plasmids pAKF01 + pLG575. Direct production of PHB
with the phaABC operon and expression of the GFP-PhaC fusion protein with the phaP1hylA secretion system both under lactose control. Once PHB granule is generated PhasinHlyA is bound to the granule and is targeted for secretion. Granule localization is
monitored with GFP-PhaC.
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3.3

Fluorometry
A fluorescent 96 well plate reader was used to measure GFP fluorescence. Prior to

testing samples, OD600 was measured and samples will normalized to an OD600 of 1 to
ensure that approximately the same number of cells where being tested. Samples were
loaded into a Costar® 96-well black plate (Corning Incorporated, Corning, NY) and
loaded into a Synergy 2 microtiter plate reader (BioTek, Winooski, VT). The cycle 3
GFP mutant has an excitation of approximately 395 nm and an emission of 509 nm, thus
the filter set used in this study was a 360/40 nm for excitation and a 528/20 nm for
emission.

3.4

Fluorescent microscopy
The microscope setup used in this study was the same as that used in a previous

study to monitor GFPuv secretion [8]. This setup consisted of an inverted Nikon Eclipse
Ti-U (Melville, NY), Photometrics® CoolSNAP HQ2 high-resolution camera, and B-2A
Longpass Emission filter set. For the purposes of this study, a 100x oil immersion
objective lens and NIS-Elements AR software were used for capturing fluorescence
images.

3.5

Recovery of secreted PHB and associated proteins
A calcium chloride (CaCl2) method was used to separate the secreted PHB and

protein from the cell fraction developed in a prior study. Breifly, 0.1 M CaCl2 (final
concentration, Avantor Performance Materials, Inc. Center Valley, PA) was added to the
culture and mixed. Tube were allow to sit for 10 min then via differential centrifugation
the secreted fraction was separated from the cell mass [10].
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3.6

PHB quantification
PHB was quantified for samples to demonstrate that PHB producing strains were

capable of PHB generation. Methods of PHB quantification were followed similar to the
methods seen in previous studies [32, 33].

3.7

Statistical analysis
Data from fluorometry studies were processed with Statistical Analysis Software

(SAS 9.4, SAS Institute Inc., Cary, NC). Two-way analysis of variance (ANOVA) was
performed on the data collected at 24 and 48 h after induction. Tukey post hoc
comparison was performed on significant results with a confidence level of 95%.

4.

Results and Discussion
PHB production and GFP fluorescence was observed for all strains upon IPTG

induction. To quantitatively demonstrate secretion of GFP bound PHB granules cultures
were subjected to CaCl2 treatment and differential centrifugation to separate secreted
PHB from cell mass [10]. 100µL of samples were then loaded onto Costar® 96-well black
plate and fluorescence was measured. Fluorescence values were corrected by subtracting
the autofluorescence of the background media. The results of this study are shown in
Figure 5.2 where the study was carried out at 24 and 48 h for the pAKF02+pLG575 (nonsecreting) and pAKF01+pLG575 (secreting) strains respectively. These results suggest
that there is significantly more fluorescence observed in the secreting strain’s secreted
fractions at 24 and 48 h compared to the non-secreting strain at the same time points
(p<0.05). While the average fluorescence from the secreting strain (pAKF01+ pLG575)
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was higher at 48 h compared to 24 h, there was no statistical significant difference in
fluorescence between these time points.
The non-secreting strain does demonstrate some fluorescence even after
background correction, this could be attributed to the differential centrifugation method
allowing some whole or lysed cells through. In a previous study it was observed that
there was some PHB present in the secreted fraction of a similar non-secreting strain and
it was attributed to liberated PHB due to cell lysis or some cells in the secreted fraction
[10].
600000
24 h
500000

48 h

RFU

400000
300000
200000
100000
0
pAKF02+pLG575

pAKF01+pLG575

Figure 5.2. Fluorescence measurements in relative fluorescent units (RFUs) of GFP in the
media at 24 and 48 h of the E. coli XL1 Blue strains harboring the pAKF02+pLG575 (hlyA/+hlyBD, non-secreting) and pAKF01+pLG575 (+hlyA/+hlyBD, full secretory
system) plasmids respectively.
Figure 5.3 A and B shows GFP fluorescence inside E. coli XL1 Blue harboring
the pAKF01 (+hlyA/-hlyBD) and pAKF02 (-hlyA/-hlyBD) plasmids respectively after 24
h of growth. The cells visually demonstrate accumulation of GFP tagged PHB granules
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inside the cell. From observation this shows approximately 50 % PHB of the cells total
volume. There are visible small granules inside the bacteria suggesting that GFP-PhaC is
bound to the granule surface and potentially reducing granule size. Figure 5.3 C, pAKF02
(-hlyA/-hlyBD), shows groups of cells containing individual granules of PHB inside the
cells. Interestingly, in Figure 5.3 C some cells also have a large accumulation of GFP
tagged PHB at one of the cell poles, this phenomena was also observed in another study
[34].
Figure 5.4 A demonstrates pAKF01 + pLG575 (+hlyA/+hlyBD, full secretory
system) expressed in XL1 Blue after 24 h of culturing. Similar to pAKF01 being
expressed alone there are fluorescently tagged spherical PHB granules inside the cell.
Previous studies have also demonstrated spherical shaped PHB granules [19, 20]. To the
author’s knowledge, the fluorescently tagged PHB granules in this study are smaller than
observed in other studies and this could be in part due to the overexpression of both the
PhaC and Phasin. It has previously been reported that overexpression of Phasin reduces
the PHB granule size considerably [35]. Additionally, there are preliminary signs of
secretion occurring from one of the poles of the cell (indicated with arrows).
Figure 5.4 B shows a cell exhibiting early secretion, this cell also has large PHB
granules in the middle of the cell. Previous studies reported that larger granules that
accumulate in the middle of the cell are actually cells undergoing the process of cell
division and that PHB granule was located at the new septum or future cell poles [19, 34].
Figure 5.4 C and Figure 5.4 D show PHB-GFP secretion 48 h post induction. Comparing
the fluorescent images seen in Figure 5.4 B and Figure 5.4 C to the SEM image seen in
Rahman et al. [10] it can be confirmed that secretion of PHB occurs at the polar regions
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of the cell. Also in Rahman et al. it was suggested that secretion occurs between 24 and
48 h, from the GFP labeled PHB it is clear that secretion is occurring between these time
points. Cells expressing the pAKF02 and pLG575 plasmids (-hlyA/+hlyBD, nonsecreting strain) were also observed under the fluorescent microscope at 24 and 48 h.
Figure 5.5 A shows the accumulation of the majority of the PHB at each of the cell poles.
Figure 5.5 B shows a typical non-secreting cell at 48 h post induction. Similar to
Figure 5.4B, the cell in Figure 5.5 B suggests that PHB granules are accumulating at the
new septum or cell division sites. Interestingly, many of the cells at 48 h were elongated
or filamented, with clear regions of internally accumulated fluorescent PHB. The
filamented bacteria suggest that accumulation of PHB affects cell division, this was also
observed in a previous study [36]. It was suggested that the reason for filamentation was
due to stress on the E. coli caused by accumulation of a non-native molecules such as
PHB. The stress on the cells due to PHB production inhibits the activity of the FtsZ
protein that is required for cell division [37]. FtsZ proteins are essential for the beginning
of cell division as they form a ring and framework for other division proteins [38]. A
study by S.Y. Lee in 1994 overexpressed the ftsZ gene in E. coli harboring the PHB
operon cells and demonstrated lower likelihood for filamentation [37]. An additional
study by the same group also showed that production of PHB was significantly increased
when FtsZ was overexpressed thus suppressing filamentation [39]. Interestingly, in the
secreting strain (Figure 5.4C/D) at 48 h cells were observed to be slightly elongated when
compared to 24 h. Total filamentation was not seen at 48 h in the secreting strain and thus
suggests that secretion of PHB from the cell poles potentially reduces the likelihood for
filamentation of E. coli.
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A

B

C
Figure 5.3. Fluorescent microscope images of GFP bound PHB granules in E. coli after
24 h of growth A) pAKF01 (+hlyA/–hlyBD) and B/C) pAKF02 (-hlyA/-hlyBD). White
bar represents 5 µm.
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A

C

B

D

Figure 5.4. Fluorescent microscope images of GFP bound PHB granules in pAKF01 +
pLG575 (+hlyA/+hlyBD, full secretory system). A) E. coli after 24 h of growth, cell
exhibiting accumulation and secretion, B) E. coli after 24 h of growth cell showing
secretion and accumulation of PHB at the new septum, and C/D) E. coli after 48 h of
growth cell showing secretion of GFP tagged PHB. Arrows denotes secretion from the
polar regions of the cell. White bar represents 5 µm.
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A

B
Figure 5.5. Fluorescent microscope images of GFP bound PHB granules in pAKF02 +
pLG575 (-hlyA/+hlyBD, non-secreting system) E. coli after A) 24 h and B) 48 h of
growth. White bar represents 5 µm.

Future work will be conducted on optimization of the separation of secreted PHB
from cellular mass with CaCl2. Additionally, other groups have demonstrated that by
overexpressing the ftsZ gene total PHB production was increased, another study would be
to overexpress ftsZ and observe its effect on cell division and PHB secretion.
Furthermore, functionalization of the PHB granule by fusing a different protein to PhaC
other than GFP could be carried out to increase the utility of having co-secretion and cofunctionalization of the PHB granule.

5.

Conclusions
This study used a GFP-PhaC binding partner to fluorescently tag PHB granules

and a Phasin-HlyA fusion for secretion. PHB production was observed for all strains
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carrying the GFP-PhaC fusion system. In most samples, individual granules could be
visualized with a fluorescent microscope. These fluorescently labelled granules can be
monitored in real time for internal localization and secretion of PHB and it was found
that 24 and 48 h post induction, secretion was highest when compared to a non-secreting
control.
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CHAPTER 6
A SYNTHETIC BIOLOGICAL ENGINEERING APPROACH TO PRODUCE
ARGIOPE AURANTIA SPIDER SILK IN ESCHERICHIA COLI

1.

Abstract
Dragline spider silk possesses a combination of tensile strength, elasticity, and

biocompatibility unmatched by any other biomaterial. These unique characteristics give
spider silk a wide range of potential applications. Farming spiders for production of
dragline spider silk is not feasible, thus different host organisms need to be used for large
scale manufacturing. This study demonstrates the use of synthetic biological engineering
and BioBricks™ to produce a synthetic dragline spider silk MaSp2 protein from Argiope
aurantia in Escherichia coli. We constructed fourteen repeats of a modified MaSp2 gene
from A. aurantia for recombinant expression in E. coli. Spider silk sequences were codon
optimized for expression in E. coli and the corresponding tRNAs were co-expressed to
increase spider silk protein production. The spider silk expression system was assembled
using standard BioBrick™ assembly techniques and the completed composite system was
transformed into BL21 for protein expression. Spider silk protein (85.7 kDa) was purified
using 10x His-Tags and a nickel affinity column. To qualitatively demonstrate increased
expression with tRNAs, the green fluorescent protein (GFP) was fused to the C-terminal
of the spider silk protein and fluorescence was measured with and without tRNAs. It was
observed that expression of the specific tRNAs produced higher levels of fluorescence,
indicating higher spider silk protein yields.
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2.

Visual Abstract
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3.

Introduction
Spider silk is an ancient biomaterial with remarkable properties such as

extraordinary strength and elasticity [1]. Orb-web weaving spiders have up to seven
different types of silk glands, with each gland producing a different spider silk protein
with unique properties [2]. Interestingly, the dragline spider silk has a strength of
approximately 4x109 N/m2 and an energy to break of 4x105 J/kg [3]. These mechanical
properties are similar or superior to other more commonly used materials such as Kevlar
and rubber [3]. In the future, there is a possibility for spider silk proteins to replace
manmade materials and have a wide range of potential applications if the spider silk
protein can be sustainably produced in large quantities [4].
Spiders can produce six different fibers, one of which is the major ampullate or
dragline silk. Dragline silk consists of two proteins: the major ampullate Spidroins
MaSp1 and MaSp2 [5] and is produced in many different species of spiders such as the
Nephila clavipes and Argiope aurantia. A study by Brooks et al. 2005 reported that N.
clavipes dragline spider silk consisted of 81% MaSp1 and 19% MaSp2, whereas A.
aurantia dragline spider silk contained 41% MaSp1 and 59% MaSp2 [6]. The synthetic
MaSp2 protein from A. aurantia consists of different motifs giving the protein a wide
range of potential properties. The GPGXX motif is directly responsible for increase in
type II β-turns, with an increasing number of GPGXX repeats reported to have an
increase in elasticity of the silk fiber. The polyalanines motif is responsible for the βsheet formation that correlates to the strength of the spider silk fiber [7].
Spider silk proteins have been expressed in a variety of different organisms, for
example: yeast [8], plants [9, 10], silkworms [11], mammalian cells [12], Salmonella
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[13], and Escherichia coli [7, 14]. Each host production system has its advantages and
disadvantages ranging from ease of upstream bioprocessing, yield of protein generated,
cost of production, and total production time.
From the different aforementioned host organisms, E. coli is potentially the best
industrial production host in which spider silk DNA can be cloned and expressed [15]. It
was chosen as the organism to express MaSp2 from the spider A. aurantia in this study.
MaSp2 from A. aurantia contains six amino acids in a highly repetitive system, thus
allowing for straightforward assembly of the modular gene. There has been a variety of
cloning methods and genetic engineering strategies used to assembly large repeats of
spider silk monomers in E. coli and these are reviewed elsewhere [16, 17].
In this study, a synthetic biological engineering approach known as BioBrick™
standard assembly RFC 23 was used [18]. Using this approach, multiple repeats of the
spider silk monomer can be assembled together quickly and easily. Another advantage of
using the BioBrick™ standard assembly is that different sizes of spider silk monomers
can be assembled together to produce a variety of different synthetic spider silk sizes.
This is advantageous as it has been reported that spider silk proteins of higher molecular
weight have better overall mechanical properties [19].
BioBrick™ standard assembly RFC 23 is one of the most robust molecular
cloning techniques and allows rapid in frame assembly of functioning molecular systems
in different organisms. One of the disadvantages of this assembly method is the
generation of “scar” threonine and arginine between the two fused proteins. Arginine is
not present in abundance in E. coli and hence could lead to lower protein yields. Highly
repetitive constructs such as those used to produce synthetic spider silk in E. coli will
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contain many “scar” regions and hence could deplete the available tRNA pool for
arginine in E. coli.
In this study we demonstrate the effect of additional specific tRNAs to support
synthetic spider silk production in E. coli. Along with measuring spider silk yields
directly, a cycle 3 green fluorescent protein (GFP) mutant fused to the C-terminal of the
spider silk protein was used as an indirect means of measuring spider silk production
levels.

4.

Materials and Methods
All chemicals and reagents were purchased from Thermo Fisher Scientific Inc.

(Pittsburgh, PA) unless mentioned otherwise. DNA constructs denoted with ‘BBa’ are
available at partsregistry.org. Cloning was conducted with the RFC 23 standard assembly
[18]. Spider silk producing genes were expressed in pSB1C3 and tRNA supporting
constructs were expressed in pSB3K3. E. coli XL1-Blue was used for cloning, while
protein expression and fluorescence studies were conducted in BL21.

4.1

Media preparation
All initial growth experiments during cloning were carried out in LB media [20]

with appropriate antibiotic added at a final concentration of 34 μg/mL chloramphenicol
(Acros Organics, Fair Lawn, NJ) and 50 µg/mL Kanamycin (Gold Biotechnology, Inc.
St. Louis, MO). Cultures were grown at 37oC on an orbital shaker at 220 rpm.

4.2

Design and optimization of spider silk sequences for tRNA usage
MaSp2 from A. aurantia uses only six amino acids (glycine, tyrosine, proline,

alanine, glutamine, and serine) and thus overexpression of the silk protein in E. coli could
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potentially lead to the depletion of charged tRNA molecules in the host cell. Depletion of
charged tRNAs molecules could reduce the yields of the spider silk protein. A review by
Makrides highlights several studies that demonstrated significant increase in recombinant
protein levels when expressing specific tRNAs [21]. Makrides also highlights the
consideration of the expression of arginine in E. coli as these codons are rarely used [21].
As mentioned, the use of arginine cannot be avoided with a BioBrick™ assembly system
as RFC 23 generates arginine (AGA) as a result of restriction enzyme ligation scar [18].
Codon optimization for specific tRNAs has not been well documented in literature,
however, a recent study by Xia et al. demonstrated an increase in N. clavipes synthetic
spider silk protein production in E. coli when the glycine-tRNA pool was increased [22].
Codon optimization for specific tRNAs in this study was performed based on the
amino acid sequence of MaSp2 from A. aurantia in Brooks et al. [7]. A list of tRNA
genes in E. coli K-12 was acquired from the Genomic tRNA Database
(http://gtrnadb.ucsc.edu/Esch_coli_K12/eschColi_K12-tRNAs.fa, accessed September
2012). Finding the specific tRNA to overexpress from the host organism is vital to
increasing expression of spider silk proteins. In this study, specific codons were chosen
so that they contained the lowest possible GC% for each specific amino acid.
The spider silk construct was designed using a balanced codon construction
(BBa_K844004, partsregistry.org). This gene uses two codons for glycine (ggt & gga),
two for proline (cct & cca), and two for serine (agt & tct) as these were the only amino
acids out of the six that had multiple codons options with low GC%. Alanine also had
two codons with low GC%, but additional codons could not be utilized since a PstI
restriction site would be created in the construct, which is incompatible with RFC 23
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assembly [18]. Thus, a single codon for Alanine (gca) was used in the construct design
(BBa_K844004). Table 6.1 shows the codon usage in E. coli (DNA 2.0, Menlo Park,
CA), MaSp2 in Brooks et al. [7], and MaSp2 in this study. Distribution of the different
codons in the BBa_K844004 construct was also taken under consideration where, the two
codons for the glycine, proline, and serine amino acids were distributed evenly.
The amino acid sequence and codon usage for MaSp2 A. aurantia (BBa_844004)
is shown in Figure 6.1. This sequence contains two repeats of the elastic unit
(GGYGPGAGQQGPGSQGPGSGGQQGPGGQ) followed by a GPYGPS linker and 6
polyalanines, modified from the amino acid sequence for MaSp2 from A. aurantia [7]. It
is well documented that the polyalanines form the β-sheets that are directly related to the
strength of the fiber [23].
The tRNA plasmid p6x5x consisted of a pSB3K3 plasmid backbone with
BBa_K844012 and BBa_K844013 BioBrick™ parts (partsregistry.org). These two parts
consisted of specific tRNAs for each codon optimized amino acid in the MaSp2
sequence. The promoter chosen for tRNA expression of each tRNA was based on the 12x
promoter from the study by Bauer et al. [24].
An additional spider silk BioBrick™ was created to contain a start codon (atg) to
allow for direct translation of the mRNA. Start codons were added to each BBa_K844004
spider silk piece with the use of a site directed mutagenesis kit (Agilent Technologies,
Santa Clara, CA).

4.3

BioBrick™ Assembly
All BioBricks™ were constructed in pSB1C3 [25] according to BioBrick™

standards [18, 26]. All the spider silk repeat units as well as the 10x His-Tag were
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assembled according to RFC 23, which allows for in frame protein fusions. All
completed parts were transformed via electroporation into E. coli XL1-Blue (Agilent
Technologies, Santa Clara, CA) to generate higher plasmid levels as BL21 has low plasid
copy numbers.
The Lac promoter and ribosome binding site (BBa_R0010 and BBa_B0034,
partsregistry.org) were used as it had been previously demonstrated to work in other
protein expression systems such as that for green fluorescent protein (GFP) expression
and translocation [27]. Furthermore, the ribosome binding site BBa_B0034 was reported
as one of the most useful parts from the parts registry [28]. One MaSp2 spider silk
subunit, BBa_K84408 (containing atg), was first cloned proceeding the ribosome binding
site followed by 13 repeats of BBa_K844004. Finally the C-terminal 10x His-tag
(BBa_K844000) and double terminator (BBa_B0015) were subsequently cloned into the
system to give pB14. The 10x His-tag was placed at the C-terminal end to ensure that
only fully translated spider silk protein was purified. Sequencing was carried out using
primers VF2 (BBa_G00100, partsregistry.org) and VR (BBa_G00101, partsregistry.org)
to confirm correct construction (partsregistry.org). Detailed descriptions of strains and
plasmids used in this study are shown in Table 6.2 and Figure 6.2, respectively.
Another plasmid, pB14GFP, containing the lac promoter, rbs, and 14x spider silk
was constructed with green fluorescent protein (GFP) and a 10x His-Tag at the Cterminal. The GFP (BBa_K208000) and was amplified using primers AR5 and AR6.
Primers were designed in accordance with RFC 23 and to remove the stop codon in GFP
so that a GFP and 10x His-Tag fusion could be formed. In addition, constructs containing
4x, 12x, and 16x spider silk subunits with GFP fused at the C-terminal were also built.
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4.4

Fluorescence studies
Cultures were grown in LB media with appropriate antibiotics. 0.1 mM Isopropyl

β-D-1-thiogalactopyranoside (IPTG) (Gold Biotechnology, Inc. St. Louis, MO) was
added at time=0 and cultures were allowed to grow overnight (~15 hours) in an orbital
shaker at 220 rpm, 37oC. The IPTG concentration of 0.1 mM was chosen as this
demonstrated optimal protein expression in studies with the same promoter system [27,
29]. Overnight cultures were standardized based on OD600. 200 μL of each sample was
loaded into three separate wells of a Costar® 96-well black plate (Corning Incorporated,
Corning, NY). Fluorescence analysis was then conducted using a Synergy 2 microtiter
plate reader (BioTek, Winooski, VT) with an excitation of approximately 395 nm and
emission of 509 nm for GFP. Filter wheels used in study were: excitation 360/40 nm and
emission 528/20 nm. Background fluorescence values for BL21 Gold cells not containing
any fluorescence were subtracted from the values obtained from samples containing GFP.
The studies were carried out in triplicate.
Fluorescent microscopy was also used to image the cells, using an inverted
Eclipse Ti-U (Melville, NY), Photometrics® CoolSNAP HQ2 high-resolution camera,
and B-2A Longpass Emission filter set with 100 x objective [27].

4.5

Bioreactor scale-up
To analyze MaSp2 production, pB14 with and without tRNAs (p6x5x) were

grown overnight in 100 mL seed cultures on a shaker table at 220 rpm, 37°C with
appropriate antibiotics. Seed cultures and bioreactors had the same media composition.
Seed cultures were added to 10 L Winpact Bioreactor and Fermentors (GMI, Inc.,
Ramsey, Minnesota) for protein production.
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Figure 6.1.Nucleotide and amino acid sequence for one monomer of MaSp2 dragline
spider silk from Argiope aurantia (BBa_K844004). Codon usage: glycine (G=2 (ggt,
gga)), tyrosine (Y=1 (tat)), proline (P=2(cct, cca)), alanine (A=1(gca)), glutamine (Q=1
(caa)), and serine (S=2 (agt, tct)). GC content approximately 55%.

Figure 6.2. Spider silk production system constructed using the BioBrick™ assembly
standard RFC 23 (pB14). BBa_K208010 is a composite part consisting of a Lac Promoter
and Ribosome Binding site. BBa_K84408 is the spider silk subunit of the MaSp2 gene
from Argiope aurantia containing a methionine (atg). 13 repeats of BBa_K844044 are
spider silk subunits of the MaSp2 gene from A. aurantia. BBa_K844000 is a 10x His-tag
with a double stop codon. BBa_B0015 is a double terminator.
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Table 6.1. Codon usage for one repeat of MaSp2 A. aurantia spider silk containing two
elastic units (2E). Escherichia coli B codon usage (DNA 2.0, Menlo Park, CA),
Unoptimized DNA sequence (Brooks et al. 2008), Balanced codon usage (this study).
Not shown are the codons for the scar region (2 amino acids that are between each of the
spider silk subunits): T-Threonine (ACT codon) and R-Arginine (AGA codon).

% Codon Usage
Amino acid
Amino Acid composition (%) Codon
in MaSp2
GCT
GCC
Ala (A):
11.80
GCA
GCG
CAA
Gln (Q):
17.6
CAG
GGT
GGC
Gly (G):
44.1
GGA
GGG
CCT
CCC
Pro (P):
14.7
CCA
CCG
TCT
TCC
TCA
Ser (S):
7.4
TCG
AGT
AGC
TAT
Tyr (Y):
4.4
TAC

Unoptimized
Escherichia
Balanced (this
MaSp2 (Brooks et
coli B
study)
al. 2008)
22
25
0
26
25
0
27
25
100
25
25
0
35
33
100
65
67
0
34
57
50
29
40
0
19
0
50
17
3
0
24
0
50
16
0
0
23
0
50
37
100
0
18
0
40
14
0
0
18
0
0
11
0
0
18
0
60
20
100
0
65
100
100
35
0
0
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Table 6.2. Strains and plasmids used in this study

Relevant Characteristics

Reference

Strains
XL1 Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB
lacIqZΔM15 Tn10 (Tetr)]

Agilent Technologies

BL21 Gold

E. coli B F- ompT hsdS(rB– mB–) dcm+ Tet+ gal endA Hte

Agilent Technologies

Plasmids
pSB1C3

High copy BioBrick™ vector, pMB1 origin, CMR

[25]

Spider silk production vector. Lac promoter +RBS
(BBa_K208010), spider silk subunit (BBa_K84408), 13x spider
silk subunit (BBa_ K844004), 10x His-tag (BBa_ K844000), and
double terminator (BBa_ B0015) in pSB1C3.

This study

Spider silk production vector with GFP fusion at C terminal. Lac
promoter +RBS (BBa_K208010), spider silk subunit
(BBa_K84408), 13x spider silk subunit (BBa_ K844004), modified
GFP with stop codons removed (BBa_K208000), 10x His-tag
(BBa_ K844000), and double terminator (BBa_ B0015) in
pSB1C3.

This study

pB04GFP

Similar to pB14GFP but with 4x repeats of spider silk subunit

This study

pB12GFP

Similar to pB14GFP but with 12x repeats of spider silk subunit

This study

pB16GFP

Similar to pB14GFP but with 16x repeats of spider silk subunit

This study

tRNA plasmid pSB3K3 containing both BBa_K844012 and
BBa_K844013 composite BioBrick™ parts.

This study

pB14

pB14GFP

p6x5x

Oligonucleotides
AR5

AR6

5’-tctggaattcgcggccgcttctagaatggctagcaaagga-3’
Forward primer to amplify GFP (BBa_K208000)
5’- tctgctgcagcggccgctactagttttgtagagctcatc-3’
Reverse primer to amplify GFP (BBa_K208000) with no stop
codon (taa removed)

This study

This study
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Media used for these studies were modified based on Chen et al. [30]. Briefly, the
bioreactor medium consisted of 15 g/L Hy-Express™ System II (Sheffield Bio-Science,
Beloit, WI), 5 g/L Hy-Yest™ 444 (Sheffield Bio-Science, Beloit, WI), 20 g/L Glucose,
16 g/L Glycerol (Amresco, Solon, OH), 7.1 g/L Na2HPO4, 6.8 g/L KH2PO4, and 3.3 g/L
(NH4)2SO4. Additionally, trace elements were added as mentioned in Chen et al. [30]. A
dissolved O2 level of 40% was controlled and monitored by gassing with air, O2, and
agitation. NH4OH was used to maintain pH at 6.0 and Himar FGK antifoam (Jeneil
Biotech Inc., Saukville, WI) was added automatically via a controller during
fermentation. Protein expression was induced with 0.1 mM IPTG and was added at a
culture OD600 of approximately 20. Cultures were harvested approximately 4-5 h after
IPTG induction using a CEPA Z41 continuous flow centrifuge (Eppendorf, Hamburg,
Germany) and cell pellets were immediately stored at -80oC.

4.6

Protein purification
Approximately 50 g of wet biomass were sonicated for 10 min in binding buffer

(5 mM Imidazole, 0.5 M NaCl, 20 mM tris-HCl, and 4 M Urea) and lysates were
centrifuged at 5000 x g for 10 min. The supernatant fractions were passed through an
AKTA Avant system (GE Healthcare Biosciences, Pittsburgh, PA) with a 5 mL HisTrap
FF crude nickel column (GE Healthcare Biosciences, Pittsburgh, PA) for spider silk
protein purification. Non-specifically bound protein, flow through, and lysed cell debris
was saved for analysis. Spider silk protein was dialyzed using Fisherbrand regenerated
cellulose dialysis membranes, MWCO 3500 (Fisher Scientific, Pittsburgh, PA). Dialysis
was conducted over 48 h in ddH2O similar to a previous study [31]. Once the protein was
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desalted, it was frozen to – 80oC and then lyophilized in a FreeZone 4.5 L benchtop
freeze dry system (Labconco, Kansas City, MO).

4.7

PAGE/Western
Proteins were mixed with loading buffer, and heat treated for 1-3 min at 90oC. 30

μL of protein and buffer at a 1:1 ratio were loaded into precast 4-20% Precise Protein
gels (Thermo Scientific Inc., Rockford IL). Precision Plus Protein™ marker (Bio-Rad,
Hercules, CA) was used to visualize protein propagation. Gels were run at 100 V with
Tris-HEPES running buffer. For visualization, gels were stained with Bio-Safe
Coomassie Stain overnight (Bio-Rad, Hercules, CA) and de-stained in ddH2O.
For Western Blot analysis, proteins were electroblotted from protein gel to
nitrocellulose membrane (Bio-Rad, Hercules, CA) and blocked with 5% non-fat milk
TBS-Tween-20 for 30-60 min. Primary antibody, Anti-6X His Epitope tag (Mouse)
Monoclonal Antibody (Rockland Immunochemicals Inc., Gilbertsville, PA) was used in a
1:1000 ratio. The membrane was then washed 3 times with TBS-Tween-20 and blocked
with blocking solution. Secondary antibody anti-Mouse IgG H&L ab6729 1:1000
(Abcam Inc., Cambridge, MA) was added to 2nd block for 30 min, washed 3 times with
TBS-Tween-20. 1-Step NBT/BCIP substrate (Thermo Fisher Scientific Inc., Rockford,
IL) was added and chemiluminescence was allowed to occur for 10 min.

4.8

Spinning spider silk
Desalted spider silk protein was spun using a DACA fiber spinning system

(DACA Instruments, Santa Barbara, CA). Major ampullate MaSp2 silk protein dopes
were generated by dissolving different ratios of silk protein into 1,1,1,3,3,3-hexafluoro-2-
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propanol (HFIP). The protocol for dissolving and spinning the silk was adapted from
Teule et al. [32]. After the silk has been completely dissolved in HFIP the silk mix was
extruded through a needle into a coagulation bath containing isopropanol at room
temperature. The strand of silk is then wound through a set of godets and collected as a
fiber. Fibers are then glued to cards and diameters are calculated before strength testing
was carried out.

5.

Results and Discussion

5.1

Spider silk expression studies with green fluorescent protein (GFP)
To demonstrate that tRNAs can help increase spider silk protein expression levels

in E. coli, GFP was tagged to the C-terminus of different sized silk proteins. Proteins with
different spider silk repeat numbers with and without additional tRNAs were expressed in
E. coli and GFP fluorescence was measured. The benefit of having GFP at the C-terminal
means that only fully transcribed DNA sequences will have spider silk and GFP
expression. From Figure 6.3 it can be observed that fluorescence levels for samples with
tRNAs are higher than those samples without tRNAs. Interestingly, spider silk constructs
that were shorter in length had higher levels of fluorescence which demonstrates that
either: 1) the duration of time to express different spider silk proteins is longer for a
larger protein or 2) smaller spider silk proteins are produced at a higher level, thus higher
overall GFP fluorescence. This GFP fluorescence study indirectly demonstrates that
additional tRNAs increase overall spider silk production. Furthermore this system is also
useful for real time analysis of spider silk production in E. coli. Figure 6.4 shows
fluorescent microscope images of the E. coli expressing different sizes of the spider silk
fused to GFP.
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Figure 6.3. GFP fluorescence for different repeats of spider silk subunit with GFP fused
to the C-terminus of the spider silk protein. Each repeat was tested for fluorescence with
and without tRNAs. ‘B’ denotes ‘balanced’ construct and the subsequent number is the
number of spider silk gene repeats.

Figure 6.4. Fluorescent microscope images of E. coli cells expressing different sizes of
MaSp2 Argiope aurantia spider silk fused to green fluorescent protein. A) 4 repeats, B)
12 repeats, and C) 16 repeats of the MaSp2 subunit.

5.2

Preliminary protein purification results
Lysed cell extracts were passed onto a nickel column for purification of synthetic

spider silk protein. Figure 6.5 and Figure 6.6 show chromatographs of protein
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purification (nickel affinity chromatography) from E. coli strains without and with tRNAs
respectively. The blue lines in Figure 6.5 and Figure 6.6 show absorbance at 280 nm. The
first blue line peak shows the wash fraction that indicates non-specifically bound protein
being washed off the nickel column and the second peak shows the elution fraction from
the nickel column.
In order to compare the approximate yield of spider silk protein with and without
tRNAs, HPLC was carried out as demonstrated in Figure 6.7. It was observed that when
tRNAs were expressed the overall yield of spider silk was increased approximately 20
fold between 2.45 and 2.55 min.

2
1

Figure 6.5. Nickel affinity chromatography results for spider silk production system
without tRNA expression. Blue line indicates absorbance at UV 280 nm, where first peak
is wash fraction and second peak is elution fraction.
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2

1

Figure 6.6. Nickel affinity chromatography results for spider silk production system with
tRNA expression. Blue line indicates absorbance at UV 280 nm, where first peak is wash
fraction and second peak is elution fraction.

Figure 6.7. HPLC on elution fractions from spider silk sample with and without tRNAs.
Construct that has tRNAs demonstrates increased production of spider silk. Peak of
interest is between 2.45 and 2.55 min.
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Figure 6.8. SDS polyacrylamide gel (A) and corresponding immunoblot (B) for: Cell
lysate, Flow through, wash fractions, elution fraction, and Precision Plus Protein™
Marker.

5.3

Analysis of spider silk protein production
The Coomassie stained SDS polyacrylamide gel (Figure 6.8 A) showed bands at

approximately 85.7 kDa in elution fraction. Additionally, the corresponding immunoblot
(Figure 6.8 B) showed the presence of a band of approximately 85.7 kDa in elution
fraction.

6.

Conclusions
A synthetic biological engineering approach can be used to systematically

assemble spider silk subunits together to create functioning systems. This step-wise
assembly method using BioBrick™ assembly standard RFC 23 opens up many different
possible sizes of spider silk repeats that could be assembled together and expressed.
Studies with GFP demonstrate that spider silk production levels can be increased with the
use of specific tRNAs. This study demonstrated that E. coli harboring the pB14 plasmid
can produce 85.7 kDa MaSp2 spider silk proteins from A. aurantia with the use of
BioBrick™ standard assembly.
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Future work will include comparing results from this study to another system that
uses a lower plasmid copy number system, increasing the number of spider silk repeats
(hence increase overall protein size), modifying the growth media for increased protein
expression, and spinning fluorescent spider silk proteins.
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CHAPTER 7
BIOREMEDIATION OF DOMESTIC WASTEWATER AND PRODUCTION OF
BIOPRODUCTS FROM MICROALGAE USING WASTE STABILIZATION
PONDS2

1.

Editorial
Domestic wastewater treatment and remediation is an expensive process due to

significant time and planning needed for successful treatment. Modern wastewater
treatment plants are highly mechanized and expensive to build and maintain. In less
economically developed parts of the world alternative methods of wastewater treatment
are required. Waste stabilization ponds, or lagoons, provide an ideal solution for
wastewater treatment in developing countries and rural areas. These ponds facilitate the
oxidation of organic matter through complex symbiotic relationships between bacterial
consortiums and assimilation of wastewater nutrients with photoautotrophic microalgae
[2]. In the United States more than 7,000 lagoon systems are used to treat domestic
wastewater (U.S. EPA, 2002, Report No. EPA 832-F02-014) [1]. Most domestic
wastewater is considered weak or medium in strength with nitrogen levels between 20-40
mg/L and phosphorus levels between 4-8 mg/L [3]. These concentrations of nitrogen and
phosphorus are undesirable as they can lead to considerable pollution and eutrophication
of downstream waterways [2].
Open pond lagoon systems have many advantages over mechanicalized methods
and are able to remove nitrogen and phosphorus to required EPA levels. Interestingly,
nitrogen and phosphorus found in weak domestic wastewater are at an ideal level for

2

Co-authors: Joshua T. Ellis and Charles D. Miller
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microalgae cultivation and growth. Microalgae can grow to high densities by assimilating
nitrogen and phosphorus, thus removing these inorganic nutrients from the wastewater. In
addition, open pond lagoon systems also allow ideal mixing and adequate light exposure
for microalgae growth. Microalgae play a vital role in recycling carbon in the biosphere
by converting carbon dioxide into organic compounds through photosynthesis [1], while
also producing oxygen via the oxidation of water. Metal compounds such as Cr, Cu, Pb,
Cd, Mn, As, Fe, Ni, Hg, and Zn can also be bioremediated by microalgae. Microalgae
such as Chlorella and Scenedesmus have shown tolerance and bioremediation capabilities
to certain heavy metals [5]. Additionally, microalgae have been used for the
bioremediation of textile dyes in wastewater from industrial textile processes. These
bioremediation capabilities of microalgae are useful for environmental sustainability and
algal biomass can be used as feedstock for the production of high energy compounds [4,
6].
Algal biomass can be processed chemically and biologically to produce high
value products such as bioacetone, biobutanol, biodiesel, and biomethane. Microalgae as
feedstocks provide high densities of carbohydrates (typically comprising glucose units),
triacylglycerides and free fatty acids that can be used to produce biofuels and biodiesel. It
has been demonstrated that microalgae can be a promising feedstock and will play a vital
role in the future production of clean and renewable energy [1, 4].
The disadvantages to an open pond lagoon system are that the microalgae nutrient
requirement may not match the stoichiometric ratio of the microalgae biomass, where the
optimum nitrogen to phosphorus ratio for microalgae growth is 16:1. Thus,
photoautotrophic bioremediation of inorganic compounds might not be carried out to
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adequate levels. To meet nutrient requirements for microalgae growth, additional
chemicals (usually nitrogen rich sources) may need to be supplemented to the
wastewater, which is undesirable.
Microalgae grown in open pond lagoon systems are at low densities and
specialized harvesting technologies need to be implemented in order obtain suitable
biomass yields. Harvesting techniques such as a Rotating Algal Biofilm Reactor (RABR)
[1], filtration, sedimentation, and dissolved air flotation (DAF) units can be employed to
harvest the microalgae from open pond lagoon systems. There are advantages and
disadvantages to each method, but the cost of harvesting is currently high and more
efficient technologies need to be created [2].
To summarize, waste stabilization ponds provide an active bioremediation system
to clean domestic wastewater, and they can also produce microalgal feedstocks for the
production of high value bioproducts. Interest in the use of microalgae will continue to
grow as rural cities and developing countries look for sustainable and affordable ways to
clean domestic wastewater. Processes where wastewater is bioremediated through
heterotrophic and photoautotrophic organisms, and in turn high value bioproducts are
generated have great potential to stimulate regional and local economic development [2].
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CHAPTER 8
EFFECTS OF WASTEWATER MICROALGAE HARVESTING METHODS ON
POLYHYDROXYBUTYRATE PRODUCTION3

1.

Abstract
Microalgae have gained considerable attention recently as a sustainable means to

produce biofuels and bioproducts. It has previously been demonstrated that single strain
microalgae can be harvested and processed through a wet lipid extraction procedure
(WLEP). After WLEP processing, acetone, butanol, ethanol, and biodiesel can be
produced, and growth of recombinant Escherichia coli can be achieved from the
microalgae. This study demonstrates the application of different wastewater microalgae
harvesting techniques and processing through WLEP on the production of
polyhydroxybutyrate (PHB) by E. coli. The harvesting techniques include: cationic potato
starch (CPS), cationic corn starch (CCS), aluminum sulfate, and centrifugation. The
microalgae-based media were used to grow E. coli to ~1013 CFU/mL and produce
approximately 7.8% of dry cell weight as PHB. This study demonstrates the feasibility of
harvesting wastewater algae to produce PHB and the potential for bioproduct generation.

2.

Introduction
Polyhydroxyalkanoates (PHAs) are promising alternatives to petroleum based

plastics (Gumel et al., 2012). PHAs have a diverse range of potential applications due to
their chemical and physical properties that are comparable to traditional petroleum
derived plastics (Rehm, 2010). A wide variety of PHAs exist, including
3

Coauthors: Renil J. Anthony, Ashik Sathish, Ronald C. Sims, and Charles D. Miller

152

polyhydroxybutyrates (PHB), which are short chain length polymers with 3-5 carbon
monomers (Agnew et al., 2013). Production of PHB can be accomplished by recombinant
Escherichia coli containing the phaCAB operon (isolated from Ralstonia eutropha) that
encodes for a three step enzymatic process to convert a carbon substrate into PHB
(Spiekermann et al., 1999).
Despite the similar material characteristics to petroleum derived plastic, high
costs of PHA production have limited its widespread use. It has been reported that PHA
production can cost approximately $2.65-5/kg compared to petroleum derived plastics
costing $1.57-1.67/kg (Choi and Lee, 1997). The economic production and scale-up of
PHB is dependent on inexpensive carbon substrates. Studies have shown that the carbon
substrate accounts for approximately 40% of the total cost of recombinant production of
PHB in E. coli (Choi and Lee, 1999). Hence there is motivation to use inexpensive
carbon substrates, ideally from waste products of other processes. Previous studies have
demonstrated production of PHB from: anaerobic digesters (Linton et al., 2012), food
wastes (Hafuka et al., 2011), and waste glycerol from biodiesel production using a variety
of microorganisms (Dobroth et al., 2011).
Microalgae have been extensively studied as a feedstock for biodiesel production
(Chisti, 2007). High growth rates, low fresh water requirement, and high photosynthetic
efficiency are few of the important characteristics that have made microalgae the obvious
choice as a biodiesel production platform (Christenson and Sims, 2011). Microalgae can
remediate wastewater by assimilating phosphorus and nitrogen as growth nutrients,
thereby achieving tertiary treatment (Rahman et al., 2012). In the United States over
7,000 lagoon systems are used to treat domestic waste water (U.S EPA, 2002, Report No.
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EPA 832-F02-014) (Christenson and Sims, 2012). Lagoon systems are an ideal solution
to wastewater treatment compared to modern wastewater treatment plants and are
suitable for developing countries and rural areas. The city of Logan, Utah processes
approximately 15 million gallons per day of its wastewater in a 460 acre (~1.9 km 2) open
pond facultative lagoon system. This system consists of seven ponds with an average
depth of five feet (~1.5 m). Microalgae grown in these ponds can be harvested to provide
a sustainable supply of biomass for bioproduct generation (Christenson and Sims, 2012).
We have previously demonstrated a “biorefinery” approach to harvesting single
strain algae (Scenedesmus obliquus) and subsequent production of acetone, butanol,
ethanol, biodiesel, and growth of genetically engineered E. coli (Anthony et al., 2013).
S. obliquus was grown in Solar Simulated Bioreactors (SSR) and harvested with cationic
starches, alum, and centrifugation. The algae were then processed via a wet lipid
extraction procedure (WLEP) creating four streams, three of which have been previously
utilized (Anthony et al., 2013; Sathish and Sims, 2012). The first stream (hydrolyzed
algal biomass) was used to generate acetone, butanol, and ethanol (ABE) by Clostridium
saccharoperbutylacetonicum N1-4 fermentation (Ellis et al., 2012). The remaining two
side streams, the lipid extract and resultant aqueous phase, were used to produce
biodiesel and to grow genetically engineered E. coli respectively.
In this study, mixed culture microalgae were collected from the Logan lagoon
wastewater treatment plant (Logan, UT) using different harvesting methods. After
harvesting, algae were fractionated via the WLEP (Anthony et al., 2013; Sathish and
Sims, 2012) to obtain an aqueous phase. This aqueous phase was then used as the
substrate for growth of genetically engineered E. coli and production of PHB. The
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objective of this study was to evaluate the effect of various wastewater microalgae
harvesting techniques, including flocculation with cationic potato starch (CPS), with
cationic corn starch (CCS), with aluminum sulfate, and centrifugation, on the resulting
algae-based media’s (from WLEP) ability to support E .coli growth and production of
PHB.

3.

Materials and Methods
All chemicals and reagents were purchased from Thermo Fisher Scientific

(Pittsburgh, PA) unless stated otherwise. Reagents used for the processing of algal
biomass post harvesting using WLEP included ACS grade sulfuric acid from EMD
Chemicals (Gibbstown, NJ) and sodium hydroxide from Avantor Performance Chemicals
(Center Valley, PA).

3.1

Cationic starch synthesis and microalgae harvesting
The methods for cationic potato starch (CPS), and cationic corn starch (CCS)

synthesis were adopted from a previous study (Anthony and Sims, 2013). Briefly, potato
starch and corn starch (acquired locally, Logan, UT) were dissolved in ceric ammonium
nitrate (Sigma Aldrich, St. Louis, MO) and heated for 30 min. 3-methacryloyl amino
propyl trimethyl ammonium chloride (MAPTAC, Sigma Aldrich, St. Louis, MO) was
added, and mixtures were heated for a further 2 h. Final products were washed with
ethanol. The total nitrogen content present in CPS and CCS was measured using Hach
Test 'N Tube (Loveland, CO) employing the 4500-N B Standard Methods (Clescerl et al.,
1998). The degree of substitution (DS) was calculated as described previously (Anthony
et al., 2013).
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Methods for harvesting single strain S. obliquus are described in Anthony et al.
2013 (Anthony and Sims, 2013), similar methods were used in this study for harvesting
mixed culture lagoon algae and processing via the WLEP. Briefly, microalgae were
harvested from the Logan lagoons (Logan, UT) using CPS, CCS, aluminum sulfate
(alum, Sigma Aldrich, St. Louis, MO), and centrifugation (8000 rpm x 10 min) at pH 7.0.
Dosage amounts of each compound are provided in Table 8.1. Apart from centrifugation,
lagoon microalgae were harvested by the reduction of the negative zeta potential of algae
to 0 mV by the addition of CPS, CCS, and alum. Zeta potential measurements were
performed using a ZetaPlus zeta meter (Brookhaven Instruments Corporation, Holtsville,
NY). Lagoon microalgae were collected by adding predetermined concentrations of the
coagulants, flash mixing, and allowing flocculation and settling for approximately 1 h.
Samples for zeta potential measurement were collected before and after addition of CPS,
CCS, and alum. A sample of the harvested biomass from each method was washed with
0.1 M NaOH to remove associated coagulant and obtain the true weight of microalgae in
the biomass.

3.2

Processing of harvested algal biomass via WLEP
Once mixed culture algae were harvested via one of the four methods, they were

processed through the wet lipid extraction procedure (WLEP) as described in previous
studies (Anthony et al., 2013; Sathish and Sims, 2012). The WLEP was performed to
produce four side streams of which one, the aqueous phase, was of interest for the
purposes of this study as it had been previously demonstrated to allow for E. coli growth
(Anthony et al., 2013).

156

3.3

Production of Polyhydroxybutyrate (PHB)
E. coli XL1-blue (Stratagene, La Jolla, CA) containing the pBHR68 plasmid

(Spiekermann et al., 1999) was cultured on the four different aqueous phase media. The
pBHR68 plasmid contains the three genes (phaA, phaB, and phaC) needed for PHB
synthesis and confers ampicillin resistance. Gene expression was controlled by a lac
promoter. E. coli containing the pBHR68 plasmid was cultured in each of the different
aqueous phase media similar to the methods used in a previous study (Anthony et al.,
2013). Briefly, aqueous phase media were autoclaved, 100 μg/ml ampicillin (IBI
Scientific, Peosta, IA) and 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, Gold
Biotechnology, Inc. St. Louis, MO) were added to each aqueous phase flask at time 0 h.
E. coli harboring the pBHR68 plasmid was grown in LB media the previous day and was
used to seed each aqueous phase flask at an initial OD600 of 0.05. Flasks containing the
aqueous phase media and cells were placed in an orbital shaker operating at 225 rpm and
37oC. CFU/mL and PHB content were measured after 48 h of growth. Experiments were
carried out in triplicate.
PHB analysis was carried out using a direct polyhydroxyalkanoate analysis with
1

H NMR as described previously (Linton et al., 2012). Briefly, after 48 h of growth in

aqueous phase media, PHB producing E. coli were centrifuged at 3500 rpm for 20 min
and pellets were lyophilized. Approximately 15 mg of lyophilized cells were dissolved in
0.7 mL of 5% sodium hypochlorite and 1 ml of CDCl3 (0.03% TMS). Samples were then
vortexed, placed on a shaker table, and the organic phase was analyzed for PHB in a Jeol
ECX-300 NMR spectrometer (Jeol USA, Inc., Peabody, MA). A standard NMR/GC
correlation was used to determine PHB concentrations as described in Linton et al. 2012.
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3.2

Statistical analysis
The comparisons of CFU/mL and PHB yields obtained from the aqueous phase of

microalgae harvested by each of the different harvesting methods were statistically
analyzed using one-way analysis of variance (ANOVA) with REGWQ as the post-hoc
comparison (confidence level of 95%). Statistical Analysis Software (SAS 9.3, SAS
Institute Inc., Cary, NC) was used for the analysis.

4.

Results and Discussion

4.1

Cationic starch and microalgae harvesting
The degree of substitution (DS) for CPS and CCS was 0.04 ±0.005 and 0.06

±0.01, respectively. Higher DS for the starch molecules (CPS and CCS) suggests that
they have higher nitrogen content and thus will have better dewatering performance. As
mentioned in Anthony et al. (2013), CPS has a lower zeta potential compared to CCS,
thus giving CPS a lower DS. Lagoon microalgae harvested via centrifugation contained
approximately 96 % microalgae with the remainder attributed to undissolved salts and
other particulates in the wastewater (Table 8.1). CPS needed 4.56 g to harvest 8.4 g of
microalgae and CCS required 3.15 g to harvest 11.5 g algae (Table 8.1). The amount of
respective flocculants used in this study to harvest wastewater microalgae was similar to
that used in previous studies (Anthony et al., 2013; Vandamme et al., 2010). The amount
of alum required for coagulation and flocculation of microalgae was much higher than
CPS and CCS. The mass of alum used was similar to that of the mass of lagoon algae
harvested, approximately 11.2 g of alum to harvest 9.2 g of microalgae (Table 8.1).
Additionally, only 42% of the mass harvested with alum was microalgae, compared to
70% and 82% from CPS and CCS. The reason for the higher amounts of alum needed for
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harvesting microalgae is potentially due to alum having a lower zeta potential, and thus
higher dosages are needed to harvest similar quantities of microalgae compared to CPS
and CCS. Comparing the results in Table 8.1 for wastewater microalgae (this study) to
that of harvesting single strain S. obliquus in a previous study (Anthony et al., 2013), the
mass of CPS and CCS needed was higher for wastewater microalgae than single strain
algae. Furthermore, the percent dry weight of algae of total biomass (%) was lower for
the mixed algae in this study compared to that seen in the previous single algal strain
study. The higher amounts of CPS and CCS used to flocculate mixed culture algae could
be due to various types of algae requiring additional coagulant for charge neutralization.
Additionally, wastewater contains other additional particulates and salts that could reduce
the interaction of the algae with CPS and CCS.

Table 8.1. Total weight of biomass, mass of algae, % dry mass of algae, and amount of
coagulant used.

Where CPS: Cationic potato starch, CCS: Cationic corn starch, and Alum: aluminum
sulfate
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4.2

Bacterial growth and production of Polyhydroxybutyrate (PHB)
The growth of E. coli on WLEP aqueous phase from CPS, CCS, alum, and

centrifuged wastewater was determined 48 h after induction. Figure 8.1 A shows the
highest E. coli growth of approximately 1013 CFU/mL was observed in the aqueous phase
media from centrifuged algae, this was higher than that seen in the aqueous phase media
from CPS (~105 CFU/mL), CCS (~105 CFU/mL), and alum (~106 CFU/mL).
The PHB yields were highest from the centrifuged algae aqueous phase media
(Figure 8.1 B) compared to CPS, CCS, and alum. E. coli was able to produce
approximately 7.8 ± 1.5 % PHB of its dry cell weight in the centrifuged algae aqueous
phase. The PHB produced in the centrifuged aqueous phase was statistically different
(p<0.05) from the PHB produced in the CPS, CCS, and alum aqueous phases. The PHB
produced in the CPS and CCS, were not statistically different from each other (p>0.05).
No PHB was detected from E. coli growing in alum aqueous phase media. Growth
(CFU/mL) of E. coli in aqueous phase media from CPS, CCS, and alum were not
significantly different (p>0.05). The higher CFU/mL from centrifuged algae aqueous
phase (~1013 CFU/mL, Figure 8.1) correlates to higher PHB production. This would be
expected as a higher CFU/mL shows that there are more viable cells and hence more
PHB produced 48 h after induction. Studies have suggested that the use of alum (or other
metal salts such as: ferric chloride or ferric sulfate) for algae harvesting purposes could
potentially affect downstream processes (Molina Grima et al., 2003). From this study, the
aqueous phase derived from the alum harvested algae did not allow for PHB production.
Alternative genes for the generation of other products could be incorporated into
E. coli and grown on aqueous phase media, making for a flexible biorefinery platform.
From a biorefinery standpoint, production of more than one bioproduct from microalgae
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could generate a more economical and sustainable production platform. Future work can
also include harvesting waste water microalgae with a rotating algae bioreactor (RABR)
(Christenson and Sims, 2012) and processing the algae with the WLEP.

Figure 8.1. CFU/mL (A) and PHB% (% of dcw) (B) of E. coli XL1-blue harboring the
pBHR68 plasmid 48 h after induction, grown on different WLEP aqueous phases from
cationic potato starch (CPS), cationic corn starch (CCS), aluminum sulfate (Alum), and
centrifuged mixed culture algae. Numbers are averaged from triplicate experiments.
* indicates statistical significance (p<0.05).
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5.

Conclusions
This study demonstrated four different harvesting techniques of mixed wastewater

microalgae, and the processing of microalgae using WLEP to create a medium for E .coli
growth and PHB production. The aqueous phase from centrifuged wastewater microalgae
produced the highest E. coli growth (~1013 CFU/mL) and PHB production (~7.8 % of dry
cell weight). CPS, CCS, and alum flocculated wastewater microalgae aqueous phase
media reduced the potential for E. coli growth and PHB production. Understanding the
effects of harvesting on the contents of the aqueous phase will be important moving
forward.
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CHAPTER 9
SUMMARY
Synthetic biological engineering provides the ability to program an organism to
carry out a specific function that could potentially lead to many newfound applications in
the future. The studies presented in this dissertation added some useful applications to the
synthetic biological engineering toolbox in the form of: increasing bioproduct production
with secretion and codon optimization for specific tRNA expression. The hope is that this
toolbox can be greatly expanded in the future to allow others to improve upon existing
parts and devices to further the various bioproduct production systems.
This dissertation showed the successful design, building, and testing of a synthetic
biological engineering PHB secretion system in E. coli. It was found that 36% of the total
PHB produced by the cell could be secreted. As with any recombinantly produced
product, downstream processing is a consideration. Secretion of this polymer could
potentially reduce the costs associated with separation of PHB from biomass.
Additionally, PHBs have similar properties to their petroleum based plastic counterparts,
this is beneficial in two ways: 1) downstream processing of PHB would be similar to that
seen with petroleum based plastics and 2) there is a potential for hybrid materials to be
made by combining PHB and petroleum based plastics. Similar to biofuels, viable
bioplastic production systems need to act as ‘drop in’ technologies, and thus can be
incorporated into the current infrastructure system without any major hurdles.
Monitoring the PHB secretion system using a synthetic biological engineering
approach with GFP also highlights the importance of understanding and improving upon
a biological system. As engineers, optimization of existing production systems can go a
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long way into making a process more efficient. In this study, GFP was successfully
tagged to PHB granules using a PhaC intermediate and granules were visible under
fluorescent microscopy. The hope is that by understanding type I secretion of PHBs this
information can be applied to other products such as potentially secreting of spider silk
from E. coli.
The work of this dissertation also explored the potential to use wastewater
microalgae to create media suitable for E. coli cultivation and bioproduct production. As
an example, E. coli grown on a wastewater microalgae based media was able to grow to
approximately 1013 CFU/mL and accumulate up to 7.8% PHB.
Future work
In this study it was demonstrated that multiple proteins could be bound to the
PHB granules. Proteins such as phasin and PHA synthase were used as intermediate
proteins for functionalization of the PHB granules for the purposes of secretion and
visualization with GFP. The studies represented in this dissertation only focused on
secretion of short chain length (scl) PHB, an additional study could utilize the same
secretion system to secrete medium chain length PHAs. Building on the success of this
research, the idea to further functionalize the granules by fusion of spider silk protein to
the PHB granules via an intermediate protein partner could open the possibilities for
creation of new novel biomaterials.
Spider silk proteins could be fused to PHB granules using either Phasin or PhaC
as an intermediate. The reason for this would be to enhance the properties of PHB as
spider silk has significantly higher elasticity and tensile strength than PHB. Using Phasin,
the spider silk protein could be fused to the C-terminal and with PhaC spider silk protein
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could be fused to the N-terminus. A comparison between the effectiveness of C-terminal
and N-terminal spider silk fusion to a PHB granule could then be studied.
Future work could include building upon the microalgae-to-bioproducts procedure
to expand the biorefinery model. This could include growing different bioproduct
producing E. coli strains in various algae-based media. For example the PHB secreting
strain and spider silk production strains could be cultured on the algae-media and
monitored for production. Additionally, other algae sources could be utilized to find the
greatest levels of bioproduct production. Further work should be conducted to fully
characterize the algae-media and optimize it for production purposes. A technoeconomic
study could also be conducted to further understand viable recombinant bioproduct
generation from a wastewater-microalgae standpoint.
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APPENDIX A-FUTURE WORK

A1. Scaling up of PHA production
Recovery of polyhydroxyalkanoates from microorganisms is currently a
bottleneck during scale up. This bottleneck is one of the reasons why the production of
polyhydroxyalkanoates from microorganisms is less economically viable when compared
to traditional petroleum based plastic production. Currently, manufacturers of
biodegradable plastics are able to produce on average 1000-20,000 tons per year,
compared to a single petroleum based polyethylene plant which has a capacity of 300,000
tons per year [1]. Two of the major problems are: 1) the cost of the carbon substrate for
bacterial PHA production is expensive and 2) recovery of polyhydroxyalkanoate is
expensive.
Studies have been carried out with several different PHA producing bacterial
strains at the pilot plant scale, some examples follow. Metabolix, Inc. overexpressed the
PHB gene in E. coli K12 and produced 100 g/l PHB in 40 h. An Austrian company used
Alcaligenes. latus DSM1124 and showed that it could accumulate up to 80% PHB of the
cell weight, the biomass density obtained was 60 g/l. An academic group used
Cupriavidus Necator H16, PHB was accumulated in the cells up to 76% in 50 hours
giving a biomass of 164 g/l with a PHB concentration of 121 g/l [1].
There is a number of different scaling up methods that have been used in
bioreactor design, including, batch and fed batch reactors. Table A1 provides examples
of:

different

bioreactors,

microorganisms,

biomass,

and

polyhydroxyalkanoate

concentrations achieved. There are variations of polyhydroxyalkanoate yields from the
different types of strains and reactors used. This gives some indication that reactor type is
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significant in deciding how to scale up production effectively. A suggested schematic to
scale up PHA production from a PHA secreting strain of E. coli is shown in Figure A1.
As PHA is being secreted it can be collected in a chamber while cell mass is recycled
back into the bioreactor in a semi-continuous fashion.

Table A1. Examples of different types of bioreactors used and respective biomass and
polyhydroxyalkanoate concentrations achieved.
Microorganism

Process of
production
Two-step
fed-batch
culture

Biomass
concentration
100 g/l

PHA
concentration
2.5 g/l h PHB

Source

Escherichia coli K12

Not
Mentioned

Not Mentioned

100 g/l PHB

[2]

Alcaligenes latus
DSM1124

one-step fedbatch

60 g/l

48 g/l

[3]

Cupriavidus necator
H16

fed-batch

164 g/l

121 g/l PHB

[1]

Cupriavidus necator
H16

fed-batch

Not Mentioned

110 g/l PHBV

[4]

Cupriavidus necator
DSM 545

batch

10.3 g/l

7.3 g/l PHB

[5]

Bacillus flexus

batch

2.5 g/l

1.3 g/l PHB

[6]

Bacillus cereus SPV

batch

2.5 g/l

0.725 g/l PHB

[7]

Bacillus cereus SPV

fed-batch

3.0 g/l

1.14 g/l PHB

[7]

Cupriavidus necator,
NCIB 11599

[1]
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Figure A1. Bioreactor design and downstream processing of PHA from E. coli. Vessel A
is a 5 L bioreactor (with attached pH, DO and temperature probes), Vessel B is a 500 ml
glass column packed with a material to remove secreted PHA. V1-V5 are flow control
valves. S1-S6 are stream numbers. Stream S1 brings fresh media into the system and
stream S5 removes media out of the system in a semi-continuous process.
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Abstract
Bioproduct production from wastewater microalgae has the potential to contribute
to societal needs with value added chemicals. Microalgae can remediate wastewater to
remove nitrogen, phosphorus, and heavy metals and can be processed to produce biofuels
and bioproducts. It was previously demonstrated that recombinant Escherichia coli could

produce polyhydroxybutyrates (PHB) when cultured on a wastewater microalgae wet
lipid extracted media. In this present study, microalgae were harvested from the effluent
of a wastewater treatment facility via centrifugation and hydrolyzed to create a liquid
medium for recombinant E. coli growth and PHB production. Standard E. coli growth
media was supplemented with various concentrations of hydrolyzed algal extract to
produce a maximum of 31% PHB of the E. coli dry cell weight.

Keywords
Wastewater, Microalgae, Bioproduct, Polyhydroxybutyrate

172

1. Introduction
Microalgae have been well studied for production of biodiesel (Chisti, 2007) and
recently microalgae has been proposed to be the basis for a biorefinery model where
multiple chemicals can be produced simultaneously (Anthony et al., 2013b). By
producing several chemicals from the same algae feedstock, it could potentially make the
production of multiple commodity chemicals from a biological resource economically
viable. The limitations to microalgae culturing are well-documented, including but not
limited to: nutrient supply, water scarcity, and low energy harvesting and dewatering
(Christenson et al., 2011).
The City of Logan, UT has a 460 acre seven pond facultative lagoon system to
treat weak domestic wastewater. Weak domestic wastewater contains approximately 20
mg/L nitrogen and 4 mg/L phosphorus and is ideal of microalgae growth (Tchobanoglous
et al., 1991). Facultative lagoon systems can be used to culture mixed consortia of
microalgae to remediate the wastewater by removal of phosphorus and nitrogen. These
microalgae can then be used as a feedstock for production of bioproducts (Rahman et al.,
2012; Rawat et al., 2011). There are a wide range of methods that have been employed to
harvest the microalgae from an open pond system, these include (but not limited to):
rotating algal biofilm reactor (RABR) (Christenson et al., 2012; Kesaano et al., 2014),
biological and chemical flocculants (Anthony et al., 2013a; Anthony et al., 2013b), and
centrifugation (Greenwell et al., 2010).
Escherichia coli is a robust microorganism that can be used to produce a wide
range of bioproducts such as biofuels and bioplastics. Its ease of culturing and fast
doubling time make it an ideal candidate for production of recombinant bioproducts.
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Polyhydroxybutyrates (PHB) are bioplastics that can be recombinantly produced in E.
coli to sufficiently high levels. PHB is a potentially useful polymer, in addition to being
completely biodegradable, it has similar properties to traditional petrochemically derived
plastics such as polypropylene and polystyrene (Khanna et al., 2005). Three genes are
needed for the conversion of acetyl-coA to PHB in E. coli. The pBHR68 plasmid
contains the lac promoter and three genes (phaA, phaB, and phaC) needed for production
of the bioplastic PHB (Spiekermann et al., 1999).
PHB production is not widely produced in part due to the cost of the carbon
substrate. It has been estimated that the carbon substrate in a large scale manufacturing
context would constitute approximately 37% of the total production cost (Choi et al.,
1999). Due to the high cost of carbon, an alternative low cost substitute is needed to
culture E. coli in order to make PHB production economically viable. In a previous study,
it was demonstrated that E. coli harboring the pBHR68 plasmid was able to successfully
grow on a Scenedesmus obliquus algae-based media (Anthony et al., 2013b). In this
previous study, different harvesting methods were used to collect the microalgae and then
the harvested algae was processed via the wet lipid extraction procedure (WLEP) to
generate a variety of side streams and bioproducts (Anthony et al., 2013b; Sathish et al.,
2012). One of the side streams, termed ‘aqueous phase’ was used to culture E. coli and it
was established that the upstream harvesting method of S. obliquus affected the growth of
the E. coli in the aqueous phase media. The most successful microalgae harvesting
method for high levels of E. coli growth after 48 h (1012-1013 CFU/mL) was observed
when the S. obliquus was centrifuged (Anthony et al., 2013b). The same experiment was
extended to harvesting wastewater mixed culture microalgae from the City of Logan, UT
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treatment plant pond E. Different harvested wastewater microalgae samples were
subjected to the WLEP to generate the aqueous phase. It was found that centrifugation
gave the best E. coli growth (~1013 CFU/mL) and PHB production (7.8% PHB dry cell
weight) (Rahman et al., 2014).
Since centrifuged microalgae processed via the WLEP demonstrated highest
levels of E. coli growth and PHB production, it was decided to use this as the preferred
harvesting method. Additionally, the previous studies (Anthony et al., 2013b; Rahman et
al., 2014) used an unmodified aqueous phase media to culture E. coli, and a subsequent
study used a fraction of the aqueous phase with standard E. coli media and obtained
promising PHB yields (Sathish et al., 2014). The main objectives of this current study
were to demonstrate E. coli growth and PHB production from an effluent wastewater
microalgae-based media. Figure 1 depicts the steps conducted in this study to remove
microalgae from wastewater effluent of the treatment facility, hydrolysis of dried
microalgae, and E. coli growth to produce the polymer polyhydroxybutyrate.
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Figure 2. Overall schematic for production of polyhydroxybutyrates in Escherichia
coli from wastewater microalgae

2. Materials and methods
All chemicals and reagents were purchased from Thermo Fisher Scientific
(Pittsburgh, PA) unless stated otherwise.
Algae harvesting and processing
Wastewater microalgae were harvested from the City of Logan, UT wastewater
treatment facility from the effluent stream leaving the facultative lagoons. Algae were
centrifuged using a continuous centrifuge and subject to drying in a temperature
controlled oven. After drying, algae were stored at -20oC until the hydrolysis step.
A modified algae hydrolysis method was used similar to Ellis et al. 2012, where
hydrolyzed microalgae was used to culture Clostridia to produce Acetone, Butanol, and
Ethanol (Ellis et al., 2012). Briefly, 10 g of dry algae was dissolved into 0.5 M (final
concentration) sulfuric acid (H2SO4) with a total volume of 100 ml, the solution was
placed on a stir plate and heated to 90oC for 30 min. After cooling to room temperature,
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the solution was neutralized to pH 7 with sodium hydroxide (NaOH). This neutralized
solution was then centrifuged at 3500 rpm for 30 min to clarify the solution. The
supernatant was then used for culturing E. coli.
Bacterial growth
Supernatant from hydrolyzed algae was used as the sole carbon source and was
substituted into standard E. coli M9 growth media (Sambrook et al., 2001) in 1 and 2%
ratios (weight dry algae: volume culture). An additional study was conducted with
culturing E. coli in a 10% hydrolyzed algae solution (w/v). The hydrolyzed algae
supernatant was not autoclaved to demonstrate that E. coli growth and PHB production
could occur from a non-sterile carbon source. In addition to the liquid algal extract,
growth media also contained M9 salts (Becton, Dickinson and Co, Sparks, MD), 0.002 M
MgSO4 (Kang et al., 2008; Rahman et al., 2013), and 50 µg/mL ampicillin (IBI
Scientific, Peosta, IA).
The E. coli strain, XL1 Blue (Agilent Technologies, Santa Clara, CA) harboring
the pBHR68 plasmid (Spiekermann et al., 1999) was grown in LB media (Sambrook et
al., 2001) overnight (~15 h). Cultures were then used to start larger 50 mL cultures with
an initial optical density (OD600) of 0.05. Isopropyl β-D-1thiogalactopyranoside (0.1 mM)
(Gold Biotechnology, Inc. St. Louis, MO) was added at 0 h to induce expression of the
phaCAB genes. Bacterial growth was measured using optical density (OD600) at 0, 4, 8,
12, 24, and 48 h.
Sugar analysis
Total sugar analysis was conducted using a modified phenol-sulfuric acid method
(Ellis et al., 2012). Briefly, 3 µL of 85% (w/v) phenol solution and 150 µL of 12 M
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sulfuric acid was added to the samples and the mixture was heated for 5 min at 90oC.
After cooling to room temperature for 5 min in an ice bath absorbance (A490 nm) was
measured using a Synergy 2 microtiter plate reader (BioTek, Winooski, VT). Sugar
concentrations were calculated based on a glucose standard.
Polyhydroxybutyrate analysis
PHB analysis was carried out on samples after 48 h of bacterial culturing.
PHB concentration was determined from a 1H NMR/GC correlation as mentioned
previously (Linton et al., 2012). Briefly, 15 mg of lyophilized sample were dissolved in a
deuterated chloroform/bleach solution. Samples were vortexed, incubated, and
centrifuged. PHB phase was run on a Jeol ECX-300 NMR (Jeol USA, Inc. Peabody,
MA).
Statistical analysis
Data was processed with Statistical Analysis Software (SAS 9.4, SAS Institute
Inc., Cary, NC). One-way analysis of variance (ANOVA) was conducted on the data
collected at 48 h for % PHB for the three different media types. REGWQ post hoc
comparison was performed on significant results with a confidence level of 95%. All
%PHB experiments were conducted in triplicate.
3. Results and discussion
E. coli harboring the pBHR68 plasmid was grown on 1%, 2%, and 10% algae-M9
media. The maximum optical density (OD600) for E. coli grown in 1% media was around
1.3 where stationary phase was reached at approximately 12 h post induction (Figure 2).
The 2% and 10% samples reach stationary phase at around 24 h and reached a maximum
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OD600 of 2.5 and 7.6 respectively. Cultures were allowed to continue growing until 48 h
as this allowed time for PHB accumulation.
Results of the total sugar analysis indicated that simple sugars was present in the
algae extract and was being consumed during the course of bacterial growth. The 1%
sample had 152 mg/L total sugar at time 0 and after 48 h of bacterial growth had 132
mg/L. The 2% sample had 320 mg/L sugar at time 0 and after 48 h had 267 mg/L. The
10% sample had 1890 mg/L total sugar and finished with 1344 mg/L sugar.
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Figure 3. Growth of E. coli harboring the pBHR68 plasmid on 1%, 2%, and 10%
algae media.
Comparing PHB yields 48 h post-induction, it was observed that the M9 media
containing 1% and 2% algae extract (v/v) had the most PHB (as a percentage of dry cell
weight). The 1% and 2% samples had 31 ± 8.9 % and 28.2 ± 2.1 % PHB respectively
(Figure 3). In comparison, E. coli cultured in 10% algae extract media that had an
average PHB accumulation of 4.6 ± 0.7 %. From statistical analysis the p-value was
0.0081 indicating significant results (confidence of 95%, p<0.05). Post-hoc comparison
using REGWQ indicated that the PHB production levels at 1% and 2% were not
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significantly different from each other. The PHB production from 1% and 2% media
samples were both significantly different from the PHB yields observed from E. coli
grown in 10% algal extract.
The percentage PHB accumulated in bacterial cells cultured in the 1% and 2%
algae-M9 media are slightly lower than that seen in E. coli harboring pBHR68 grown in
M9-glucose media (Table 1). In a previous study, it was found that E. coli harboring the
pBHR68 plasmid grown in M9 media supplemented with 1.5% glucose could accumulate
up to 47.24 ± 6.0 %, 48 h post induction (Rahman et al., 2013). Achieving approximately
31 ± 8.9 % demonstrates the potential of using algae as the sole carbon source in media
for E. coli culturing and bioproduct production. Addition of an external carbon substrate
such as glucose to the algae-based media could potential increased the growth and yields
of PHB in E. coli. It was demonstrated in a previous study that 1% glucose addition to an
algae-based media to culture Clostridia tripled the yield of solvent production (Ellis et
al., 2012).
Comparing the 10% algae extract media (with no M9 addition) to that of a similar
study (Rahman et al., 2014) it was found that this 10% media did not perform as well as
the previous study. In the previous study, approximately 9.6 g of algae (dry weight
equivalent) were extracted (via centrifugation) from the City of Logan, UT wastewater
treatment facility pond E and subjected to the wet lipid extraction procedure (WLEP) to
produce approximately 7.8% PHB. In the present study, algae extracted from the effluent
of the wastewater treatment plant generated 4.6% PHB. The lower PHB yield could be
attributed to the fact that in this study the microalgae harvested could have already been
lysed and thus lowering the yield of sugars extracted. There could have also been some
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inhibitory effect in the media that was more concentrated, thus reducing the production
capacity of the E. coli.
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Figure 3. Polyhydroxybutyrate production from the different algae-based cultures
(where %PHB is a proportion of E. coli dry cell weight).

Table 2. Production and yields of PHB produced from Escherichia coli XL1 Blue
harboring the pBHR68 plasmid grown in M9 media supplemented with wastewater
algae hydrolyzed fraction.
Carbon
Source in
M9 media

PHB%

g PHB /L

g PHB/ g
carbon
substrate

Carbon
needed (kg)
needed to
produce 1 kg
PHB
4.3

Reference

1% Algae
media
2% Algae
media
10% Algae
media
1.5%
Glucose

30.97 ± 8.9

2.30 s1

0.232

28.19s5.1

2.09±0.5

0.104

9.5

This study

4.60s0.7

0.32s0.1

0.003

305.2

This study

47.24s6.0

5.43s1.7

0.40s0.12

2.5

(Rahman et
al., 2013)

This study

Table 1 shows the yields of PHB obtained from the different experiments carried
out in this study compared to that of another study with the same strain of E. coli

181

(Rahman et al., 2013). In addition to PHB% as a fraction of dry cell weight, the total
carbon substrate needed to produce 1 kg PHB was also estimated. It was predicted that
using the 10% algae in M9 media would need approximately 4.3 kg of dry algae to
produce 1 kg of PHB. This is comparable to a standard 1.5% glucose M9 media in the
previous study that was predicted to need 2.5 kg of glucose to make 1 kg of PHB. This
estimate assumed a linear scaling from shaker flask volume of 50 ml to a large scale
bioreactor, in order to get more accurate measurement additional parameters would need
to be considered.
4. Conclusions
This study built upon the work previous done with production of PHB from a
microalgae feedstock. From this study growth of recombinant E. coli harboring the
plasmid pBHR68 (containing the phaCAB operon) on microalgae-based media was
observed for all samples. It was found that the maximum PHB accumulation in E. coli
was approximately 31 ± 8.9 % seen on the 10% algae-M9 media 48 h post induction.
Future work could include determining the effects of production of additional
bioproducts using E. coli grown on wastewater algae media and the addition of a
traditional carbon source to the algae-based media.
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APPENDIX E- STRAINS, PLASMIDS, AND OLIGONUCLEOTIDES

Table E1. Strains used in this study
Name

Relevant characteristics

Reference

XL1 Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’proAB
lacIqZΔM15 Tn10 (Tetr)]

Agilent Technologies

DH5α

F– Φ80lacZΔM15 Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi1 gyrA96 relA1
E. coli B F– ompT hsdS(rB– mB–) dcm+ TetR gal λ(DE3) endA
Hte
E. coli B F- ompT hsdS(rB– mB–) dcm+ Tet+ gal endA Hte
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74
recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ- rpsL
(StrR) nupG trfA tonA pcnB4 dhfr
MG1655 ΔaraBAD ΔfadR ΔfadIJ fadBA::Φ(Ptrc-BTE)
Wild type, PHA producing

Agilent Technologies

BL21-Gold (DE3)
BL21 Gold
CopyCutter EP1400

SA01

Cupriavidus
necator H16

Agilent Technologies
Agilent Technologies
Epicentre

[11]
ATCC 17699

Table E2. Plasmids used in this study
Name

Relevant characteristics

Reference

pBHR68
pLG575
pSB1AK3
pSB1C3
pSB3K3
pSB1A3
pET-14b
pCR2.1-TOPO

pBluescript SK−, phbCAB genes from R. eutropha
pACYC184 derivative, HlyBD, p15A origin, CmR
High copy BioBrick™ vector, pMB1 origin, AmpR and KanR
High copy BioBrick™ vector, pMB1 origin, CmR
Medium copy BioBrick™ standard vector, p15A origin, KanR
High copy BioBrick vector, pMB1 origin, AmpR
Ampicillin plasmid, T7 promoter, pBR322 origin
Ampicillin plasmid, Plac promoter, pBR322 origin
PhaP1, C-terminal BioFusion with HlyA signal peptide, Lac
promoter(BBa_R0010), RBS(BBa_B0034), in pSB1A3
phaP1, C-terminal BioFusion with HlyA signal peptide, Lac
promoter (BBa_R0010), RBS (BBa_B0034), in pSB3K3
phaP1, C-terminal BioFusion with HlyA signal peptide, Lac
promoter (BBa_R0010), RBS(BBa_B0034), in pBHR68
Phasin(ns) in pSB1C3
Phasin(ns)_GFP in pSB1C3
Phasin(ns)_GFP_B0015 in pSB1C3
Promoter + rbs_ Phasin(ns)_GFP_B0015 in pSB1C3
Phasin(ns)GFP(ns) in pSB1C3
Phasin(ns)+GFP(ns)+HlyA in pSB1C3
Phasin(ns)+GFP(ns)+HlyA+B0015 in pSB1C3
Promoter + rbs_ Phasin(ns)+GFP(ns)+HlyA+B0015 in

[12]
[13]
[14]
[14]
[14]
[14]
Novagen
Life Technologies
[15]

pCMEL1
pCMEL2
pCMEL3
pKF01
pKF02
pKF03
pKF04
pKF05
pKF06
pKF07
pKF08

[15]
[15]
This study
This study
This study
This study
This study
This study
This study
This study
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pKF09
pKF10
pKF11
pKF12
pKF13

pKF14
pKF15
pKF16
pKF17
pKF18
pKF19
pKF20
pKF21
pKF22
pGFPuv
pKF23
pKF24
pKF25
pKF26

pKF27
pKF28
pKF29
p4MT
pKF30
pKF31
pAKF01
pAKF02
pDA-JAC
pET14b_gfp_phaC_
MalE
pAR2
pARNH1
pARNH2
pB14

pB14GFP

pSB1C3
PhaC1(ns) in pSB1C3 amplified from BBa_K934001 with
KFphaC1F and KFphaC1R
PhaC1(ns)_GFP in pSB1C3
PhaC1(ns)_GFP_B0015 in pSB1C3
Promoter + rbs_ PhaC1(ns)_GFP_B0015 in pSB1C3
Promoter + rbs_ PhaC1(ns)_GFP(mut)_B0015 in pSB1C3 GFP
mutated to remove XhoI site using KFc426g_antisense and
KFc426g
pKF13 in pSB3K3
pCMEL2 +pKF14 in pSB3K3
EcoRI/XhoI fragment from pKF15 in pBHR68
EcoRI/XhoI fragment from pKF14 in pBHR68
PhaC1(ns)_GFP(ns) in pSB1C3
PhaC1(ns)_GFP(ns)_HlyA in pSB1C3
PhaC1(ns)_GFP(ns)_HlyA_B0015 in pSB1C3
Promoter + rbs_ PhaC1(ns)_GFP(ns)_HlyA_B0015 in pSB1C3
phaC1 in pSB1C3, amplified from BBa_K934001 in pSB1C3
Green fluorescent protein (GFP), BBa_K208000 in pSB1AK3
Green fluorescent protein (GFP) amplified from pGFPuv. Stop
codon removed and XhoI site mutated, in pSB1C3
GFP(mut)(ns)_PhaC1 in pSB1C3
GFP(mut)(ns)_PhaC1_B0015 in pSB1C3
In frame fusion [RFC 23] of GFPmut (pKF23) with phaC1
(pKF22). Lac promoter (BBa_R0010),
RBS(BBa_B0034), and double terminator (BBa_B0015), in
pSB1C3
EcoRI/SpeI fragment pKF26 and pCMEL2 in pSB1C3
EcoRI/PstI fragment of pKF27 in pSB1AK3
EcoRI/PstI fragment of pKF28 in pSB3K3
promoter (BBa_R0010), RBS(BBa_B0034), phaP1, and double
terminator (BBa_B0015) in pSB1AK3
EcoRI/SpeI fragment of pKF26 in p4MT
EcoRI/PstI fragment of pKF30 in pSB3K3
EcoRI/XhoI fragment of pKF29 (+HlyA) in pBHR68.
EcoRI/XhoI fragment of pKF31(-HlyA) in pBHR68.
pDA-JC with PP_0763 cloned between phaJ3 and phaC2
gfp-phaC-malE fusion in pET14b
gfp-phaC-malE fusion from pET14b in pCR2.1
patgPhasin(ns)hlyAB0015 in pDA-JAC
KF08 in pDA-JAC
Spider silk production vector. Lac promoter +RBS (BBa_K208010),
spider silk subunit (BBa_K84408), 13x spider silk subunit (BBa_
K844004), 10x His-tag (BBa_ K844000), and double terminator
(BBa_ B0015) in pSB1C3.
Spider silk production vector with GFP fusion at C terminal. Lac
promoter +RBS (BBa_K208010), spider silk subunit (BBa_K84408),
13x spider silk subunit (BBa_ K844004), modified GFP with stop
codons removed (BBa_K208000), 10x His-tag (BBa_ K844000), and
double terminator (BBa_ B0015) in pSB1C3.

This study
This study
This study
This study
This study

This study
This study
This study
This study
This study
This study
This study
This study
This study
[10]
This study
This study
This study
This study

This study
This study
This study

[16]
This study
This study
This study
This study
[17]
[18]
This study
This study
This study
This study

This study
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pB04GFP
pB12GFP
pB16GFP
p6x5x

Similar to pB14GFP but with 4x repeats of spider silk subunit
Similar to pB14GFP but with 12x repeats of spider silk subunit
Similar to pB14GFP but with 16x repeats of spider silk subunit
tRNA plasmid pSB3K3 containing both BBa_K844012 and
BBa_K844013 composite BioBrick™ parts.
Note: All BioBrick™ constructs are RFC 23 compatible

This study
This study
This study
This study

Table E3. Oligonucleotides used in this study
Name
VF2
VR

Relevant characteristics
5'-tgccacctgacgtctaagaa-3'
Fwd sequencing primer for BioBrick vectors
5'-attaccgcctttgagtgagc-3'
Rev sequencing primer for BioBrick vectors

Reference
[14]
[14]
[15]

PhaP1FOR

5’-gaattcgcggccgcttctagaatgatcctcaccccggaaca-3’

PhaP1REV
g114t
g114t_antisense
KFc426g_antisense

5’- ctgcagcggccgctactagttcaggcagccgtcgtcttct-3’
5’-cgtcgagctgaaccttcaggtcgtcaagact-3’
5’-agtcttgacgacctgaaggttcagctcgacg-3’
5'-gtgagttatagttgtactccagtttgtgtccgagaatgt-3'
Fwd primer for mutation of XhoI site from GFP
5'-acattctcggacacaaactggagtacaactataactcac-3'
Rev primer for mutation of XhoI site from GFP
5'-attgtgtgagttatagttgtattcgagtttgtgtccgagaatg-3'
Fwd primer for mutation of XhoI site from GFP
5'-cattctcggacacaaactcgaatacaactataactcacacaat-3'
Rev primer for mutation of XhoI site from GFP
5’-tctggaattcgcggccgcttctagaatggctactgggaaaggagc- 3’
Forward primer to amplify phaC1 from BBa_K934001
5’- tctgctgcagcggccgctactagttcacgcttttgcttttacat- 3’
Reverse primer to amplify phaC1 from BBa_K934001
conserving stop codon
5’ tctgctgcagcggccgctactagtcgcttttgcttttacatagc 3’
Reverse primer to amplify phaC1 from BBa_K934001 without
stop codon
5’ tctggaattcgcggccgcttctagaatgatcctcaccccggaaca 3’ to
amplify PhaP1 (Forward primer with ATG codon
5’ tctggaattcgcggccgcttctagaatcctcaccccggaacaagt 3’ to
amplify PhaP1 (Forward primer without ATG codon)
5’ tctgctgcagcggccgctactagtggcagccgtcgtcttctttg 3’ to
amplify PhaP1 (Reverse primer without stop codon)

[15]
[15]
[15]

5’-tctggaattcgcggccgcttctagacatcatcaccatcaccaccatcatcaccat3’
10x His Tag No Stop forward primer
5’-tctgctgcagcggccgctactagtatggtgatgatggtggtgatggtgatgatg- 3’
10x His Tag No Stop reverse primer
5’-Catggatgagctctacaaatactagagcatcatcacc- 3’

This study

KFc426g
KFg429a_antisense
KFg429a
KFphaC1F
KFphaC1RStp

KFphaC1R

KFphaP1FStr
KFphaP1F
KFphaP1R

AR1

AR2
AR3

This study
This study

This study
This study
This study
This study

This study

This study
This study
This study

This study
This study
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AR4
AR5
AR6

NH1

NH2

NH3

NH4

NH9

NH10

CT294

CT295

CT296

CT297

CT298
CT299

CT300
CT301

CT302

GFPHT to mutate stop codon from GFP Fwd primer
5’-Ggtgatgatgctctagtatttgtagagctcatccatg- 3’
GFPHT to mutate stop codon from GFP Rev primer
5’-tctggaattcgcggccgcttctagaatggctagcaaagga-3’
Forward primer to amplify GFP (BBa_K208000)
5’- tctgctgcagcggccgctactagttttgtagagctcatc-3’
Reverse primer to amplify GFP (BBa_K208000) with no stop
codon (taa removed)
5’-Tctgacatgtcaatacgcaaacc- 3’
Fwd primer for amplifying patgphasin(ns)hlyAB0015 with
restriction site PciI into pDA-JAC
5’-Tctgacatgttataaacgcagaa- 3’
Rev primer for amplifying patgphasin(ns)hlyAB0015 with
restriction site PciI into pDA-JAC
5’-Tctgacatgtcaatacgcaaaccgcctctc- 3’
Fwd primer for amplifying patgphasin(ns)hlyAB0015 with
restriction site PciI into pDA-JAC
5’-Tctgacatgttataaacgcagaaaggccca- 3’
Rev primer for amplifying patgphasin(ns)hlyAB0015 with
restriction site PciI into pDA-JAC
5’-Tctgcaatacgcaaaccgcctctc- 3’
Forward primer to amplifying patgphasin(ns)hlyAB0015
without restriction site
5’-Tctgtataaacgcagaaaggccca- 3’
Reverse primer to amplifying patgphasin(ns)hlyAB0015
without restriction site
5’-tctggaattcgcggccgcttctagaatgagtaaaggagaag- 3’ Fwd
Amplification of GFP-PhaC gene from
pet14b_GFP_PhaC_malE
5’-tctgctgcagcggccgctactagttgccttggctttgac- 3’ Fwd
Amplification of GFP-PhaC gene from
pet14b_GFP_PhaC_malE
5’-tctgctgcagcggccgctactagtttattatgccttggctttgac- 3’ Rev
Amplification of GFP-PhaC gene from
pet14b_GFP_PhaC_malE plasmid (added stop codon)
5’-tctggaattcgcggccgcttctagaatgactgacgttgtc- 3’
Forward Primer for Amplification of phaA gene from
pBHR68
5’-tctgctgcagcggccgctactagtttattatttgcgctcgac- 3’
Reverse Primer for Amplification of phaA gene from pBHR68
5’-tctgGaattcgcggccgcttctagaatgactcagcgcattg- 3’
Forward Primer for Amplification of phaB gene from
pBHR68
5’-tctgctgcagcggccgctactagtttattagcccatatgcag- 3’
Reverse Primer for Amplification of phaB gene from pBHR68
5’-tctggaattcgcggccgcttctagaatggcgaccggcaaag- 3’
Forward Primer for Amplification of phaC gene from
pBHR68
5’-tctgctgcagcggccgctactagtttattatgccttggctttg- 3’
Reverse Primer for Amplification of phaC gene from pBHR68

This study
This study
This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study
This study

This study
This study

This study
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CT303

CT304

CT305

CT306

CT307

CT308

CT313

CT314

CT315

CT327
CT328
CT329
CT330

5’-tacatcctggacctacagccggagagctc- 3’
Forward Mutagenesis Primer for removal of PstI (#1) from
phaC genes (CTGCAG > CTACAG)
5’-gagctctccggctgtaggtccaggatgta- 3’
Reverse Mutagenesis Primer for removal of PstI (#1) from
phaC genes (CTGCAG > CTACAG)
5’-gcgccacacctacctacagaacgagctcaag- 3’
Forward Mutagenesis Primer for removal of PstI (#2) from
phaC genes (CTGCAG > CTACAG)
5’-cttgagctcgttctgtaggtaggtgtggcgc- 3’
Reverse Mutagenesis Primer for removal of PstI (#2) from
phaC genes (CTGCAG > CTACAG)
5’-cgcctttgccggtcgcgctagttttgtatagttc- 3’
Forward Mutagenesis Primer for removal of SpeI from GFPphaC fusion gene (ACTAGT > GCTAGT)
5’-gaactatacaaaactagcgcgaccggcaaaggcg- 3’
Reverse Mutagenesis Primer for removal of SpeI from GFPphaC fusion gene (ACTAGT > GCTAGT)
5’-tctggaattcgcggccgcttctagaatgaaaatcgaagaag- 3’
Forward Primer for BioBrick of malE binding domain from
pet14b_GFP_PhaC_malE plasmid
5’-tctgctgcagcggccgctactagtttattacttggtgatacgagtc- 3’
Reverse Primer for BioBrick of malE binding domain from
pet14b_GFP_PhaC_malE
5’-cgcctgggcgatacgtcaaagccaag- 3’
Forward Primer for sequencing of malE binding domain from
pet14b_GFP_PhaC_malE plasmid (starts in phaC 3' end)
5’-tctggaattcgcggccgcttctag- 3’
RF10 Fwd primer
5’-tctgctgcagcggccgctactagta- 3’
RFC10 Rev primer
5’-tctggaattcgcggccgcttctaga- 3’
RF23 Fwd primer
5’-tctgctgcagcggccgctactagt- 3’
RFC23 Rev primer

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study
This study
This study
This study
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Sustainable Energy, 2012, 1 (1), 1-10.
5. Asif Rahman, Josh T. Ellis, Charles D. Miller. Bioremediation of domestic
wastewater and production of bioproducts from microalgae using waste
stabilization ponds. Journal of Bioremediation Biodegradation, 2012, 3 (6).
6. Elisabeth Linton, Asif Rahman, Sridhar Viamajala, Ronald C. Sims, and Charles
Miller. Polyhydroxyalkanoate quantification in organic wastes and pure cultures
using a single-step extraction and 1H NMR analysis. Water Science and
Technology, 2012, 66(5), 1000-1006.
7. Asif Rahman, Mohammed Farid, and Michelle Dickinson. Microindentation of
microencapsulated phase change materials. Advanced Materials Research.
2011, 275, 85-88.
Manuscripts in preparation
1. Asif Rahman, Ryan J. Putman, Neal Hengge, and Charles D. Miller.
Understanding type I polyhydroxybutyrate secretion from Escherichia coli.
Journal of Biological Engineering.
2. Asif Rahman, Ryan J. Putman, Cody A. Tramp, Randolph V. Lewis, and Charles
D. Miller. Increased production of BioBrick synthetic Argiope aurantia spider silk
supplemented with tRNAs. ACS Synthetic Biology.
3. Asif Rahman, Kadriye Inan, Fulya Ay Sal, Terence Smith, Foster A. Agblevor,
Ronald C. Sims, and Charles D. Miller. Microbubble assisted
polyhydroxybutyrate production from wastewater microalgae. Bioresource
technology.

Patents
1. Rahman A., Miller C.D., Tramp C.A., Hinman M., and Lewis R. V. Expression
system for the production of synthetic spider silk, September 2013. US Nonprovisional (Utility) Patent Application no.14/042,183. Patent Cooperation Treaty
(PCT) no. PCT/US2013/062722.
2. Rahman A., Sims R.C., Miller C.D., Ellis J.T., Sathish A., and Anthony R.J.
Methods for Harvesting and Processing Biomass. June 2013. US Nonprovisional (Utility) Patent Application no. 13/915,612.
3. Rahman A., Miller C.D., Sims R.C., Sathish A., and Anthony R.J. Methods of
bioplastic production. June 2013. US Non-provisional (Utility) Patent Application
no.13/914,461(US2013/0344550).
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Presentations
25 total (11 international, 2 invited*)
Underlined indicates primary presenter
1. *Asif Rahman, Neal Hengge, Ryan Putman, Charles Miller, and Ronald Sims.
iGEM and IBE from a Students’ perspective. American Society of Agricultural and
Biological Engineers. Montreal, Canada, 14 July, 2014. (Podium)
2. Asif Rahman, Ryan Putman, Ronald Sims, and Charles Miller.
Polyhydroxyalkanoate production in Escherichia coli from alternative carbon
sources. UNLV-USU Symposium on Biotechnology, Renewable Energy, and
Novel Materials, Las Vegas, Nevada, USA, 6 May, 2014. (Poster)
3. Asif Rahman, Ryan Putman, Ronald Sims, and Charles Miller. Production of
Polyhydroxyalkanoates in Escherichia coli from alternative carbon sources.
Institute of Biological Engineering conference, Lexington, Kentucky, USA, 7-9
March, 2014. (Poster)
4. Asif Rahman, Ryan Putman, Ronald Sims, and Charles Miller. Secretion of
biomaterials from Escherichia coli using a synthetic biological engineering
approach. Institute of Biological Engineering conference, Lexington, Kentucky,
USA, 7-9 March, 2014. (Podium)
5. Asif Rahman, Ryan Putman, Ronald Sims, and Charles Miller. Production of
Polyhydroxyalkanoates in Escherichia coli from algae-based carbon sources.
Synthetic Biomanufacturing Institute Science & Technology Review Winter
Meeting, February, 2014. (Poster)
6. Ashik Sathish, Kathryn Glaittli, Asif Rahman, Ronald Sims, and Charles Miller.
Production of poly (3-hydroxybutyrate) (PHB) from recombinant Escherichia coli
grown using an algae based media generated from a wet lipid extraction
procedure. Algal Biomass, Biofuels & Bioproducts conference, Toronto, Canada,
16-19 June, 2013. (Poster)
7. Asif Rahman, Ronald Sims, and Charles Miller. A secretion based approach to
produce Polyhydroxyalkanoates in Escherichia coli. American Society of
Microbiology annual conference. Denver, Colorado, 18-21 May, 2013. (Poster)
8. Ashik Sathish, Joshua Ellis, Asif Rahman, Reese Thompson, Issa Hamud,
Charles Miller, and Ronald Sims. Utilization of wastewater derived algal biomass
for the production biofuels and bioproducts via a wet lipid extraction procedure.
International BIOMASS Conference & Expo, Minneapolis, Minnesota, USA, 8-10
April, 2013. (Poster)
9. Asif Rahman, Ronald Sims, and Charles Miller. Economic production of
Polyhydroxyalkanoates in Escherichia coli. Institute of Biological Engineering
conference, Raleigh, North Carolina, USA, 7-9 March, 2013. (Podium and
Poster)
10. Ryan Putman, Asif Rahman, and Charles Miller. Arachnicoli: Production and
Purification of Spider Silk Proteins in Escherichia coli. Synthetic
Biomanufacturing Institute Science & Technology Review Winter Meeting,
February, 2013. (Poster)
11. Asif Rahman, Ronald Sims, and Charles Miller. Secretion of bioplastic from
Escherichia coli. Synthetic Biomanufacturing Institute Science & Technology
Review Winter Meeting, February, 2013. (Poster)
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12. Renil Anthony, Asif Rahman, and Ronald Sims. Bacterial Putrecine production
for synthesis of cationic amino starch for algae dewatering. Institute of Biological
Engineering western regional conference, Logan, Utah, USA, 26 October, 2012.
(Podium).
13. Renil Anthony, Ashik Sathish, Joshua Ellis, Asif Rahman, Charles Miller, Ronald Sims.
Effects of coagulant/flocculants on the production of biodiesel, biosolvents, and
bioplastic from microalgae. Algal Biomass, Biofuels and Bioproducts conference, San
Diego, California, USA, 9-13 June, 2012. (Podium)
14. Asif Rahman, Ronald Sims, and Charles Miller. Real time analysis of secreted
Polyhydroxyalkanoates
from Escherichia coli. Intermountain Graduate Research Symposium, Logan, Utah,
USA, 5-6 April, 2012. (Podium)
15. Elizabeth Osei, Asif Rahman, and Charles Miller. The impact of bioplastic
secretion of cell viability. Institute of Biological Engineering conference,
Indianapolis, Indiana, USA, 1-3 March, 2012. (Poster, 1st Place)
16. Asif Rahman, Ronald Sims, and Charles Miller. Polyhydroxyalkanoate production
from Escherichia coli: carbon sources and scale up. Institute of Biological
Engineering conference, Indianapolis, Indiana, USA, 1-3 March, 2012. (Poster)
17. Asif Rahman, Ronald Sims, and Charles Miller. Secretion of
Polyhydroxyalkanoates from Escherichia coli. Institute of Biological Engineering
conference, Indianapolis, Indiana, USA, 1-3 March, 2012. (Podium)
18. Elizabeth Martinez, Rachel Jackson, Asif Rahman, Charles Miller, and Timothy
Taylor. Scale-up secretion of green fluorescent protein using the yeast Pichia
Pastoris. Institute of Biological Engineering western regional conference, Logan,
Utah, USA, 28 October, 2011. (Poster)
19. Cody Tramp, Joshua Ellis, Asif Rahman, Sarah Allred, Eric Anderson, Charles
Barentine, Victor Carlson, Cole Peterson, Ashlyn Tucker, H. S. Hinton, Ronald
Sims, Charles Miller. Bioproduct Production and Optimization in a Cyanobacteria
Platform. Institute of Biological Engineering western regional conference, Logan,
Utah, USA, 28 October, 2011. (Poster)
20. Asif Rahman, Michelle Dickinson, and Mohammed Farid. Nanoindentation of
Microcapsules. NanoUtah conference, Salt Lake City, Utah, USA, 13-14 October,
2011. (Poster)
21. Asif Rahman, Elisabeth Linton, and Charles Miller. Polyhydroxybutyrate secreted
from Escherichia coli. Utah Biomedical Engineering Conference, Salt Lake City,
Utah, USA, 10 September, 2011. (Poster)
22. Elisabeth Linton, Alex Hatch, Asif Rahman, and Charles Miller. Development of a
bioplastic secretion system. Biochemical and Molecular Engineering XVII,
Emerging Frontiers, Seattle, Washington, USA, 26-30 June, 2011. (Poster)
23. Asif Rahman, Ronald Sims, and Charles Miller. Scale-up and isolation of
Polyhydroxyalkanoates from Escherichia coli. Intermountain Graduate Research
Symposium, Logan, Utah, USA, 31 March, 2011. (Poster, 1st place)
24. Asif Rahman, Michelle Dickinson, and Mohammed Farid. Strength testing of
microencapsulated phase change materials. International Conference on
Structural Integrity and Failure, Auckland, New Zealand, 4-7 July, 2010.
(Podium)
25. *Asif Rahman, Invited Guest speaker, ‘The Graduate School Experience.’
University of Auckland Postgraduate Cocktail Function, Auckland, New Zealand,
20 May, 2010. (Podium)
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Awards and Scholarships
·
·
·
·
·
·
·

·
·

Outstanding Engineering Graduate Scholar-Student, April, 2014.
Grand Prize for Poster Presentation, Institute of Biological Engineering, March,
2014.
Utah State University, International Student of the Year 2012-2013, April, 2013.
1st Place for Poster Presentation, Institute of Biological Engineering, March,
2013.
Graduate student professional conference travel award Utah State University,
2012, 2013, & 2014.
Utah State Department of Biological Engineering Award for Outstanding
Achievement in the Field of Excellence, December, 2012.
New Zealand Aluminum Smelters (part of Rio Tinto Alcan) Masters Prize in
Engineering 2011 (awarded to best Thesis in Materials & Materials Processing
Research), March, 2012.
1st Place for Poster Presentation Intermountain Graduate Research
Symposium. Logan, Utah, USA, 31 March, 2011.
Utah Science Technology and Research (USTAR) PhD fellowship August 2010present.

Professional Affiliations and Service
Reviewer
·
·
·
·

Energy, reviewer 2013
Open Journal of Renewable Energy and Sustainable Development, editorial
board 2013-2015
Open Journal of Chemical Engineering and Science, editorial board 2013-2015
Chemeca conference, proceedings reviewer, 2012

Membership
·
·
·
·

Member, American Society of Microbiology
Member, Institute of Biological Engineering
Member, American Institute of Chemical Engineers
Member, American Society of Agricultural and Biological Engineers

Professional Organizations
Elected to serve as Graduate student council representative for the Institute of
Biological Engineering (IBE) 2013 & 2014.
Conference Activities
·

Student social co-chair. Institute of Biological Engineering conference, Lexington,
Kentucky, USA, 7-9 March, 2014.
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·

·

Student Conference Chair and abstract reviewer. Institute of Biological
Engineering (IBE) Western Regional Conference, Logan, Utah, USA 2012 &
2011.
Bioprocess Session Chair and abstract reviewer. Institute of Biological
Engineering (IBE) Western Regional Conference, Logan, Utah, USA 2010.

Mentoring
·

Graduate Advisor, Utah State University iGEM team (International biotechnology
competition) 2011, 2012, 2013, and 2014
iGEM projects:
2013: AMPed Up E. coli - Won gold medal
2012: Arachnicoli: Production and Purification of Spider Silk Proteins in
Escherichia coli
-Won gold medal, Best New BioBrick Device-Engineered,
Regional finalist-second runner up, Best Manufacturing Project
overall-world championship
2011: CyanoBricks: Expression testing and Bioproduct development -Won gold
medal

·

I have directly supervised undergraduate research projects and capstone
projects at Utah State University in the Department of Biological Engineering.
Directly mentored over 24 students.

Other activities
·
·

·

Engineering State, Utah State University (1 week undergraduate recruiting for
faculty of engineering), summer 2011, 2013, 2013, and 2014.
Discover Biological Engineering, Utah State University (1 week undergraduate
recruiting for department), summer 2011, 2012, 2013, and 2014.
USA Science and Engineering Festival, Institute of Biological Engineering Booth,
Washington DC, 2014.

